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General introduction
chapter 1
8Abbreviations: AFAP, attenuated familial adenomatous polyposis; APC, adenomatous polyposis coli; 
CA, cholic acid; CDCA, chenodeoxycholic acid; CHRPE, congenital hypertrophy of the retinal pigment 
epithelium; COX, cyclooxygenase; DFMO, difluoromethylornithine; EPA, eicosapentaenoic acid; FAP, 
familial adenomatous polyposis; IPAA, ileal pouch-anal anastomosis; IRA, ileorectal anastomosis; 
Lef, lymfhoid enhancer factor; MAP, MYH associated polyposis; MCR, mutation cluster region; 
NSAID, non-steroidal anti-inflammatory drug; PDT, photodynamic therapy; PPPD, pylorus-preserving 
pancreaticoduodenectomy; PSD, pancreas-sparing duodenectomy; Tcf, T cell factor family; TGF-α, 
transforming growth facter α; UDCA, ursodeoxycholic acid; Whipple, Whipple’s pancreaticoduodenectomy
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General introduction
1familial adenomaTous polyposis
Familial adenomatous polyposis (FAP) is an inheritable disease that is characterized classically 
by the development of hundreds to thousands adenomatous polyps in the colorectum during 
the second and third decade of life.1 In approximately 10% of cases, the disease is less severe, 
with a lower number of colorectal polyps and a higher average age of onset of disease. This 
variant is called attenuated FAP (AFAP).2 Virtually all patients with FAP will develop colorectal 
cancer before the age of 40 to 50 years, unless prophylactic colectomy is performed. At 
present, ileorectal anastomosis (IRA) and ileal pouch-anal anastomosis (IPAA) are the surgical 
procedures of choice.
In addition to colorectal abnormalities, patients with FAP are at risk for extra-colonic 
manifestations of their disease. These include epidermoid cysts, lipomas, desmoid tumors, 
osteomas, dental abnormalities, congenital hypertrophy of the retinal epithelium, adrenal 
tumors, thyroid carcinomas, brain tumors, pancreatic cancer, hepatoblastomas and upper 
gastrointestinal adenomas and carcinomas.3,4 By convention, the clinical association of FAP with 
desmoid tumors and osteomas is referred to as Gardner syndrome, whereas Turcot syndrome is 
characterized by the association of FAP with tumors of the central nervous system, in particular 
medulla blastoma.
All clinicians involved in management of patients with FAP should be aware of all these 
possible extra-intestinal manifestations, as FAP related complications for which medical 
attention is essential, are not rare and their estimated lifetime risk is presumed to exceed 30%.4
Based on data from Northern European Polyposis registries, FAP has a reported prevalence 
of 26 to 32 patients per million, an incidence of 0.86 to 2.38 patients per million per year, and 
a frequency at birth of approximately one in 7,000 to one in 25,000.5-7 In the past decades, 
prognosis of FAP has improved considerably, owing to a substantial reduction in the prevalence 
of colorectal cancer, as a result of the establishment of numerous national and regional registers 
all over the world.8,9 The centralized registration has facilitated the identification of family 
members at risk and early diagnosis. Prophylactic colectomy substantially improved prognosis 
in the past decades.10 As a result, the mortality pattern has changed with duodenal cancer and 
desmoid tumors now being the main cancer-related causes of death.11-14 In this thesis, studies 
are described that address treatment and chemoprevention of duodenal neoplasms, primarily 
in patients with FAP.
upper gasTroinTesTinal manifesTaTions of fap
Duodenal polyps were first described by Funkenstein in the year 190415 and the first case of a 
FAP related duodenal carcinoma was reported by Cabot in 1935.16 Although interest for upper 
gastrointestinal polyposis grew after the first publication in the late 1960s, suggesting regular 
upper gastrointestinal surveillance for patients with FAP to detect polyps, even after the 
introduction of endoscopy in the 1970s surveillance was not performed systematically.17 The 
first publication of upper gastrointestinal endoscopic screening was published in 1977.18
10
Gastric lesions associated with FAP frequently are fundic gland polyps, while gastric 
adenomas are found in 6% of patients.19 An increased risk of gastric cancer is not found in 
patients with FAP compared to the general population.20 Data on the prevalence of duodenal 
adenomas in patients with FAP vary widely with rates from 20 to 100%, depending on the 
type of endoscope used and the method of tissue sampling.17,21,22 With the use of side-
viewing endoscopy and random biopsies of endoscopically normal appearing mucosa, 
remarkably high rates of duodenal and periampullary adenomas of over 70% were found, 
with a considerable prevalence of microadenomas in papillary and periampullary mucosa.21 
Polyps can be found throughout the duodenum, but the second and third segment and 
the periampullary region are most commonly affected. This distribution corresponds with 
mucosal exposure to bile acids, suggesting that these substances are involved in duodenal 
carcinogenesis.23,24
Duodenal adenomatosis is generally graded according to the endoscopically and 
histologically based semi-quantitative scoring system by Spigelman.23 In this scoring system, 
severity of duodenal polyposis is expressed according to the endoscopic evaluation of number 
and size of the polyps, in combination with histology and grade of dysplasia in biopsies of 
duodenal lesion. The scoring system describes five (0-IV) stages (see Table 1). Stage I (1-4 points) 
indicates mild disease, whereas stages III-IV (>6 points) imply severe duodenal polyposis.
Table 1. Spigelman classification for duodenal adenomatosis with recommendations for management.22,25
Criterion
Points
1 2 3
Number 1-4 5-20 >20
Size (mm) 1-4 5-10 >10
Architecture Tubular Tubulovillous Villous
Dysplasia Mild Moderate Severe
Stage 0 (0 points) and stage I (1-4 points): endoscopic surveillance every 5 years; stage II (5-6 points): endoscopic 
surveillance every 2-3 years; stage III (7-8 points): endoscopic surveillance every 1-2 years with consideration for 
surgery; stage IV (9-12 points): surgery should be considered.
The Spigelman classification of duodenal adenomatosis allows duodenal polyposis to 
be compared over time and between observers, and is helpful in estimating the cancer risk. 
Progression of duodenal adenomatosis is slow, particularly in patients with less advanced 
stages of disease.25-28 In two large studies, no malignant progression was present after 10 years 
of follow-up in patients with Spigelman stage 0 or I.25,27 In these studies, the cumulative 
incidence of malignancy was 0.7-1.9% for patients with Spigelman stages 0 to III, and 7-36% for 
patients with Spigelman stage IV. The risk of developing stage III or IV disease exponentially 
increases after the age of 40.28 In patients reaching 75 years of age, 20% to 52% had developed 
Spigelman IV duodenal adenomatosis, with an estimated cumulative incidence of duodenal 
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adenocarcinoma between 4 and 33%.25,29 This illustrates that, in contrast to colorectal polyps, 
duodenal polyps do not invariably progress to adenocarcinomas. However, the relative risk for 
duodenal adenocarcinoma or ampullary carcinoma in patients with FAP was estimated 331 and 
124 times higher respectively, as compared to the general population.20 In general, it is assumed 
that life-time risk of duodenal carcinoma in patients with FAP is 2-7%.21,25,27,29,30 Noteworthy, an 
increase in severity of duodenal polyposis as reported in recent years is determined by time-
lapse, technological advances, and changes in dysplasia-reporting. These changes suggest that 
a revision of the Spigelman classification is warranted.31
APC geneTics and funcTion
FAP is an autosomal dominant disease caused by germline mutations in the tumor suppressor 
adenomatous polyposis coli (APC) gene.32 Approximately 25% of all cases of FAP are caused by 
de novo mutations, which means there is no family history of colorectal lesions or identified 
APC germline mutation.33 Linkage analysis of families with FAP led to the localizing of the APC 
gene on chromosome 5.32 In 1991, the gene was identified on chromosome 5q21-22 and further 
characterized.34-36 The APC gene consists of 8,538 base pairs spanning 15 exons, encoding a 
protein consisting of 2,843 amino acids. Exon 15 is the largest exon containing over 75% of the 
coding sequence.35
With conventional techniques for genetic testing, in approximately 20-50% of patients 
with clinical presentation of FAP or AFAP no mutation can be detected.37 More recently, a 
mutation in the MYH gene, involved in oxidation-induced DNA damage repair, was identified 
in APC mutation-negative patients with multiple colorectal polyps.38 This MYH associated 
polyposis (MAP) with an autosomal recessive pattern of inheritance could account for up to 
30% of APC mutation-negative polyposis patients.39 Other germline mutations may contribute 
to the APC mutation-negative group as well, e.g. mutations in the CRAC1 or AXIN2 genes.40,41 
Moreover, the severity and progression of adenomatosis may not be determined by the APC 
gene alone. The discovery of a modifier Mom1 gene in the APCMin mouse polyposis model42 led 
to the identification of a possible modifier gene on human chromosome 1p35-36, which may 
contribute to the clinical heterogeneity of FAP.43,44 Variations in the N-acetyltransferase loci 
NAT1 and NAT2, located on chromosome 8p22, have also been shown to affect disease severity.45
In accordance with Knudson’s ‘two-hit’ hypothesis46, patients with FAP inherit one germline 
mutation and develop tumors from cells in which a ‘second hit’ or loss of the other APC allele 
(loss of heterozygosity) is acquired somatically.47 Somatic mutations in the colorectal polyps of 
patients with FAP do not seem to occur randomly. Over 60% of all somatic mutations in APC 
occur clustered in the region between codons 1286 and 1513, therefore called the colorectal 
‘mutation cluster region’ (MCR).48 The localization of the germline mutation also seems to 
determine the type of somatic ‘second hit’ mutation in colorectal polyps: germline mutations 
close to codon 1300 are associated with loss of heterozygosity, and germline mutations 
elsewhere in the gene are associated with truncating somatic mutations in the MCR.47 The vast 
majority of germline mutations in the APC gene result in a truncated nonfunctional protein, 
either by a nonsense mutation (30%) or by a frameshift mutation (68%), with most of the 
12
mutations (germline and somatic) occurring in the first half of the coding region of the gene.49 
Germline mutational hotspots are located at codons 1061 and 1309.49,50
The APC gene encodes a large protein with multiple domains related to multiple cellular 
processes. It is involved in oligomerization, cell migration and adhesion, β-catenin binding and 
degradation, axin binding, microtubule binding, chromosome segregation, cell cycle regulation 
and apoptosis.51,52 It is hypothesized that the critical tumor suppression activity involves the 
intracellular Wnt signaling pathway, more specifically by downregulation of β-catenin through 
phosphorylation and degradation in association with axin and GSK-3β (see Figure 1).53,54 Loss 
of functional APC results in accumulation of cytosolic β-catenin and subsequent translocation 
to the nucleus.52 Inside the nucleus, β-catenin associates with members of the T cell factor 
 
 
Figure 1. APC function and the Wnt signaling/β-catenin pathway - adapted from Fearnhead et al.52 A: 
In the absence of Wnt ligand and with normal functioning APC, β-catenin is phosphorylated by GSK-
3β in a complex with APC and Axin. Phosphorylated β-catenin is rapidly degradated. Furthermore, β-
catenin is associated with E-cadherin and α-catenin which binds actin and actin-associated proteins of 
the microtubule cytoskeleton. B: Inactivated GSK-3β by binding of Wnt ligand to its receptor (known 
as Frizzled) or loss of functional APC, results in accumulation of cytosolic β-catenin, which translocates 
to the nucleus. Inside the nucleus, β-catenin associates with members of the T cell factor (Tcf) and 
lymphoid enhancer factor (Lef) family of transcription factors. The Tcf/β-catenin complex activates 
several transcriptional targets, including c-MYC, cyclin D, connectin 43, and matrilysin. In addition, 
other cellular functions of APC and β-catenin are also disturbed. 
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(Tcf) and lymphoid enhancer factor (Lef) family of transcription factors, e.g. Tcf4 which is 
expressed in the nuclei of intestinal epithelial cells. The β-catenin/Tcf4 complex activates 
several transcriptional targets, including the oncogene and cell cycle regulator c-MYC55, 
the G1/S-regulating gene cyclin D156, the gap junction protein connectin  4357, and the gene 
encoding the matrix-degrading metalloproteinase matrilysin.58 In addition to controlling 
the Wnt signaling pathway, APC has other functions. In this regard, β-catenin also functions 
as an essential component of epithelial intercellular adherens junctions, where it links the 
cytoplasmic tail of E-cadherin to α-catenin which binds actin and actin-associated proteins 
of the microtubule cytoskeleton.59 In summary, the role of APC in intestinal carcinogenesis is 
attributed largely to the Wnt signaling pathway, but disruption of intercellular adhesion and 
stability of the cytoskeleton seems to be involved as well.52
adenoma-carcinoma sequence
‘The adenoma-carcinoma sequence’ is the term for the histological stepwise progression 
of normal colorectal mucosa to aberrant crypt foci, adenoma, and finally invasive colorectal 
cancer (see Figure 2). The stepwise progression of normal colorectal mucosa to carcinoma in 
patients with FAP is paralleled by a series of genetic and cellular changes that involves activation 
of oncogenes (e.g. K-ras) and inactivation of tumor suppressor genes (e.g. p53 and SMAD4).59 
Based on epidemiological data of differences in age between presentation with benign and 
malignant neoplasms, a similar adenoma-carcinoma sequence was suggested to apply also to 
carcinogenesis in the small intestine including the duodenum.60 Histopathological evidence for 
this includes the finding in patients with FAP, that adenomas occurred either as a component 
of duodenal carcinomas or in mucosa adjacent to duodenal carcinomas in 84% of patients, 
suggesting that a carcinoma is preceded by a noninvasive adenomatous precursor lesion.30
The biallelic mutations in the APC gene with activation of the Wnt signaling pathway are the 
earliest genetic alterations and seem to be required to initiate the sequence, both in hereditary 
predisposed patients with FAP, as well as in sporadic carcinomas.62 Findings that support the 
concept of progressive cellular alteration include the following. First, no somatic ‘second hit’ 
to duodenal carcinomas in 84% of patients, suggesting that a carcinoma is preceded by a noninvasive 
ade omat us precursor lesion.30 
 
 
Figure 2. Colorectal adenoma-carcinoma sequence - adapted from Brosens et al.61 The histological 
stepwise progression of normal colorectal mucosa to aberrant crypt foci, adenoma, and finally 
invasive colorectal cancer, is paralleled by a series of genetic and cellular changes that involve 
activation of oncogenes (e.g. K-ras) and inactivation of tumor suppressor genes (e.g. p53 and 
SMAD4). A similar adenoma-carcinoma sequence is suggested to apply to carcinogenesis in the 
duodenum. 
 
The biallelic mutations in the APC gene with activation of the Wnt signaling pathway are the earliest 
genetic alterations and seem to be required to initiate the sequence, both in hereditary predisposed 
patients with FAP, as well as in sporadic carcinomas.62 Findings that support the concept of 
progressive cellular alteration include the following. First, no somatic ‘second hit’ APC mutations 
were detected in normal duodenal mucosa of patients with FAP63, but were observed in 10-67% of 
periampullary adenomas and carcinomas.63-65 Second, oncogenic K-ras mutations were detected in 
duodenal adenomas and carcinomas.64-67 Third, overexpression of p53 was noted in 0% of normal 
mucosa, 25% of tubular, 72% of tubulovillous or villous adenomas, and 100% of duodenal 
carcinomas.68 As detection of  p53 gene mutation is generally low or absent, p53 overexpression 
rather seems to reflect intracellular abnormalities possibly related to tumorigenesis.66,67 Fourth, 
several cellular abnormalities were found to be already present in normal duodenal mucosa of 
patients with FAP when compared to non-FAP controls, including increased cell proliferation69,70, 
increased expression of cyclooxygenase-2 (COX-2)71, increased number of Paneth cells and endocrine 
cells in the mucosal crypts72, and loss of extracellular E-cadherin.73 Fifth, the extent of transforming 
growth factor α (TGF-α) expression was found to be greater in duodenal carcinomas than in 
adenomas, and increased progressively in adenomas relative to the degree of dysplasia (mild, 
moderate, severe) and histological architecture (tubulous, tubulovillous, villous) of these lesions.74 
Altogether, these studies, at least to some extent, reveal the molecular and genetic alterations that 
are involved in the transition of normal duodenal mucosa into adenoma and carcinoma. 
 
Genotype-phenotype correlation 
Figure 2. Colorectal adenoma-carcinoma sequence - adapted from Brosens et al.61 The histological 
stepwise progression of normal colorectal mucosa to aberrant crypt foci, adenoma, and finally invasive 
colorectal cancer, is paralleled by a series of genetic and cellular changes that involve activation of 
oncogenes (e.g.  K-ras) and inactivation of tumor suppressor genes (e.g. p53 and SMAD4). A similar 
adenoma-carcinoma sequence is suggested to apply to carcinogenesis in the duodenum.
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APC mutations were detected in normal duodenal mucosa of patients with FAP63, but were 
observed in 10-67% of periampullary adenomas and carcinomas.63-65 Second, oncogenic K-ras 
mutations were detected in duodenal adenomas and carcinomas.64-67 Third, overexpression of 
p53 was noted in 0% of normal mucosa, 25% of tubular, 72% of tubulovillous or villous adenomas, 
and 100% of duodenal carcinomas.68 As detection of p53 gene mutation is generally low or 
absent, p53 overexpression rather seems to reflect intracellular abnormalities possibly related 
to tumorigenesis.66,67 Fourth, several cellular abnormalities were found to be already present in 
normal duodenal mucosa of patients with FAP when compared to non-FAP controls, including 
increased cell proliferation69,70, increased expression of cyclooxygenase-2 (COX-2)71, increased 
number of Paneth cells and endocrine cells in the mucosal crypts72, and loss of extracellular 
E-cadherin.73 Fifth, the extent of transforming growth factor α (TGF-α) expression was found to 
be greater in duodenal carcinomas than in adenomas, and increased progressively in adenomas 
relative to the degree of dysplasia (mild, moderate, severe) and histological architecture 
(tubulous, tubulovillous, villous) of these lesions.74 Altogether, these studies, at least to some 
extent, reveal the molecular and genetic alterations that are involved in the transition of normal 
duodenal mucosa into adenoma and carcinoma.
genoType-phenoType correlaTion
The correlation between the location of germline mutations in the APC gene and the clinical 
presentation in patients with FAP, the genotype-phenotype correlation, was first recognized and 
described in relation to the number of colorectal polyps in 1992.75 The phenotype with profuse 
colorectal polyposis of thousands (over 5000) polyps was linked to mutations between codons 
1250 and 1464. In the attenuated phenotype AFAP with less than one hundred polyps, mutations 
were reported at the 5’ end spanning exons 4 and 5 before codon 157, within the alternative 
spliced region of exon 9, and at the 3’ end of the gene beyond codon 1595.76 An intermediate 
phenotype of one hundred to several thousand polyps was correlated to the rest of the gene 
(see Figure 3). In addition to the severity of colorectal polyposis, the age of onset was also 
found to be associated with the localization of the APC germline mutation. Patients carrying 
an APC mutation at codon 1309, a germline mutational hotspot as mentioned before, showed 
an age of onset of disease 10 years earlier (mean age of 20 years) compared with patients with 
other mutations between codons 168 and 1580 (mean age of 30 years), whereas patients with 
mutations at the 5’ end of codon 168 or the 3’ end of codon 1580 were diagnosed at a mean age 
of 52 years.50
Genotype-phenotype correlations of extra-colonic manifestations have not been well 
established, with the exception of the occurrence of congenital hypertrophy of the retinal 
pigment epithelium (CHRPE), which is restricted to families with mutations between codons 311 
and 1465.76 The multiple bilateral presence of these ophthalmic lesions appears to be a highly 
specific marker for FAP and can therefore be used to identify carriers in FAP families.77
In relation to upper gastrointestinal polyps, evidence for a genotype-phenotype correlation 
is not conclusive. In several studies, no association was found between localization of APC 
mutations and duodenal polyposis.50,78,79 However, there is evidence suggesting that proximal 
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mutations of the APC gene are related to a smaller risk of duodenal adenomas compared to 
mutations downstream, that is beyond codon 47980, or on codons 564-1465.81 A three to fourfold 
increased risk of duodenal adenomas for patient with APC gene mutations on codons 976-1067 
was found as compared to patients with mutations on codons 159-495.82 Moreover, highest 
frequencies of gastric and duodenal adenomas and periampullary cancer was associated with 
mutations on codons 1395-1493.83 A history of periampullary adenomas or adenocarcinomas 
was associated with mutations downstream of codon 1051.84
 
Figure 3. Genotype-phenotype correlation: the localization of mutations in the APC gene in 
association with the clinical colorectal phenotype - adapted from Nieuwenhuis et al.85 Evidence on 
genotype-phenotype of duodenal adenomas however is not straightforward.80-84 Abbreviations: 
CHRPE, congenital hypertrophy of the retinal pigment epithelium; MCR, mutation cluster region. 
 
Management of duodenal adenomatosis 
The clinical challenge is to identify patients with high-risk duodenal adenomas and intervene before 
progression to cancer has occured. Therefore, surveillance gastroduodenoscopy is recommended 
from around the age of 25-30 years, ideally using a side-viewing video-endoscope for optimal view of 
the ampullary region, and including taking biopsies of mucosal lesions as well as randomly.22 
Surveillance interval and treatment according to the Spigelman stage is depicted in Table 1. 
 
Endoscopic treatment options for duodenal lesions include snare excision, thermal ablation, argon 
plasma coagulation, and photodynamic therapy (PDT). In contrast to colorectal polyps, duodenal 
adenomas are often flat non-polypoid structures and therefore difficult to remove using 
conventional snare excision.61 Submucosal injection of saline/adrenaline before removal is a strategy 
that reduces risk of haemorrhage and perforation.27 Local treatment of duodenal polyposis with 
polypectomy or ampullectomy, endoscopically as well as surgically, is a relatively safe option, but 
high adenoma recurrence rates of up to almost 100% have been reported.86-89 The relief of cancer 
threat therefore seems only temporary and ongoing endoscopic surveillance is mandatory. 
Moreover, patients that were previously treated for Spigelman stage IV demonstrated an increased 
disease progression, as compared to patients with natural disease progression, and for these former 
stage IV patients, more frequent surveillance is advised than general recommendations based on 
current Spigelman stage.90 When local treatment is no longer deemed possible, more extensive 
Figure 3. Genotype-phenotype correlation: the localization of mutations in the APC gene in association 
with the clinical colorectal phenotype - adapted from Nieuwenhuis et al.85 Evidence on genotype-
phenotype of duodenal adenomas however is not straightforward.80-84 Abbreviations: CHRPE, congenital 
hypertrophy of the retinal pigment epithelium; MCR, mutation cluster region.
managemenT of duodenal adenomaTosis
The clinical challenge is to identify patients with high-risk duodenal adenomas and intervene 
before progression to cancer has occured. Therefore, surveillance gastroduodenoscopy 
is recommended from around the age of 25-30 years, ideally using a side-viewing video-
endoscop for optimal vi w of the ampullary region, and including taking biopsies of mucosal 
lesions as well as randomly.22 Surveillance interval and treatment according to the Spigelman 
stage is depicted in Table 1.
Endoscopic treatment options for duodenal lesions include snare excision, thermal 
ablation, argon plasma coagulation, and photodynamic therapy (PDT). In contrast to colorectal 
polyps, duodenal adenomas are often flat non-polypoid structures and therefore difficult to 
remove using conventional snare excision.61 Submucosal injection of saline/adrenaline before 
removal is a strategy that reduces risk f haemorrhage nd perforation.27 Local treatment of 
duod nal polyposis with polypectomy or ampullectomy, endoscopically as w ll as surgically, 
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is a relatively safe option, but high adenoma recurrence rates of up to almost 100% have 
been reported.86-89 The relief of cancer threat therefore seems only temporary and ongoing 
endoscopic surveillance is mandatory. Moreover, patients that were previously treated for 
Spigelman stage IV demonstrated an increased disease progression, as compared to patients 
with natural disease progression, and for these former stage IV patients, more frequent 
surveillance is advised than general recommendations based on current Spigelman stage.90 
When local treatment is no longer deemed possible, more extensive surgical procedures 
such as classical Whipple’s pancreaticoduodenectomy (Whipple), pylorus-preserving 
pancreaticoduodenectomy (PPPD) or the more recently introduced pancreas-sparing 
duodenectomy (PSD) need to be considered.91-93 However, these interventions bring about 
substantial risk of morbidity and mortality.92,94-96 Furthermore, although these extensive surgical 
procedures offer the chance of a prolonged disease-free interval, recurrence of adenomas97,98 
and even cancer arising from the remaining duodenal mucosa have been reported.99 Moreover, 
cancer recurrence at the hepaticojejunostomy was described thirteen years after PPPD for 
nonampullary duodenal cancer, as described in Chapter 2 of this thesis.100 Chemopreventive 
treatment is highly desirable to postpone or even avoid the necessity for radical prophylactic 
surgery, or as adjuvant treatment after prophylactic duodenal resection is performed.
chemoprevenTion
Theoretically, all cellular processes involved in initiation or progression of adenomas or 
carcinomas are potential targets for pharmacological intervention in the carcinogenesis. 
Cyclooxygenase (COX) inhibiting non-steroidal anti-inflammatory drugs (NSAIDs) have been 
subject of much investigation as potential chemopreventive agents. Two COX isoenzymes 
exist. Whereas the COX-1 isoenzyme is constitutively expressed in a wide range of tissues 
and is considered a housekeeping enzyme, the COX-2 isoenzyme is an inducible enzyme that 
produces prostaglandins in inflammatory and tumorigenic settings.101 Overexpression of COX-2 
is linked to evasion of apoptosis, enhanced cell growth, tumor angiogenesis, tissue invasion, 
and metastasis through several signalling pathways.101
In 1983, the first report was published on regression of colorectal polyps in a patient with 
FAP treated with sulindac, a non-selective cyclooxygenase inhibitor.102 Subsequently, in the 
first randomized controlled trial, sulindac was found to significantly reduce the number of 
rectal polyps, as compared to placebo.103 The effects of sulindac were also examined in the 
duodenum, but results were disappointing. Of the 8 patients with FAP with large duodenal 
polyps treated with sulindac for 6 months, 3 patients discontinued treatment because of 
significant side effects, in 3 patients large polyps recurred, and in one patient even invasive 
cancer developed.104 However, sulindac was found to regress small duodenal polyps, but this 
effect was limited, despite larger effects on colorectal polyposis.105,106
The inhibition of the COX-1 isoenzyme appears to cause the major side effects common 
to NSAIDs, in particular the gastrointestinal complications.107 Subsequently, studies in which 
COX-2 was specifically targeted by administration of the selective COX-2 inhibitor celecoxib, 
showed significant decrease in the occurrence of sporadic colorectal adenomas, not only by 
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suppressing the growth of existing adenomas, but also by preventing the formation of new 
adenomas.108 COX-2 inhibition in murine models of intestinal polyposis resulted in a substantial 
decrease in adenoma size and number.109,110 Confirming the findings from animal studies, 
administration of celecoxib was associated with regression of adenomas of both the colon and 
rectum in patients with FAP.111
The value of COX inhibiting agents for regression of duodenal polyposis however, is not well 
established.61 Celecoxib was found to significantly reduce duodenal adenomatosis in a subset 
of patients with FAP with significant duodenal adenomatosis, after 6 months of treatment 
with high dosage of 400mg twice daily112, a finding that was confirmed by us, as described in 
Chapter 6 of this thesis. Unfortunately, due to increased risks of adverse cardiovascular events, 
clinical trials involving selective COX-2 inhibitors as chemopreventive agents for colorectal 
cancer have cast doubt on the suitability of these agents for long-term use.108,113
The search for effective chemopreventive treatment is ongoing and strategies of 
investigational interest in patients with FAP include sulindac and difluoromethylornithine 
(DFMO)114, curcumin and quercetin115, and eicosapentaenoic acid (EPA).116 Another promising 
strategy is combining celecoxib, preferably in lower dosage regimens to minimize cardiovascular 
toxicity, with other substances such as ursodeoxycholic acid (UDCA).
As previously mentioned, distribution of duodenal polyps corresponds with mucosal 
exposure to bile acids, suggesting their involvement in carcinogenesis.23,24 Primary bile acids 
are synthesized in the liver, excreted in the biliary tract, and released into the duodenum 
for digestive processes. In the terminal ileum, most of the bile acids are reabsorbed. Only 
approximately 5% of the bile acid pool enters the colon, where intestinal flora is responsible 
for the transformation of primary bile acids to secondary bile acids. These secondary bile acids 
are known tumor promotors in the gastrointestinal tract.117,118 After prophylactic colectomy 
in patients with FAP is performed, the content of the circulating bile acid pool changes and 
gallbladder and duodenal bile largely constitutes of glycine or taurine conjugated cholic acid 
(CA) and chenodeoxycholic acid (CDCA) derivates, both in equivalent amounts.119,120 By treating 
patients with FAP with high dosage of UDCA, enrichment with UDCA of duodenal bile of up 
to 50% of the total amount of bile acids was reached, with a reduction in concentration of 
the cytotoxic bile acid CDCA.121 In in vitro models of human colonic epithelial cells, UDCA, 
and taurine-conjugated UDCA in particular, significantly reduced cytotoxicity of secondary 
bile acids.122 Data from clinical studies support the notion of a possible chemopreventive 
effect of UDCA on development of colorectal neoplasms, in patients with sporadic colorectal 
adenomas123 and patients with ulcerative colitis and primary sclerosing cholangitis.124,125 UDCA 
was found to reduce COX-2 expression in a rat model of colon carcinogenesis126, suggesting 
an alternative and possibly complimentary pathway for inhibition of COX-2.127 However, in a 
recent clinical trial in patients with FAP, no effect of low dose UDCA after 24 months as mono-
treatment was found on Spigelman scores.128 Interestingly, a synergistic effect of sulindac and 
UDCA in the prevention of intestinal adenomas was found in a murine model of FAP.110 In this 
thesis, the chemopreventive potential of the combination of celecoxib and UDCA is studied in 
vitro as well as in vivo, as described in Chapter 4, and Chapters 6 & 7, respectively.
18
ouTline of This Thesis
The main objectives of this thesis are:
1. To evaluate the management and its outcome of sporadic duodenal adenomas and 
duodenal adenomatosis in patients with FAP, as employed in past decades, to further define 
their clinical significance and implication, and its management.
2. To explore the chemopreventive effects on duodenal adenomatosis of potentially effective 
substances in a preclinical setting, either as single treatment or in combination, for 
development of future chemopreventive strategies in patients with FAP.
3. To investigate the chemopreventive effects on duodenal adenomatosis in patients with FAP 
of treatment with celecoxib and UDCA in a multicentre randomized clinical trial.
Management and follow-up of duodenal adenomatosis, as it was practiced in the past decades, 
is studied in the first section of this thesis. In Chapter 2, surgical management and follow-up 
of advanced duodenal adenomatosis and duodenal cancer in patients with FAP is reviewed 
retrospectively, using data from the Dutch polyposis registry in Leiden. In Chapter 3, results 
are presented of the retrospective review of management and follow-up of sporadic duodenal 
adenomas, as it was employed at our institute over the past decades.
In the second section, potential chemopreventive strategies for management of duodenal 
adenomatosis in patients with FAP are explored by in vitro studies on gastrointestinal tumor cell 
line models. In Chapter 4, the chemopreventive potential of curcumin, quercetin and EPA are 
investigated by studying their effects on expression and activity of the important detoxification 
enzymes glutathione S-transferase and UDP-glucuronosyltransferase in cells of four different 
gastrointestinal tumor cell lines. In Chapter 5, celecoxib and UDCA co-treatment is studied by 
evaluating effects on cell growth and COX-2 mRNA expression in two different colorectal tumor 
cell lines.
In the third section of this thesis, results of a multicentre randomized clinical trial are 
presented. The effect of celecoxib and UDCA co-treatment on duodenal adenomatosis in 
patients with FAP is evaluated in a randomized, double-blind study in patients with Spigelman 
stages II or III duodenal adenomatosis, receiving either celecoxib & UDCA or celecoxib 
&  placebo treatment. Chapter 6 focuses on the endoscopic and histopathological effects of 
the two treatment arms in this intervention study. In Chapter 7, effects on duodenal mucosal 
mRNA levels of nine potential risk parameters for malignant transformation are studied in 
the two treatment arms in patients with FAP. In addition, baseline levels in duodenal biopsy 
specimens of patients with FAP are compared with levels in non-FAP patient controls.
In Chapter 8, the results described in this thesis are summarized and reviewed, and future 
perspectives are postulated. Chapter 9 presents a summary of this thesis in Dutch.
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aBsTracT
Duodenal cancer is a major cause of mortality in patients with familial adenomatous polyposis 
(FAP). The clinical challenge is to perform duodenectomy before cancer develops. However, 
procedures are associated with complications. Our aim was to gain insight into the pros and 
cons of prophylactic duodenectomy. Patients with FAP from the nationwide Dutch polyposis 
registry who underwent prophylactic duodenectomy or were diagnosed with duodenal 
cancer were identified and classified as having benign disease or cancer at preoperative 
endoscopy. Surveillance, clinical presentation, surgical management, outcome, survival, and 
recurrence were compared. Of 1,066 patients with FAP in the registry, 52 (5%; 25 males) were 
included: 36  with benign adenomatosis (median: 48 years old; including two (6%) cancer 
cases diagnosed after operation), and 16 with cancer (median: 53 years old). Cancer cases had 
been diagnosed with colorectal cancer more often (6% vs 44%; p<.01). Forty-three patients 
underwent duodenectomy (35 benign/eight cancer): 30-day mortality was 4.7% (n=2), and in-
hospital morbidity occurred in 21 patients (49%), without differences between patients with 
benign adenomatosis and cancer. Adenomas recurred in reconstructed proximal small bowel 
in 14 of 28 patients (50%, median time to recurrence: 75 months), and one patient developed 
cancer. Median survival of all 18 cancer cases in the registry (1.7%; 12 ampullary/six duodenal) 
was 11  months. In conclusion, prognosis of duodenal cancer in patients with FAP is poor, 
which justifies an aggressive approach to advanced benign adenomatosis. Strict adherence 
to recommended surveillance intervals is essential for a well-timed intervention. Given the 
substantial morbidity and mortality of duodenectomy, patients’ individual characteristics 
are to be critically evaluated preoperatively. As adenomas recur, postoperative endoscopic 
surveillance is mandatory.
Keywords: familial adenomatous polyposis; duodenal adenomatosis; prophylactic duodenectomy; 
duodenal cancer; surveillance; surgical outcome; survival; recurrence
Abbreviations: APC, adenomatous polyposis coli; FAP, familial adenomatous polyposis; FDG-PET, 
fludeoxyglucose positron emission tomography; IPAA, ileal pouch-anal anastomosis; IRA, ileorectal 
anastomosis; NFDHT, Netherlands Foundation for Detection of Hereditary Tumours; PPPD, pylorus-
preserving pancreaticoduodenectomy; PSD, pancreas-sparing duodenectomy; Whipple, Whipple’s 
pancreaticoduodenectomy
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Familial adenomatous polyposis (FAP) is an autosomal-dominant disease caused by germline 
mutations in the tumor suppressor gene APC (adenomatous polyposis coli).1 Classically, FAP is 
characterized by the development of hundreds to thousands of adenomatous polyps in the 
colorectum.2 Unless a prophylactic colectomy is performed, virtually all patients will develop 
colorectal cancer before the age of 50 years. In the past, surveillance and prophylactic colorectal 
surgery for patients at risk improved prognosis substantially by preventing colorectal cancer.3-6 
As a result, duodenal cancer is now the main cancer-related cause of death in patients who 
underwent prophylactic colectomy.7-9
Although the lifetime risk of duodenal adenomas approaches 100% in patients with FAP,10 
in contrast to colorectal polyps, duodenal polyps do not inevitably transform to cancer. 
Approximately 3-4% of patients eventually develop duodenal cancer.11,12 The relative risk of 
duodenal adenocarcinoma and ampullary carcinoma in patients with FAP was estimated 
at, respectively, 331 and 124 times greater than in the general population in which duodenal 
carcinoma is rare.13
The clinical challenge is to identify the patients at high risk of developing duodenal cancer 
because duodenal cancer has been associated with a poor prognosis.11,14-16 The Spigelman stages 
of duodenal disease severity assessed by surveillance endoscopy have been shown to correlate 
with the risk of developing duodenal cancer, with a risk of 36% during a 10-year period for the 
most advanced stage IV.17 Endoscopic surveillance is recommended to start when the patient is 
25-30 years of age, and frequency of surveillance and further management are determined on 
the basis of the Spigelman classification (Table 1).10,18
Local treatment of duodenal polyposis with polypectomy or ampullectomy, endoscopically 
as well as surgically, is a relatively safe option, but high rates of adenoma recurrence up to almost 
100% have been reported.19-22 The relief of cancer threat, therefore, seems only temporary, and 
ongoing endoscopic surveillance is mandatory. When local treatment is no longer deemed 
possible, more extensive operative procedures such as classical pancreatoduodenectomy, 
pylorus-preserving pancreatoduodenectomy (PPPD), or the more recently introduced pancreas-
sparing duodenectomy (PSD) need to be considered.23 These interventions, however, bring about 
substantial risk of morbidity and mortality.24-26 Furthermore, although these extensive surgical 
Table 1. Spigelman classification for duodenal adenomatosis with recommendations for management.10,18
Criterion points
1 2 3
Number 1-4 5-20 >20
Size (mm) 1-4 5-10 >10
Architecture Tubular Tubulovillous Villous
Dysplasia Mild Moderate Severe
Stage 0 (0 points) and stage I (1-4 points): endoscopic surveillance every 5 years; stage II (5-6 points): 
endoscopic surveillance every 2-3 years; stage III (7-8 points): endoscopic surveillance every 1-2 years with 
consideration for surgery; stage IV (9-12 points): surgery should be considered.
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procedures offer the chance of a prolonged disease-free interval, the recurrence of adenomas15,27 
and even cancer arising from the remaining duodenal mucosa have been reported.28
To gain insight into the pros and cons of prophylactic duodenectomy, we reviewed data 
retrospectively of patients from the nationwide Dutch polyposis registry. Our primary aim 
was to analyze characteristics of all patients who underwent prophylactic duodenectomy 
for duodenal adenomatosis and all patients diagnosed with duodenal cancer. In addition, we 
compared both groups on features including surveillance and clinical presentation, surgical 
management and outcome, survival and causes of death, and recurrence. 
paTienTs and meThods
dutch polyposis registry
In 1985, the Netherlands Foundation for Detection of Hereditary Tumours (NFDHT) started 
a registry of patients with FAP. The main objectives of this nationwide polyposis registry are 
coordination of lifelong surveillance of at-risk patients and promotion of early detection 
of cancer in high-risk families.29 Patients with FAP are referred to this national registry by 
gastroenterologists, surgeons, or clinical geneticists. At the time of registration, written 
informed consent is obtained from the patient for collection of personal and medical data, 
including endoscopic, surgical, and histopathology reports. To date, 1,066 patients with a 
genetically and/or clinically confirmed diagnosis of FAP are registered. 
study population
For this study, we searched the FAP database of the Dutch Polyposis Registry to identify and 
include for analysis: (1) patients who underwent a classic pancreatoduodenectomy with 
antrectomy (Whipple), PPPD, or PSD for advanced benign duodenal adenomatosis; and (2) 
patients who presented with duodenal cancer, irrespective of whether duodenal surgery was 
performed. Patients were classified in 2 groups according to tumor status at preoperative 
endoscopy, as patients with benign duodenal adenomatosis or patients with duodenal cancer.
definitions and description of variables
Available medical data were evaluated, including clinical correspondence and endoscopic, 
surgical, and histopathology reports. The following data were recorded: type and indication 
of previous colorectal resection, APC mutation status, and details on endoscopic assessments, 
in particular on the assessment before duodenal surgery and follow-up assessments after 
duodenal surgery. Cancers were classified as either ampullary or duodenal; duodenal cancers 
were those that arose from nonampullary duodenum. Moreover, the mode of presentation 
was reviewed, assessing whether cancers were detected at surveillance endoscopy or whether 
cancer patients presented with disease signs or symptoms. The recommendations as depicted 
in Table 1 were generally used as standard for endoscopic surveillance in the Netherlands.
Complications after duodenectomy were classified as either in-hospital morbidity or long-term 
morbidity. Postoperative mortality was defined as 30-day mortality. Data on causes of death were 
collected, and causes were grouped as either related or unrelated to duodenal disease.
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The recurrence of adenoma was defined as the appearance of new adenomas after 
duodenectomy (Whipple, PPPD, PSD) in the reconstructed proximal small bowel involving the 
residual duodenal mucosa (after PPPD or PSD) and the proximal jejunum used for reconstruction. 
Patients with adenomas at the first postoperative follow-up endoscopy were excluded, because 
these adenomas might have been present before duodenectomy was performed. Time to adenoma 
recurrence was measured from date of resection until date of first endoscopic surveillance showing 
the recurrence of adenomas or the date of last endoscopic surveillance without recurrence. Any 
carcinoma arising in the reconstructed proximal small bowel was also recorded.
statistical analysis
Statistical analysis was performed using SPSS statistical software version 16.0 (SPSS, Chicago, IL). 
Frequency tables were provided for description of baseline characteristics. A group comparison 
was performed, primarily on the basis of tumor status at preoperative endoscopy. In addition, 
comparisons included groups defined by type of duodenectomy, surveillance status, and 
cancer localization. Differences on continuous variables including age at duodenal surgery 
were examined using Mann-Whitney U test. The Fisher’s exact test was used to compare 
discrete variables, including those representing complications after duodenectomy, and 
causes of death. Survival and adenoma recurrence data were analyzed by Kaplan-Meier survival 
analysis and Log Rank test. A p-value of <.05 (2-sided) was considered statistically significant.
resulTs
description of the study population
Of the 1,066 patients with FAP in the registry database, 53 patients (5%; 26 male, 27 female) 
met the criteria for inclusion. One male patient with duodenal cancer was excluded from all 
analyses because of missing clinical data. Subsequently, the study population comprised 52 
patients (25 male, 27 female) from 44 FAP families. The presence of a germline APC mutation 
had been confirmed by genetic testing in 44 patients (85%). Patient characteristics of the total 
study population and the subgroups classified by tumor status at preoperative endoscopy as 
either benign duodenal disease (n=36) or duodenal cancer (n=16), are summarized in Table 2. 
Patients’ tumor status, surgical approach, and outcome are shown in Figure 1.
All operative procedures were performed in large regional teaching hospitals or specialized 
university centers between 1975 and 2008. The following procedures were performed: Whipple 
(n=13), PPPD (n=8), PSD (n=22), duodenotomy with ampullectomy (n=1), and laparotomy with or 
without palliative intervention because of unresectable and/or metastatic cancer (n=7). In one 
patient, an operation was not performed because of unresectable ampullary cancer. Nearly 
all PSDs were performed in the most recent decade (Figure 2). Operative therapy for benign 
duodenal adenomatosis was performed at a median age of 48 years and duodenal cancer 
surgery at a median of 53 years (Mann-Whitney U test, p=.23).
Compared with patients with benign disease at preoperative endoscopy, patients with 
duodenal cancer at endoscopy had been diagnosed with colorectal cancer at primary colorectal 
surgery more often (6% vs 44%, respectively; Fisher’s exact test, p<.01).
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Table 2. Characteristics of the study population consisting of patients with FAP with benign duodenal 
adenomatosis and duodenal cancer at endoscopy.
Total study 
population
Cases with  
benign disease  
at endoscopy
Cases with 
duodenal cancer  
at endoscopy
Number of patients 52 (48% Male) 36 (47% Male) 16 (50% Male)
Median age at primary CR surgery (yr) 28 (range: 12-63) 28 (range: 12-49) 32 (range: 15-63)
Type of primary CR surgery
IRA 31 (60%) 21 (58%) 10 (62.5%)
IPAA 12 (23%) 10 (28%) 2 (12.5%)
Ileostomy 9 (17%) 5 (14%) 4 (25%)
Cases with cancer at primary CR surgery 9(1) (17%) 2 (6%) 7(1) (44%)
Rectum 3 - 3
Colon 8 2 6
Median age at duodenal surgery (yr) 49 (range: 31-69) 48 (range: 31-69) 53 (range: 32-67)
Spigelman stage at preoperative endoscopy
II 1 1 -
III 6 6 -
IV 29 29 -
Cancer 16 0 16
Duodenal cancer
Ampullary 12 2 10
Duodenal 7 0 6
Type of duodenal surgery
Whipple 13 (25%) 8 (22%) 5 (31%)
PPPD 8 (15%) 5 (14%) 3 (19%)
PSD 22 (42%) 22 (61%) -
Duodenotomy with ampullectomy 1 (2%) - 1 (6%)
Laparotomy with/without palliative intervention 7 (14%) 1 (3%) 6 (38%)
No surgery, irresectable cancer 1 (2%) - 1 (6%)
(1) In 2 cases synchronous cancer of colon and rectum was present at primary colorectal surgery.
Abbreviations: CR, colorectal; IRA, Ileorectal anastomosis; IPAA, Ileal pouch-anal anastomosis; Ileostomy, 
Proctocolectomy with ileostomy; Whipple, classical Whipple’s pancreaticoduodenectomy; PPPD, pylorus 
preserving pancreaticoduodenectomy; PSD, pancreas-sparing duodenectomy.
patients with benign duodenal adenomatosis at preoperative endoscopy
The 36 patients with benign duodenal adenomatosis at preoperative endoscopy were graded 
as follows: Spigelman II disease with high-grade dysplasia around the neopapilla 9 years after 
ampullectomy (n=1), and Spigelman III disease (n=6) or Spigelman IV disease (n=29). All patients 
were under surveillance except for one who underwent endoscopy for dyspepsia and was found 
to have Spigelman IV disease. Three patients previously had undergone surgical treatment for 
34
2
3
4
 
 
 
 
Total study population 
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2 Complications Whipple 
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1 Metastatic disease  
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1 Metastatic disease 
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13 Died 
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7 Metastatic disease/disease 
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Type of duodenal surgery 
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preoperative endoscopy 
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5 Whipple 
3 PPPD 
1 Duodenotomy 
6 Laparotomy 
1 No surgery 
 
Cancer 
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Benign disease 
n = 36 
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2 Died 
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4 Died 
median 16mo 
range 0-19mo 
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21 PSD 
Benign disease 
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Cancer 
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Figure 1. Flow diagram: tumor status at preoperative endoscopy, tumor status after duodenal surgery, 
type of duodenal surgery performed, outcome, and cause of death. Abbreviations: amp, ampullary; 
duod, duodenal; Whipple, classical Whipple’s pancreaticoduodenectomy; PPPD, pylorus preserving 
pancreaticoduodenectomy; PSD, pancreas-sparing duodenectomy; RectCa, rectal cancer; DuoCa, 
duodenal cancer; ThyrCa, cancer of thyroid gland.
duodenal adenomatosis, including duodenotomy with polypectomy (n=2) and ampullectomy 
with bile and pancreatic duct reconstruction (n=1).
Two patients (6%) with preoperative benign duodenal adenomatosis were diagnosed with cancer 
after a previous operation, including 1 ampullary carcinoma found at postoperative histopathology 
and 1 locally advanced ampullary tumor with liver metastasis found during laparotomy.
patients with duodenal cancer at preoperative endoscopy
The characteristics of 16 patients with duodenal cancer diagnosed at preoperative endoscopy 
are included in Table 3. Six of 16 patients were under surveillance: in 2, cancer was identified 
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by endoscopic surveillance, and 4 presented with signs or symptoms of disease. Two patients 
presented with symptoms 12 and 22 months after scheduled endoscopic surveillance, when 
their duodenal adenomatosis was graded as Spigelman III and IV disease, respectively. In the 
latter patient, the recommended surveillance interval was not followed because of additional 
morbidity. The other 2 symptomatic patients who underwent duodenotomy with ampullectomy 
and palliative laparotomy, respectively, previously were not considered candidates for 
prophylactic surgery because of a desmoids tumor and severe jejunal adenomatosis.
Ten of 16 patients were not under surveillance and had no upper gastrointestinal endoscopy 
performed for at least the previous 5 years: 8 patients presented symptomatically, 1 patient 
underwent his first surveillance endoscopy, and for 1 patient the mode of presentation was unknown.
Table 3. Characteristics of eighteen patients with duodenal cancer.
Case no Sex
Mutation Primary CR surgery Duodenal cancer and surgery Duodenal cancer and surgery (continued)
exon Codon Type Age (yr) CRC Mode of presentation Site TnM Type of surgery Age (yr) Survival (mo) Cause of death
1(1) F 15 1209 Ileostomy 27 - Surveillance (Spigelman IV) A HGD, TxNxM1(3) Lapar, no intervention 59 31 Metastatic disease, liver
2(1) F 5 178 IRA 29 - Surveillance (Spigelman IV) A T1NxMx PSD + antrum resection 60 0 Complications of surgery:
multi-organ failure
3 F 15 685 IRA 33 - Cholestasis A T1NxMx Whipple 57 Alive 86 -
4 M nk nk Ileostomy 29 Rectum Anaemia, syncope, melaena D T3NxM1 Lapar, GJS 62 9 Progression of disease,  
peritonitis carcinomatosis
5 F 11 499 Ileostomy 63 Colon Cholestasis A T3NxMx Whipple 67 133 Metastatic disease
from cancer of thyroid gland
6 M 11 516 IPAA 40 - nk A T3N1Mx PPPD 48 15 Metastatic disease
7 M nk nk IRA 40 - Anaemia, vomiting, 
weight loss
D T4NxM1(3) Lapar, GJS 57 9 Metastatic disease,
retroperitoneum and psoas
8 F 15 728 IRA 17 - Jaundice A TxN1M1(3) Lapar, GJS 32 8 Metastatic disease, liver
9 M 14 630 IRA 32 - Abdominal pain D T2N1Mx Whipple 58 48 Lung cancer
10 F 4 150 IRA 42 Colon Jaundice, vomiting A TxNxMx(3) No surgery 53 4(2) Progression of disease
11 M 13 554 IRA 25 - Surveillance (cancer) A T3N1Mx PPPD 53 76 Cardiovascular disease
12 M 13 554 IRA 25 - Surveillance (cancer) A T1N0M0(3) Duodenotomy with ampullectomy 59 Alive 37 -
13 F 12 541 IRA 36 Colon Jaundice, anaemia A TxNxMx Lapar, placement of billiary T-drain 47 3 Progression of disease
14 F 14 622 IRA 22 - Abdominal pain D T4NxM1 Lapar, repositioning of intra-
abdominal herniation
48 7 Metastatic disease,
liver and lung
15 M nk nk IRA 15 - First surveillance endoscopy D T2NxMx PPPD 49 192 Ischemic cerebrovascular disease
16 M 13 564 IPAA 18 Colon Jaundice A T1N0Mx Whipple 39 Alive 23 -
17 F 15 1464 Ileostomy 40 Colon, 
Rectum
Anaemia, weight loss A T4N0Mx Whipple 40 11 Metastatic disease from synchronous 
CR and duodenal cancer
18 F 15 1062 Ileostomy 36 Colon, 
Rectum
Abdominal pain D TxN1M1 Lapar, GJS, partial resection  
of small bowel
56 0 Complications of surgery: sepsis, 
bile leakage, bleeding
(1) Patients who underwent prophylactic duodenectomy, but were diagnosed with cancer after surgery.
(2) Patient died 4 months after diagnosis at endoscopy and radiologic assessment of irresectable ampullary cancer.
(3) No material for histopathological evaluation was obtained during duodenal surgery, TNM-classification based 
on histopathological examination of biopsy material from preoperative endoscopy, clinical observations and/
or additional radiologic evaluation.
Abbreviations: CR, colorectal; CRC, colorectal cancer; IRA, Ileorectal anastomosis; Ileostomy, Proctocolectomy 
with ileostomy; IPAA, Ileal pouch-anal anastomosis; A, Ampullary; D, Duodenal; TNM, Tumor Node Metastasis 
classification; HGD, High grade dysplasia; PSD, pancreas-sparing duodenectomy; Whipple, classical Whipple’s 
pancreaticoduodenectomy; PPPD, pylorus preserving pancreaticoduodenectomy; Lapar, laparotomy; GJS, 
gastrojejunostomy; nk, not known.
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Twelve patients presented with clinical signs or symptoms of duodenal cancer, including 
jaundice and/or cholestasis (n=6), anemia (n=4), abdominal pain (n=3), vomiting (n=2), weight loss 
(n=2), syncope (n=1), and melena (n=1). All patients presenting with jaundice and/or cholestasis 
had ampullary cancer, whereas all cases presenting with abdominal pain had duodenal cancer. 
complications after duodenectomy
Postoperative mortality and morbidity was evaluated for all patients who underwent 
duodenectomy (n=43, 35 for benign disease, 8 for duodenal cancer). Overall 30-day mortality 
was 5% (n=2). One patient died as the result of pericarditis with multiorgan failure 12 days after 
PSD for Spigelman IV disease histopathology: ampullary cancer), and one had an anastomotic 
Table 3. Characteristics of eighteen patients with duodenal cancer.
Case no Sex
Mutation Primary CR surgery Duodenal cancer and surgery Duodenal cancer and surgery (continued)
exon Codon Type Age (yr) CRC Mode of presentation Site TnM Type of surgery Age (yr) Survival (mo) Cause of death
1(1) F 15 1209 Ileostomy 27 - Surveillance (Spigelman IV) A HGD, TxNxM1(3) Lapar, no intervention 59 31 Metastatic disease, liver
2(1) F 5 178 IRA 29 - Surveillance (Spigelman IV) A T1NxMx PSD + antrum resection 60 0 Complications of surgery:
multi-organ failure
3 F 15 685 IRA 33 - Cholestasis A T1NxMx Whipple 57 Alive 86 -
4 M nk nk Ileostomy 29 Rectum Anaemia, syncope, melaena D T3NxM1 Lapar, GJS 62 9 Progression of disease,  
peritonitis carcinomatosis
5 F 11 499 Ileostomy 63 Colon Cholestasis A T3NxMx Whipple 67 133 Metastatic disease
from cancer of thyroid gland
6 M 11 516 IPAA 40 - nk A T3N1Mx PPPD 48 15 Metastatic disease
7 M nk nk IRA 40 - Anaemia, vomiting, 
weight loss
D T4NxM1(3) Lapar, GJS 57 9 Metastatic disease,
retroperitoneum and psoas
8 F 15 728 IRA 17 - Jaundice A TxN1M1(3) Lapar, GJS 32 8 Metastatic disease, liver
9 M 14 630 IRA 32 - Abdominal pain D T2N1Mx Whipple 58 48 Lung cancer
10 F 4 150 IRA 42 Colon Jaundice, vomiting A TxNxMx(3) No surgery 53 4(2) Progression of disease
11 M 13 554 IRA 25 - Surveillance (cancer) A T3N1Mx PPPD 53 76 Cardiovascular disease
12 M 13 554 IRA 25 - Surveillance (cancer) A T1N0M0(3) Duodenotomy with ampullectomy 59 Alive 37 -
13 F 12 541 IRA 36 Colon Jaundice, anaemia A TxNxMx Lapar, placement of billiary T-drain 47 3 Progression of disease
14 F 14 622 IRA 22 - Abdominal pain D T4NxM1 Lapar, repositioning of intra-
abdominal herniation
48 7 Metastatic disease,
liver and lung
15 M nk nk IRA 15 - First surveillance endoscopy D T2NxMx PPPD 49 192 Ischemic cerebrovascular disease
16 M 13 564 IPAA 18 Colon Jaundice A T1N0Mx Whipple 39 Alive 23 -
17 F 15 1464 Ileostomy 40 Colon, 
Rectum
Anaemia, weight loss A T4N0Mx Whipple 40 11 Metastatic disease from synchronous 
CR and duodenal cancer
18 F 15 1062 Ileostomy 36 Colon, 
Rectum
Abdominal pain D TxN1M1 Lapar, GJS, partial resection  
of small bowel
56 0 Complications of surgery: sepsis, 
bile leakage, bleeding
(1) Patients who underwent prophylactic duodenectomy, but were diagnosed with cancer after surgery.
(2) Patient died 4 months after diagnosis at endoscopy and radiologic assessment of irresectable ampullary cancer.
(3) No material for histopathological evaluation was obtained during duodenal surgery, TNM-classification based 
on histopathological examination of biopsy material from preoperative endoscopy, clinical observations and/
or additional radiologic evaluation.
Abbreviations: CR, colorectal; CRC, colorectal cancer; IRA, Ileorectal anastomosis; Ileostomy, Proctocolectomy 
with ileostomy; IPAA, Ileal pouch-anal anastomosis; A, Ampullary; D, Duodenal; TNM, Tumor Node Metastasis 
classification; HGD, High grade dysplasia; PSD, pancreas-sparing duodenectomy; Whipple, classical Whipple’s 
pancreaticoduodenectomy; PPPD, pylorus preserving pancreaticoduodenectomy; Lapar, laparotomy; GJS, 
gastrojejunostomy; nk, not known.
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leak with abdominal sepsis and died 19 days after Whipple for Spigelman IV disease. A third 
patient died 7 months after undergoing the Whipple procedure for Spigelman IV disease. The 
postoperative course was complicated by necrotizing pancreatitis, enterocutaneous fistula 
formation, and thrombosis of the superior caval vein. In all 3 cases of mortality, patients were 
surgically treated for what was considered to be benign duodenal disease.
An overview of all postoperative complications is shown in Table 4. A total of 33 in-hospital 
complications in 21 patients (49%; 17 benign disease, 4 cancer) were reported. There was no significant 
difference found in number of patients experiencing in-hospital complications when we compared 
patients with benign disease and patients with cancer at preoperative endoscopy (Fisher’s exact test, 
p=.62), and when we compared the 3 types of duodenectomy (Fisher’s exact test, p=.20).
Seven patients (16%; 5 benign disease, 2 cancer) needed unplanned relaparotomy because 
of intra-abdominal infection (n=3), hemorrhage (n=2), or anastomotic leakage (n=1). In 
1 patient, no abnormalities were found, and the patient was treated for pancreatitis. A total of 
10 long-term complications in 8 patients (19%; seven benign disease, 4 cancer) were reported, 
including 1 patient who previously suffered in-hospital morbidity.
survival and causes of death
As shown in Figure 1, 4 of 36 patients (11%) with benign duodenal disease at endoscopy died 
of causes related to their duodenal disease, including metastatic duodenal cancer (n=1) and 
postoperative mortality after duodenectomy (n=3); 2 other patients (6%) died of unrelated causes.
Nine of 16 patients (56%) diagnosed with cancer at preoperative endoscopy died of causes 
related to duodenal cancer, including metastatic disease or progression of disease (n=7), 
metastatic disease originating from either duodenal or synchronous rectal and colonic cancer 
(n=1), and postoperative morbidity after palliative laparotomy (n=1). Four patients (25%) died of 
unrelated causes, and 3 patients (19%) were alive at time of study closure.
Figure 2. Number and type of surgical procedures performed in five year periods. Abbreviations: Whipple, 
classical Whipple’s pancreaticoduodenectomy; PPPD, pylorus preserving pancreaticoduodenectomy; PSD, 
pancreas-sparing duodenectomy.
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The observed differences in distribution of causes of death for patients with benign 
duodenal disease or cancer at preoperative endoscopy, as either related or unrelated to 
duodenal disease, were not significant (Fisher’s exact test, p=.14). Survival of patients with 
cancer at preoperative endoscopy was less than the survival of patients who underwent 
prophylactic surgical resection for benign disease (Figure 3; log-rank test, p<.001).
When considering all 18 patients with cancer, the prognosis of duodenal cancer was 
deemed poor; the Kaplan-Meier estimated median survival was 11 months. There was a 
difference in estimated median survival of patients who underwent duodenectomy and 
patients who underwent palliative intervention (76 vs 8 months, log-rank test, p<.05). 
Estimated median survival rates for cancer patients under surveillance versus cancer patients 
not under surveillance were 9 and 11 months, respectively (log-rank test, p=.54). The difference 
in estimated median survival after duodenal surgery between patients with ampullary cancer 
and duodenal cancer (15 vs 9 months, respectively) was not significant (log-rank test, p=.77). 
recurrence
Data on endoscopic follow-up were available in 32 patients. Adenomas were seen during follow-up 
endoscopy in 18 patients. Four patients (13%) with adenomas at the first postoperative follow-up 
endoscopy were excluded because these adenomas might have been present before duodenectomy 
was performed. Hence, in 14 of 28 patients (50%) adenomas recurred with a Kaplan-Meier estimated 
median time from surgery to recurrence of 75 months. Recurrence of adenomas was seen in 3 of 7 
patients after Whipple (43%), 4 of 6 after PPPD (67%), and 7 of 15 after PSD (47%), with estimated 
Table 4. Patients with complications after duodenectomy for benign duodenal disease or cancer at 
preoperative endoscopy.
Group n Total morbidity In-hospital morbidity(1) Long-term morbidity(2)
Benign disease at endoscopy 35 23(3) (66%) 17(3) (49%) 7(3) (20%)
Whipple 8 6 5 1
PPPD 5 3(3) 3(3) 1(3)
PSD 22 14 9 5
Cancer at endoscopy 8 5 (63%) 4 (50%) 1 (13%)
Whipple 5 4 4 0
PPPD 3 1 0 1
Overall 43 28 (65%) 21 (49%) 8 (19%)
(1) In-hospital morbidity: intra-abdominal abscess (n=6), fistula formation (n=5), anastomotic leakage (n=6), 
pancreatitis (n=2), sepsis (n=4), postoperative hemorrhage (n=4), surgical site infection (n=2), trombo-embolism 
of superior caval vein (n=2, in 1 case with pulmonary embolism), occlusion of branches of the hepatic artery with 
local ischemia of liver tissue adjacent to the falciform ligament (n=1), and pericarditis with multi-organ failure (n=1).
(2) Long-term morbidity: (chronic) pancreatitis (n=3), incisional hernia (n=1), stenosis of the enterobiliary 
anastomosis (n=2, in 1 case with cholangitis), cutanous fistula and abscess formation resulting in sepsis induced 
by migrated mesh into the jejunum (n=1), anastomotic erosions/ulcer (n=3).
(3) Includes one patient with both in-hospital and long-term morbidity.
Of note: one patient can have more than one complication.
Abbreviations: Whipple, classical Whipple’s pancreaticoduodenectomy; PPPD, pylorus preserving 
pancreaticoduodenectomy; PSD, pancreas-sparing duodenectomy.
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median time from surgery to recurrence of 103, 53, and 66 months, respectively (log rank test, 
p=.28). The median score in points by Spigelman stage at recurrence was 5 (range, 3-7), with 7 cases 
of Spigelman I, 6 cases of Spigelman II, and 1 case of Spigelman III disease. Onepatient was diagnosed 
with cancer at the hepaticojejunostomy 156 months after PPPD for duodenal cancer.
discussion
In the present study, 18 patients of 1,066 patients with FAP in the Dutch registry (1.7%) were 
diagnosed with duodenal cancer between the years 1975 and 2008. Recently, a comparable rate of 
1.9% was reported on the basis of 20 cases of cancer diagnosed in the St. Mark Hospital Polyposis 
Registry between 1969 and 2005.16 Both studies suggest that the prevalence of duodenal cancer 
might be less than the 4.5% reported in the late 1980s.11 It is unclear whether this difference in 
prevalence reflects a true decrease in duodenal cancer prevalence that subsequently might be 
attributed to improved management of duodenal disease in patients with FAP.
Our results support previous findings on the poor prognosis of duodenal cancer in patients 
with FAP.11,14-16 Notably, in almost one-half of the patients presenting with duodenal cancer at 
endoscopy, the cancer stage was too advanced to perform a curative resection. The aim of 
surveillance programs is to identify patients with advanced duodenal adenomatosis before 
cancer develops. In the majority of our cancer cases, either no surveillance was performed or the 
Figure 3. Kaplan-Meier curve: survival after duodenal surgery stratified for tumor status at preoperative 
endoscopy: benign duodenal adenomatosis or duodenal cancer. (Duodenal surgery includes: classical 
Whipple’s pancreaticoduodenectomy; pylorus preserving pancreaticoduodenectomy; pancreas-sparing 
duodenectomy; laparotomy with or without palliative intervention, and duodenotomy with ampullectomy.) 
Of note: in one cancer patient no duodenal surgery was performed and survival (4 months) was measured 
from diagnostic endoscopy. 
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recommendation on surveillance interval was not followed. In contrast, nearly all patients with 
benign disease were under surveillance. The survival of patients who underwent prophylactic 
duodenectomy was far better. Our findings imply that if appropriate surveillance intervals were 
followed, nearly one-half of the cancers could have been diagnosed at a treatable stage or 
could even have been prevented by timely prophylactic intervention. Interestingly, patients 
with duodenal cancer had been diagnosed with colorectal cancer at previous initial colorectal 
surgery more often compared with patients with benign disease. All patients with FAP, but 
particularly patients diagnosed with cancer previously at initial colorectal surgery, should be 
motivated to follow strictly the recommended surveillance intervals.
Notwithstanding this recommendation, limitations in the sensitivity of endoscopic 
surveillance should be kept in mind. Two patients (6%) who underwent surgery for benign 
duodenal adenomatosis were diagnosed with cancer on the basis of histopathologic 
examination of the resected tissue. This finding illustrates that the presence of cancer may 
be underestimated by taking endoscopic biopsies of adenomas, most probably because of 
sampling error and the small size of the biopsies taken.30,31 Moreover, although the Spigelman 
classification has been shown to correlate with the risk of developing cancer17, it seems 
inadequate to assess the individual patient’s risk of cancer accurately. The classification 
focuses primarily on nonampullary duodenal disease, and the evaluation of ampullary disease 
should be taken into account separately.16 In patients with advanced duodenal adenomatosis, 
endoscopic ultrasonography may provide additional information on malignant invasion.32,33 
Fludeoxyglucose positron emission tomography (FDG-PET) has been shown to differentiate 
between adenomas and carcinomas, detecting all cancer cases in patients with FAP with 
duodenal adenomas.34 Although the role of FDG-PET at present has not been established firmly, 
it represents a promising modality in guiding treatment decisions concerning duodenectomy 
that warrants further attention.
Ideally, a prophylactic procedure should carry no risk of death and have low morbidity 
while preventing future disease. The 30 patients alive after extensive duodenectomy for benign 
duodenal adenomatosis could be considered as beneficiaries of prophylactic duodenectomy. 
Overall postoperative morbidity and mortality, however, is substantial. All 3 cases or mortality in 
our series occurred in procedures that were intended as prophylactic. In addition, postoperative 
in-hospital morbidity occurred in one-half of the patients, either after prophylactic resection or 
cancer treatment. In previous studies authors have revealed comparable rates of postoperative 
morbidity of 38-60% and mortality of 0-12% after duodenectomy (PSD and PPPD) in patients with 
FAP.25,35-37 It has been suggested that patients with FAP might be at greater risk of complications 
compared with patients without FAP because of more demanding operative conditions related 
to more technically demanding anastomotic reconstruction of a soft pancreas with a nondilated 
biliary and pancreatic ductal system, and adhesions caused by previous colorectal surgery.25,37 
Furthermore, a preoperatively undetected nonfusion of the pancreatic duct (pancreas divisum) 
was the cause of postoperative complications in patients with FAP after PSD.25,38 To prevent 
these complications, magnetic resonance cholangiopancreatography might be indicated in 
standard preoperative evaluation for PSD.
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Recurrence of adenomas in the reconstructed proximal small bowel after duodenectomy 
occurred in one-half of all patients with available postoperative endoscopic follow-up data within 
just more than 6 years, and 1 patient developed cancer after PPPD at the hepaticojejunostomy. 
These findings are in line with previous reports of recurrence of adenomas after extensive 
surgery15,39 and malignant degeneration in residual duodenal mucosa after duodenectomy.28 As 
shown by our finding of 13% of patients with adenomas at the first postoperative endoscopy, 
adenomas may already be present in the jejunum used for construction, especially in patients 
with more advanced duodenal adenomatosis.40 To avoid this possibility, preoperative 
inspection of the jejunum by single- or double-balloon enteroscopy is advised. Our findings 
support the recommendation that upper gastrointestinal surveillance should be continued 
after duodenectomy, because the risk of cancer is not entirely eliminated.28,35,36,39
The strength of our study is that we reviewed data covering the total Dutch population 
of patients with FAP who were receiving medical care in both regional hospitals as well as 
academic referral centers. We evaluated a considerably large cohort of patients with extensive 
follow-up, including not only patients with duodenal cancer, but also patients who underwent 
prophylactic duodenectomy for advanced duodenal adenomatosis. The number of cancer cases 
involved, however, is small, and power might therefore be inadequate to prove differences to 
be statistically significant. Study limitations include the retrospective study design, resulting 
possibly in a cohort effect. Missing data, although limited, might have biased the results, 
particularly where it concerns clinical follow-up data, resulting in less reported long-term 
postoperative morbidity rate and adenoma recurrence.
In conclusion, our study illustrates the poor prognosis of duodenal cancer, justifying in our 
opinion an aggressive prophylactic surgical approach to advanced benign duodenal disease, 
despite the substantial risk of morbidity and mortality. Strict adherence to the recommended 
surveillance intervals is essential for well-timed operative intervention. Treatment decisions are 
to be made by critically evaluating a patient’s individual characteristics, taking into account age, 
history of colorectal cancer, previous abdominal surgery, course of the Spigelman classification 
over time, previous treatment of duodenal adenomatosis, and additional morbidity. Even 
after radical duodenal resection, patients have to bear the continuing burden of endoscopic 
surveillance and threat of cancer. 
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ABSTRACT
With the widespread use of esophagogastroduodenoscopy, an increasing number of sporadic 
duodenal adenomas are diagnosed. An optimal algorithm for management has not been fully 
defined. Accumulating data suggest an association with colorectal neoplasms. Aim of this study 
was to evaluate management, outcome, and follow-up of patients with sporadic duodenal 
adenomas and assess the presence of colorectal neoplasms. Patients diagnosed with sporadic 
duodenal adenomas at our institute from 1986 until 2008 were retrospectively reviewed. Data 
were collected from medical records. Fifty-four patients (28 men, 52%) were diagnosed with a 
sporadic duodenal adenoma at a median age of 59 years (range, 27 to 84y); 33 patients (61%) 
underwent endoscopic or surgical intervention, 5 (9%) were only followed endoscopically, 
and 16 (30%) underwent no intervention or follow-up. Complete endoscopic removal was 
accomplished in at least 81% of cases, and no complications were reported; surgical intervention 
was complicated in 4 patients, with 1 resulting in death. Adenoma recurrence was 20% at a median 
follow-up of 18 months (range, 4 to 54mo), but no carcinoma developed. Colorectal neoplasms 
were found in 16 of 29 patients (55%) who underwent colonoscopy, including 2 cancers (7%), 
7 advanced adenomas (24%), and 7 nonadvanced adenomas (24%). In conclusion, although 
no consistent approach to management of sporadic duodenal adenomas was followed, no 
duodenal carcinoma developed during the follow-up. Endoscopic intervention is preferred 
over surgical intervention, whenever possible. Once complete removal is ascertained, there is 
no strict indication for regular follow-up esophagogastroduodenoscopy, especially in elderly 
patients or patients with relevant comorbidity. Colonoscopic assessment is warranted in all 
patients diagnosed with sporadic duodenal adenomas.
Keywords: sporadic duodenal adenomas; colorectal neoplasms; management; recurrence; follow-up
Abbreviations: FAP, familial adenomatous polyposis; EGD, esophagogastroduodenoscopy; EMR, 
endoscopic mucosal resection; GI, gastrointestinal; PD, pancreaticoduodenectomy
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Although duodenal adenomas are common lesions in patients with familial adenomatous 
polyposis (FAP) and attenuated FAP,1 sporadic duodenal adenomas are rare. With the widespread 
use of esophagogastroduodenoscopy (EGD) for evaluation of upper gastrointestinal (GI) 
complaints, the number of patients found to have duodenal lesions has increased.2-6 The 
prevalence of sporadic duodenal polyps during routine EGD was reported to range from 0.3% 
to 4.6%, but only 7% of the polyps were dysplastic lesions or adenomas.6 In accordance with 
the colorectal adenoma-to-carcinoma sequence, these small bowel adenomas are regarded 
as noninvasive premalignant lesions. This is supported by the findings of occurrence of 
adenocarcinoma within small bowel adenomas and the presence of residual adenomatous 
mucosa adjacent to or within most carcinomas.7,8
It is generally recommended to resect these lesions, with local duodenotomy or radical 
pancreaticoduodenectomy (PD) being the most common method of resection.9 More recently, 
several studies on endoscopic management of duodenal adenomas, including endoscopic 
mucosal resection (EMR) and endoscopic snare polypectomy or ampullectomy, report 
encouraging results.2,10-16
However, an optimal algorithm for treatment and follow-up of patients with sporadic 
duodenal adenomas has not yet been fully defined.17 In addition, there are accumulating 
data that support a clinically relevant association between sporadic duodenal adenomas and 
colorectal neoplasms, and it has been stated that patients with sporadic duodenal adenomas 
should therefore be screened by performing colonoscopy.18-25
To optimize patients’ management, the aim of this retrospective study was to evaluate 
the management of the sporadic duodenal adenomas, treatment outcome, and follow-up. In 
addition, we assessed the prevalence of colorectal adenomas and their pathologic features in 
patients with sporadic duodenal adenomas.
PATIenTS AnD MeTHODS
This study was conducted according to International Conference on Harmonization Good 
Clinical Practice and complied to the principles of the amended declaration of Helsinki and 
Dutch legislation. The electronic database of the Department of Pathology at the tertiary 
referral Hospital Radboud University Nijmegen Medical Centre was retrospectively reviewed 
to identify all patients diagnosed with a duodenal adenoma in the time period from January 
1st 1986 until December 31st 2008. Patients diagnosed with familial polyposis syndromes were 
not included.
Medical records, both on paper and electronic, were reviewed for patient characteristics. 
Data on features of duodenal adenoma were collected from EGD and histopathology reports, 
including endoscopic size and location, degree of dysplasia, and histologic type. When degree 
of dysplasia was scored as “intermediate” (22 of 54 cases), tissue sections were revised and 
classified as low-grade or high-grade dysplasia by an expert pathologist (IDN) according to the 
Vienna classification.26,27 When histologic type was not reported (12 of 54 cases), tissue sections 
were reevaluated by the same expert pathologist.
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Type of endoscopic and surgical intervention for duodenal adenomas and any complication 
were recorded. Total follow-up time was defined as the time interval from EGD on which the 
adenoma was diagnosed to the last EGD performed. Follow-up data were analyzed until study 
closure, December 31st 2010. Recurrence was defined as identification of an adenoma at the 
same localization of a previously successfully removed adenoma or at a different localization 
in the duodenum.
Finally, endoscopic and histopathological features of premalignant lesions found during 
any colonoscopic assessments performed in patient’s medical history, before or after the 
duodenal adenoma was diagnosed, were recorded. When multiple lesions were found, the 
most advanced colorectal lesion was considered.
Advanced adenomas (duodenal and colorectal) were defined as: size ≥10 mm, a villous 
component, and/or high-grade dysplasia. When endoscopic size was not specified, classification 
was solely on the basis of histopathologic features.
Patients were classified in 3 groups: (1) “Intervention”: patients who underwent either 
endoscopic or surgical intervention; (2) “Wait and see”: patients who were followed 
endoscopically; and (3) “No intervention or follow-up.”
statistical analysis
Statistical analysis was performed using SPSS statistical software version 16.0 (SPSS, Chicago, IL). 
Frequency tables were provided for description of patients and adenoma characteristics. 
Patient and adenoma characteristics were described by use of median and range for continuous 
variables and percentages for categorical variables. Group comparison was performed on the 
basis of the classification “Intervention” versus “Wait and see” versus “No intervention/follow-
up.” Differences in age at diagnosis were examined using Kruskal-Wallis test. Pearson χ2 test was 
used to compare discrete variables. Fisher exact test was used where appropriate. Survival data 
were analyzed by Kaplan-Meier survival analysis and log rank test. P-values <0.05 (2-sided) were 
considered statistically significant.
ReSULTS
patient and adenoma characteristics
Fifty-four patients (28 men, 52%) with sporadic duodenal adenomas were identified, with 
a median age at diagnosis of 59 years (range, 27 to 84y). Characteristics of the patients and 
the adenoma diagnosed are shown in Table 1, for the total study population and the three 
predefined groups. Characteristics of treatment, follow-up, recurrence, and survival are shown 
in Figure 1. Indications for EGD were the following: abdominal pain (n=17, 31%), anemia (n=10, 
19%), follow-up for esophageal or gastric lesions (n=9, 17%), weight loss (n=6, 11%), dysphagia 
(n=4, 7%), symptoms of reflux disease (n=3, 6%), upper GI bleeding (n=2, 4%), follow-up for 
peptic ulcer disease (n=1, 2%), diagnostic workup for liver metastases with unknown primary 
cancer (n=1, 2%), and unknown indication (n=1, 2%).
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During the time period reviewed, the mean number of diagnostic EGDs performed at our 
Department of Gastroenterology and Hepatology each year was approximately constant, on an 
average 1500 procedures each year. The increase in number of sporadic duodenal adenomas 
diagnosed per 4-year time interval is visualized in Figure 2. In the recent years from 2005 to 
2008, 11 of 19 adenomas (58%) were small adenomas (<5 mm); in the years before 2005, only 7 of 
the 18 adenomas (39%), of which size was specified, were small (χ2, p=0.248).
At study closure, 21 of 54 patients (39%) had died. Median age at death was 69 years (range, 56 
to 92y). Overall estimated median of survival after diagnosis of sporadic duodenal adenoma was 
13 years (Kaplan-Meier, 95% confidence interval, 4-22y). Survival differed significantly between 
Table 1. Patient and duodenal adenoma characteristics for the overall study population and predefined 
subgroups ‘Intervention group’, ‘Wait and see group’, and ‘No intervention/follow-up group’.
Total Intervention Wait and see
no 
intervention/
follow-up p-value
Patients 54 33 (61%) 5 (9%) 16 (30%)
Gender Male 28 (52%) 15 (45%) 4 (80%) 9 (56%) .389(1)
Female 26 (48%) 18 (55%) 1 (20%) 7 (44%)
Age (yrs, median 
[range])
60 [27-85] 58 [27-84] 69 [40-74] 60 [46-83] .302(2)
Duodenal adenomas
Localisation Bulb 17 (32%) 9 (27%) 2 (40%) 6 (38%) .522(1)
Post bulbar 22 (41%) 17 (52%) 1 (20%) 4 (25%)
Multiple 4 (7%) 2 (6%) 1 (20%) 1 (6%)
Ampulla 5 (9%) 4 (12%) 0 (0%) 1 (6%)
Not specified 6 (11%) 1 (3%) 1 (20%) 4 (25%)
Endoscopic size <5mm 18 (33%) 11 (33%) 1 (20%) 6 (38%) .068(1)
≥5, <10mm 6 (11%) 2 (6%) 0 (0%) 4 (25%)
≥10mm 13 (24%) 9 (27%) 3 (60%) 1 (6%)
Not specified 17 (31%) 11 (33%) 1 (20%) 5 (31%)
Dysplasia Low grade 47 (87%) 26 (79%) 5 (100%) 16 (100%) .089(1)
High grade 7 (13%) 7 (21%) 0 (0%) 0 (0%)
Histological type Tubular 26 (48%) 14 (42%) 2 (40%) 10 (63%) .697(1)
Tubulovillous 17 (31%) 12 (36%) 2 (40%) 3 (19%)
Villous 11 (20%) 7 (21%) 1 (20%) 3 (19%)
Non-advanced/
advanced
Non-advanced 21 (39%) 10 (30%) 1 (20%) 10 (63%) .061(1)
Advanced 33 (61%) 23 (70%) 4 (80%) 6 (38%)
(1) Pearson’s Chi-square/Fisher’s exact test test.
(2) Kruskal Wallis test.
p-values of <0.05 (two-sided) were considered statistically significant. Advanced adenomas were defined as: 
size ≥10mm, a villous component, and/or high-grade dysplasia.
52
Figure 1. Management and outcome of patients diagnosed with duodenal adenoma. Abbreviations: CI, 
confidence interval; FU, follow-up.
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Figure 2. Number of patients diagnosed with a sporadic duodenal adenomas per 4 year period at the 
Radboud University Nijmegen Medical Centre.
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the 3 groups (log rank, p=0.004, Figure 3) mainly between the “Intervention group” and “No 
intervention/follow-up group” (log rank, p=0.001). Causes of death were not related to the 
duodenal adenoma, except for 1 patient who died of complications after a Whipple procedure.
intervention group
In 33 of 54 patients (61%), with a median age at diagnosis of 58 years (range, 27 to 84y), an 
intervention for the sporadic adenoma was performed.
In 27 patients (50%) initial therapy was endoscopic intervention, including removal 
by taking biopsies (n=18), argon plasma coagulation (n=5), and snare polypectomy (n=4). 
In  22 patients (81%), complete endoscopic removal of the adenoma was accomplished, in 
1 treatment session in 20 cases, in 3 sessions in 1 case, and in 4 sessions in 1 case. Three patients 
in whom complete removal was not accomplished in 1 session were still under treatment at 
study closure. In 2  patients complete endoscopic removal was not accomplished; 1 patient 
needed surgery, and in 1 patient further treatment and follow-up was terminated because 
of comorbidity (mental retardation). No complications were reported after any of the 
endoscopic interventions.
In 6 patients (11%), initial therapy was surgical intervention in all cases for an advanced 
duodenal adenoma. Factors that were considered as decisive to perform surgery included signs 
of active bleeding (n=1), large size of the adenoma (n=3), presence of high-grade dysplasia 
(n=3), and/or ampullary localization (n=2). One patient underwent surgical intervention after 
failed initial treatment by snare polypectomy of a large ampullary adenoma with high-grade 
dysplasia. In total, 7 surgical procedures were performed: 3 duodenotomies with polypectomy/
ampullectomy, 2 partial duodenectomies, 1 pylorus sparing PD, and 1 classical Whipple PD 
(Whipple). Histopathological examination of the resected specimen did not reveal cancer in 
Figure 3. Survival after diagnosis of sporadic duodenal adenoma.
54
any of these cases. Complications after surgical interventions were reported in 4 of 7 cases 
(57%), including 2 cases after duodenotomy (liver abscess, anemia/pneumonia), 1 after 
PD (anastomotic leak and pancreatic fistula with sepsis), and 1 after Whipple (necrotizing 
pancreatitis and abdominal infection with subsequent multiple organ failure resulting in death 
25 days after surgery).
Endoscopic follow-up was performed in 30 of the 33 patients (91%) who underwent 
intervention, with a median follow-up of 25 months (range, 2 to 158mo). Duodenal adenoma 
recurred in 6 of 30 patients (20%) who underwent follow up at a median of 18 months (range, 
4 to 54mo), an advanced adenoma in 3 patients, and a nonadvanced in 3 patients. None of 
the patients developed duodenal cancer. No endoscopic follow-up was performed in 
3  of  the 33  patients (9%) who underwent an intervention, including the patient who died of 
complications after Whipple, 1 patient with comorbidity (mental retardation), and 1 patient for 
whom no follow-up was planned.
Wait and see group
Five of 54 patients (9%), with a median age at diagnosis of 69 years (range, 40 to 74y), did not 
undergo an endoscopic or surgical intervention, but were followed endoscopically. Specific 
motivation for the choice of “Wait and see” could not be identified from the medical records in 
each of these cases. Decisive factors that were mentioned included a high age at diagnosis and 
too much comorbidity to undergo surgical intervention for adenomas with low-grade dysplasia 
that were too large to resect endoscopically. Median follow-up was 23 months (range, 1 to 
56mo). No changes in size or histopathological features were reported during follow-up, and 
no additional duodenal adenomas were found.
no intervention/follow-up group
Sixteen of 54 patients (30%) with a median age at diagnosis of 60 years (range, 46 to 83y) 
underwent no therapeutic intervention or endoscopic follow-up, including 6 patients (38%) 
with an advanced duodenal adenoma. Particularly in this group, significant comorbidity was 
noted, including local progression or metastatic disease of cancer (kidney, lung, pancreas, 
esophagus, mamma, and larynx), mental retardation, Morbus Steinert, chronic obstructive 
pulmonary disease with chronic heart failure, and liver cirrhosis. Because of comorbidity, in 
over half of patients, life expectancy was limited at time of diagnosis of duodenal adenoma.
colonoscopy findings
In 29 of 54 patients (54%), a colonoscopy was performed at any time in patient’s medical history, 
as shown in Table 2. Colorectal neoplasms were found in 16 of 29 patients (55%). Two patients 
(7%) were diagnosed with colorectal cancer: 1 with a carcinoma in the transverse colon (tumor, 
node, metastasis stage unknown) and 1 with an adenocarcinoma in the cecum (T3N1M0). 
Cancers were diagnosed 7 years before and 10 years after diagnosis of duodenal adenoma, 
respectively. Another 14 patients (48%) had at least 1 colorectal adenoma, including 7 patients 
(27%) with an advanced adenoma. In 1 patient the (nonadvanced) adenoma was localized in the 
right hemicolon, in all other patients adenomas were localized in the left hemicolon. We found 
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no significant differences in number of patients with colorectal neoplasms (nonadvanced 
adenoma, advanced adenoma, or cancer) comparing patients with nonadvanced or advanced 
duodenal adenomas (χ2/Fisher exact, p>0.05; Table 2). First diagnosis of a colorectal neoplasm 
(not necessarily the most advanced lesion) was at a median of 4 months before diagnosis of 
sporadic duodenal adenoma with a wide range of 20 years before and 10 years after diagnosis 
of sporadic duodenal adenoma. The diagnosis of a sporadic duodenal adenoma was specifically 
stated as indication for colonoscopy in only 8 patients (15%). In these cases, colonoscopy 
was performed at a median of 6 months (range, 0 to 25mo) after diagnosis. In a ninth 
patient, with extensive comorbidity, presence of colorectal neoplastic lesions was examined 
by doublecontrast barium enema 3 months after diagnosis. In 4 of these 9 patients (44%), 
colorectal adenomas were found, of which 1 was an advanced adenoma.
DISCUSSIOn
Duodenal adenomas are increasingly encountered, which is explained by the widespread use of 
EGD in patients with upper GI complaints.2-6 We also found an increase in incidence of duodenal 
adenomas over the past decades, whereas the number of performed EGDs remained constant. 
Improved endoscopic techniques that enhance visualization of smaller lesions might explain 
the increase in incidence, as illustrated by our observation of an (not significant) increase in 
proportion of smaller adenomas in more recent years.
Abdominal pain and anemia were the most common indications for EGD. These and a variety 
of other nonspecific symptoms, including esophageal reflux, nausea and vomiting, dyspepsia, 
and GI bleeding, were previously reported as indication for EGD on which adenomas were 
found.12,14,18,22 In studies focusing on ampullary adenomas, jaundice and pancreatitis were also 
Table 2. Colonoscopic findings in patients with duodenal adenomas (total group and non-advanced 
vs. advanced duodenal adenomas).
Duodenal adenomas
p-valueTotal non-advanced Advanced
Number of patients 54 21 33
Number of patients who underwent 
colonoscopy
29 (54%) 11 (52%) 18 (55%) 1.000(1)
Colorectal neoplasm found
All colorectal neoplasms 16 (55%) 5 (45%) 11 (61%) .466(1)
Cancer or advanced adenoma 9 (31%) 2 (18%) 7 (39%) 1.000(1)
Cancer 2 (7%) 0 (0%) 2 (11%)
Advanced adenoma 7 (24%) 2 (18%) 5 (28%)
Non-advanced adenoma 7 (24%) 3 (27%) 4 (22%)
(1) Pearson’s χ2/Fisher’s exact test test.
p-values of <0.05 (two-sided) were considered statistically significant. Advanced adenomas (duodenal and 
colorectal) were defined as: size ≥10mm, a villous component, and/or high-grade dysplasia.
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common symptoms at presentation.10,16,28 It is unlikely that all of these symptoms are directly 
related to the presence of a duodenal adenoma. More likely, duodenal adenomas are coincidental 
findings in many cases, implicating that a substantial number of adenomas are never discovered. 
In addition, we found a relatively low number of ampullary adenomas in our series.8,18,23 This 
suggests that ampullary adenomas, which are more likely to undergo malignant transformation 
compared with adenomas originating elsewhere in the duodenum,8,29 are more frequently missed 
at diagnostic EGDs. This could be because of the use of front-viewing endoscopes and no side-
viewing endoscopes during standard diagnostic EGD. Despite the fact that numerous sporadic 
duodenal adenomas are probably not detected, prevalence of sporadic duodenal carcinomas in 
the general population is estimated to be low.30,31
The endoscopic interventions performed were standard biopsy, snare polypectomy, 
and argon plasma coagulation. Complete endoscopic removal was accomplished in a high 
percentage of cases, most requiring only one treatment session, as has been noted in a 
recently published study.14 No complications of endoscopic treatment occurred in our patients. 
In contrast, surgical treatment resulted in a significant complication rate and even one death. 
Although we recognize that some duodenal lesions cannot be treated endoscopically and 
the endoscopic removal rate is therefore subject to selection bias, findings on complications 
emphasize the preference of endoscopic treatment over surgery. Techniques of endoscopic 
removal are not standardized.17 Recent studies propose EMR as option for treatment but point 
at the relatively high incidence of bleeding as complication.11,13,15,32 Important advantage of EMR 
is that the technique permits complete and undamaged removal of the adenoma tissue for 
histopathological examination, reducing the chance of missing malignant foci because of 
sampling error and the small size of the standard biopsies taken. Complete endoscopic removal 
of the adenoma should therefore be the preferred treatment option, particularly in patients 
without significant comorbidity. Patients who have severe comorbidity at the time of diagnosis 
do not seem to benefit from treatment, as illustrated by the short survival in the subgroup of 
patients that underwent no intervention.
We found a recurrence rate of 20% in patient who underwent endoscopic or surgical 
intervention. This finding is comparable to previously reported rates ranging from 0% to 
37%.12-15 In patients who did not undergo intervention and who were followed endoscopically, 
no progression or additional adenomas were reported at follow-up. Although adenoma 
recurrence was considerable, none of the patients in our study cohort developed duodenal 
cancer during the follow-up period. Consistent with published data of a mean/median age at 
diagnosis of the sporadic duodenal adenoma ranging from 57 to 69 years,10-16,18-20,23-25 we found 
a median of 59 years at the transition of middle to old age. The average time of progression 
from adenoma to carcinoma is generally expected to be quite long. What management 
strategy should be followed once complete removal of the sporadic adenoma is ascertained, 
remains uncertain. Considering the age at diagnosis and long-term outcome after treatment 
of the duodenal adenoma, the risk of developing a duodenal carcinoma within the range of life 
expectancy seems to be negligible for the majority of patients. Age and life expectancy at the 
time of diagnosis should be decisive factors in the choice of follow-up management. Follow-up 
42
3
57
1
5
7
8
9
6
&
Management of sporadic duodenal adenomas and the association with colorectal neoplasms
seems reasonable for patient at younger age (eg, below 60y) without severe comorbidity that 
limits life expectancy.
In Table 3, to our knowledge, all studies focusing on the association of sporadic duodenal 
adenomas and colorectal neoplasms are shown.18-25 Reported prevalence of colorectal 
neoplasms in patients diagnosed with sporadic duodenal adenomas ranging from 23% to 75%, 
with colorectal carcinomas diagnosed in 0% to 21% of cases, including the results of the present 
study with a prevalence of 55% and 7%, respectively. In some patients, screening colonoscopy 
might have been performed in a regional hospital closer to the patient’s place of residence 
without our knowledge, leading to an underestimation of prevalence of colorectal neoplasms in 
patients with sporadic duodenal adenomas. In contrast, not all patients with sporadic duodenal 
adenomas in our series systematically underwent colonoscopy but rather symptomatic 
patients with an increased a-priori chance of having colorectal lesions, leading to a possible 
overestimation of the prevalence. In the subgroup of patients who underwent colonoscopy 
specifically indicated by the diagnosis of the sporadic duodenal adenoma, nearly half were 
found to have colorectal neoplasms. Although in some of the patients the association could 
be on the basis of undiagnosed attenuated FAP or MutY homolog (E. coli) gene-associated 
polyposis,18,22-24 a shared common pathway between sporadic duodenal and colorectal neoplasm 
Table 3. Reports on the association of sporadic duodenal adenomas and colorectal neoplasms.
Study type
Duodenal 
adenomas n Colonoscopy
CR 
neoplasia
CR 
carcinomas
CR 
adenomas
Adv CR 
adenoma
Murray et al.18 Retrospective 
case control
Amp & 
Non-amp
56 34 (61%) 19 (56%) 7 (21%) 12 (35%) 6 (18%)
Ford et al.19 Retrospective Amp & 
Non-amp
35 11 (31%) 4 (36%) 0 (0%) 4 (36%) 3 (28%)
Apel et al.20 Retrospective Non-amp 25 22(1) (88%) 16 (73%) 1 (5%) 15 (68%) ns -
Schneider 
et al.21
Retrospective 
case control
Amp 26(2) 26 (100%) 6 (23%) 2 (8%) 4 (15%) 3 (12%)
Pequin et al.22 Retrospective 
case control
Non-amp 44 35 (79%) 13 (37%) 2 (6%) 11 (31%) 8 (23%)
Ramsoekh 
et al.23
Retrospective 
case control
Amp & 
Non-amp
102 49 (48%) 21(3) (43%) 4 (8%) 17 (35%) 9 (18%)
Lagarde 
et al.24
Retrospective 
case control
Non-amp 29 29 (100%) 18 (62%) 3 (10%) 15 (52%) 4 (14%)
Dariusz et al.25 Retrospective 
case control
Non-amp 51 48 (94%) 36 (75%) 5 (10%) 31 (65%) ns -
Present study Retrospective Amp & 
Non-amp
54 29 (54%) 16 (55%) 2 (7%) 14 (48%) 7 (27%)
(1) One patient underwent proctoscopy.
(2) Including 7 patients with duodenal cancer.
(3) Two patients had adenomatous lesion on colonoscopy, but no histopathological confirmation was done; 
these patients were therefore excluded from further analyses.
Advanced adenomas were defined as: size ≥10mm, a villous component, and/or high-grade dysplasia.
Abbreviations: Adv, advanced; Amp, ampullary; CR, colorectal; ns, not specified; Non-amp, non-ampullary. 
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seems apparent. Therefore, screening colonoscopy in all patients diagnosed with a sporadic 
duodenal adenoma is warranted, as was previously stated.17 In patients in whom colonoscopy 
is too much of a burden, sigmoidoscopy seems a reasonable alternative, as the majority of 
the associated colorectal lesions were found in the left hemicolon. Computed tomographic 
colonography can also be considered.33
conclusions and recommendations
Our study illustrates that no consistent approach to the management of sporadic duodenal 
adenomas was followed. Despite this observation, none of the patients included in our study 
developed a duodenal carcinoma during the study period, which is of primary concern when 
a patient is diagnosed with a sporadic duodenal adenoma. We found support for the apparent 
association between the presence of sporadic duodenal adenomas and colorectal neoplasms. 
Our recommendation is to aim for complete endoscopic removal of sporadic duodenal adenoma 
whenever possible. The importance of follow-up after ascertained successful removal largely 
depends on patient’s age and life expectancy. We propose to perform follow-up only in younger 
patients (eg, under 60y) without relevant comorbidity that limits life expectancy. Given the 
strong suspicion of an increased risk of colorectal neoplasms, we underline the recommendation 
to perform colonoscopy in all patients diagnosed with a sporadic duodenal adenoma.17
To be able to develop a reliable evidence-based management protocol for patients with 
sporadic duodenal adenomas, prospective multicenter international studies are considered 
necessary, as the incidence of sporadic duodenal adenomas is low.
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ABSTRACT
Curcumin, quercetin, and eicosapentaenoic acid (EPA) are three natural compounds with the 
capacity to reduce adenoma burden in patients with familial adenomatous polyposis (FAP). The 
mechanistic basis of this anticarcinogenic capacity is largely unknown, but it was suggested that 
induction of detoxification enzymes is involved. Therefore, the effects of low-dose curcumin, 
quercetin, and EPA on phase II detoxification enzymes UDP-glucuronosyltransferase (UGT), 
glutathione S-transferase (GST), as well as on glutathione (GSH) content were analyzed in 4 cell 
line models of intestinal carcinogenesis. HT-29, HuTu 80, and Caco-2 intestinal cancer cells and 
LT97 colon adenoma cells from a patient with FAP were treated with low-dose noncytotoxic 
concentrations of curcumin, quercetin, and EPA. GST enzyme activity was measured by 
spectrophotometry, and expression of GSTA1, GSTM1, GSTP1, GSTT1, and UGT1 by Western 
blotting. Cytosolic GSH levels were determined by high performance liquid chromatography. 
An inducing effect of curcumin and quercetin on GST or UGT was seen in Caco-2, LT97, and 
HuTu 80 cells. GSH levels were reduced by quercetin and EPA in HT-29 cells and induced by 
curcumin in Caco-2 cells. In LT97 cells, GST activity and expression was reduced, but UGT1 
expression was induced by curcumin and quercetin; whereas EPA only decreased GST or UGT 
levels. In summary, enhancement of the detoxification capacity by low dose of the potential 
anticarcinogens curcumin, quercetin, or EPA seems only a minor factor in explaining their 
anticarcinogenic properties.
Key words: familial adenomatous polyposis, curcumin, quercetin, eicosapentaenoic acid, chemoprevention, 
glutathione S-transferase, UDP-glucuronosyltransferase, glutathione, Caco-2, LT97, HuTu 80, HT-29
Abbreviations: APC, adenomatous polyposis coli; COX-2, cyclooxygenase-2; CRC, colorectal cancer; 
DMEM, Dulbecco’s modified Eagle’s medium; EPA, eicosapentaenoic acid; FAP, familial adenomatous 
polyposis; GSH, glutathione; GST, glutathione S-transferase; NSAIDs, non-steroidal anti-inflammatory 
drugs; ω-3 PUFA, omega-3 polyunsaturated fatty acid; PBS, phosphate buffered saline
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Familial adenomatous polyposis (FAP) is a colon cancer predisposition caused by an autosomal 
dominant germline mutation in the adenomatous polyposis coli (APC) gene.1 The disease is 
characterized by the development of hundreds to thousands of adenomatous polyps, almost 
inevitable leading to colorectal cancer (CRC). For this reason, it is recommended to resect the 
colon to prevent development of CRC.2 After prophylactic colectomy, however, individuals 
remain at risk for recurrent rectal or duodenal adenomas and therefore undergo regular 
endoscopic surveillance.2 Nonsteroidal anti-inflammatory drugs (NSAIDs) such as sulindac 
and celecoxib have shown to significantly reduce duodenal or colonic polyp number or size in 
patients with FAP.3,4 This pharmacological chemoprevention can be combined with endoscopic 
surveillance to reduce cancer development or reoccurrence.
The main mechanism of action of NSAIDs in adenoma reduction is assumed to be the 
inhibition of cyclooxygenase-2 (COX-2), which is overexpressed in 90% of colon carcinomas and 
in 40% of colon adenomas.5 Although NSAIDs proved effective, their safety has been a source 
of controversy. Cardiovascular toxicity of celecoxib was identified in participants of sporadic 
adenoma trials6, although there is also evidence of long-term safety of sulindac in a small group 
of patients with FAP.7 Of note, the mean age of patients with FAP participating in clinical trials 
is lower than that of participants in sporadic adenoma trials. It remains unclear whether the 
use of these drugs is safe in younger individuals. Given the potential adverse effects of NSAIDs, 
alternative chemopreventive agents are required, which are effective and well tolerated over 
longer treatment periods.
Curcumin, quercetin, and eicosapentaenoic acid (EPA) are three natural compounds with 
the capacity to reduce COX-2 expression in the colon cancer cell line HT-29.8-10 Curcumin is a 
phenolic compound extracted from the spice turmeric, the powdered rhizome of the plant 
Curcuma longa. Various pharmacological properties, including the induction of apoptosis and 
the inhibition of cell proliferation, oxidative stress, and angiogenesis, make curcumin a potential 
chemopreventive agent.11 Moreover, its anticancer effect has already been demonstrated for 
several human cancers and because of its bioavailability in the gastrointestinal tract, curcumin 
might be particularly suitable to treat gastrointestinal cancers. Clinical trials analyzing the in vivo 
effects of curcumin are still in progress. However, one study showed a reduction in the number 
and size of polyps in five patients with FAP, treated with 1,440mg curcumin in combination with 
60mg quercetin daily for 6 months.12
Quercetin is a flavonoid found in many vegetables, fruits, leaves, and grains. Similar to 
curcumin, quercetin possesses a great potential in the treatment of various diseases due to 
its wide range of biological effects such as antioxidant and anti-inflammatory capacities.13 The 
antitumor effects of quercetin was recently studied in the rodent FAP model APCMin/+ mice, 
where quercetin significantly reduced polyp number and size.14
EPA is an omega-3 polyunsaturated fatty acid (ω-3 PUFA) that is found mainly in cold-
water fish. The efficacy of EPA as the free fatty acid in the protection of CRC is well supported 
by animal studies and clinical trials. EPA reduced intestinal adenoma number in the APCMin/+ 
mouse model confirming previous results of the anticarcinogenic activity of ω-3 PUFAs15-17 and 
EPA reduced polyp number and diameter in patients with FAP, consuming 2g of EPA daily for 
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6 months.18 In addition, the compound was well tolerated. Although the mechanism of action 
is still unclear, it was suggested that the anticarcinogenic effect of quercetin, curcumin, or 
EPA might be caused in part by enhancement of detoxification enzymes.12 Curcumin and/or 
quercetin have shown to influence the levels of phase II detoxification enzymes glutathione 
S-transferases (GSTs)19,20 or UDP glucuronosyltransferases (UGTs) in rats21, whereas EPA has 
shown inhibiting22 and inducing23 effects on UGTs and GSTs in human HepG2 or modified mouse 
Hepa-1c1c7 cells, respectively.
UGTs catalyze the reaction of predominantly lipophilic compounds with glucuronic 
acid24, whereas GSTs catalyze the conjugation of electrophilic substrates to glutathione.25 
Inducing the activity of these detoxification enzymes could potentially help to protect cells 
from effect of toxic and (pre)carcinogenic agents, thus reducing the risk of developing (pre)
malignancies.26,27
Although a reduction in adenoma number and size in patients with FAP has been 
demonstrated after treatment with curcumin, quercetin, and EPA, the mechanistic basis of this 
anticarcinogenic effect remains unknown. The aim of the present study is to investigate the 
effects on phase II detoxification enzymes of low-dose curcumin, quercetin, and EPA that could 
eventually be reached in clinical studies. The phase II enzymes UGT, and GST/glutathione (GSH) 
are studied in human (pre)cancerous intestinal cell line models, including an adenoma cell line 
derived from a patient with FAP (LT97).
MATeRIALS AnD MeTHODS
cell lines
All cell lines, except LT97, were obtained from the American Type Culture Collection (Rockville, 
MD). HT-29 (clone HTB 38) is a cell line derived from human colorectal adenocarcinoma, HuTu 
80 (clone HTB 40) is derived from a human duodenal carcinoma, and Caco-2 (clone HTB 37) 
is a human colorectal adenocarcinoma cell line. The human LT97 cell line was derived from 
colorectal microadenomas from a patient with FAP, as described by Richter et al.28
Cells were grown and maintained in Dulbecco’s modified Eagle’s medium (DMEM) high 
glucose with stable glutamine (PAA Laboratories GmbH, Pasching, Austria) supplemented 
with 10% heat inactivated fetal bovine serum (FBS) (Invitrogen, Paisley, UK), 2% HEPES buffer 
solution (PAA Laboratories), and 1% minimum essential medium with nonessential amino acids 
(Invitrogen).
WsT-1 cytotoxicity assay
Cytotoxicity of the test compounds was measured as follows: HT-29 and Caco-2 cells 
were seeded at 2×104 cells/well, HuTu 80 at 1.5×104 cells/well, and LT97 at 3×104 cells/well 
in 96-well plates. The following day, cells were incubated in complete medium with 0.1% 
dimethylsulfoxide (DMSO, drug vehicle) containing curcumin (Sigma, St. Louis, MO) in a 
concentration range of 0.4-400μM, quercetin (Sigma) in a concentration range of 1-1,000μM 
and eicosapentaenoic acid (EPA, Cayman Chemical Company, MI) in a concentration range 
of 0.6-600μM. After 24h, cell viability was assessed by adding the cell proliferation reagent 
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WST-1 using a 2h incubation time according to the manufacturer’s instructions (Roche 
Diagnostics GmbH, Mannheim, Germany). The absorbance of the samples was measured with 
a Thermomax microplate reader (Molecular Devices, Wokingham, UK) at wavelength 405nm 
against a reference wavelength of 620nm. Each measurement of curcumin and quercetin 
was done in triplicate, and EPA was done in sixplicate. Data shown are mean values derived 
from 2 or 3 different experiments, respectively. The highest noncytotoxic concentration in 
each of the 4 cell lines was defined as the highest concentration with maximum cell survival, 
as deducted from the cell survival curves. These highest noncytotoxic concentrations were 
used for further experiments.
cell treatment
2.5×106 cells were seeded in 75cm2 cell culture flask in complete medium. After 24h, medium 
containing curcumin, quercetin, or EPA in noncytotoxic concentrations, as determined by 
WST-1 cytotoxicity assay as described above, was added for 24h. Test compounds were dissolved 
in DMSO and diluted until the end concentration of DMSO was 0.1%, which was also added to 
the control cells.
Western immunoblotting
After incubation for 24h, cells were harvested by scraping, cells were washed thoroughly with 
phosphate buffered saline (PBS) and centrifuged for 5min at 200×g. The cell pellet was taken 
up in homogenization buffer (0.25M saccharose, 20mM Tris, 1mM dithiothreitol, pH 7.4) and 
homogenized. Protein concentration of the cell homogenate was determined by the method 
of Lowry et al.29 Cell homogenates were diluted (2:1) with loading buffer (125mM Tris, 2% SDS, 
325mM dithiothreitol, 10% glycerol, 6M urea, and 0.05% bromophenolblue), incubated for 
5min at 95°C, and subsequently loaded on 8% or 12% SDS polyacrylamide gel for UGT or GST 
analysis, respectively.
After electrophoresis, the samples were transferred to nitrocellulose (Whatman GmbH, 
Dassel, Germany) in a semi-dry blotter (V20-SDB, Scie-Plas, Cambridge, UK). Western blots were 
blocked with 2% milk powder and incubated with the appropriate primary antibody overnight. 
As primary antibodies, the mouse monoclonal antibodies WP1, GST class alpha, GST class mu, 
and GST class pi against UGT1, GSTA1-2, GSTM1- 1, and GSTP1-1 were used, respectively, which 
were all developed in our laboratory.30-33 Antibodies against GSTT1-1 were purchased from Dr. 
E. Juronen (Tartu, Estonia). Polyclonal rabbit antimouse immunoglubulins HRP (Dako Denmark 
A/S, Glostrup, Denmark) diluted 1:1,000 was used as secondary antibody.
Western blots were independently analyzed by 2 observers with the TotalLab TL100 software 
(TotalLab, Ltd., Newcastle upon Tyne, UK). Protein bands of untreated cells were set as 100%. 
Results shown are derived from 5 individual experiments and given in mean ± SD.
gsT enzyme activity
GST enzyme activity was measured spectrophotometrically at 340nm according to Habig et 
al., using 1-chloro-2,4-dinitrobenzene as substrate.34 Mean values of untreated cells were set as 
100%. Results of 5 individual experiments as mean ± SD are shown.
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cytosolic glutathione (gsh) determination
GSH concentrations were analyzed by high-performance liquid chromatography with 
fluorescent detection. The analysis of GSH was performed as described by Raijmakers et 
al.35, with minor modifications. Homogenates were diluted in homogenization buffer (0.25M 
saccharose, 20mM Tris, 1mM dithiothreitol, pH 7.4) and total GSH concentration was determined 
in 4 experiments. Mean values of untreated cells were set as 100%.
statistical analysis
The SPSS statistical package (SPSS 16.0 for Windows) was applied for all statistical analyses. 
Experiments were analyzed by an independent t-test. p<0.05 was considered statistically 
significant.
ReSULTS
The WST-1 assay was performed to assess the cell viability of the intestinal adenoma and 
carcinoma cells after treatment with varying concentrations of curcumin (0.4-400μM), 
Figure 1. Cytotoxicity of curcumin, quercetin and eicosapentaenoic acid (EPA) in HT-29, HuTu 80, Caco-2, 
and LT97 cells. A: The cells were exposed to curcumin for 24h at the concentrations 0.4-400μM. Error 
bars indicate SD of 3 experiments each measured in triplicate. B: Cells were exposed to quercetin at the 
concentrations 1-1,000μM for 24h. Error bars indicate SD of 3 experiments each measured in triplicate. 
C: Cells were exposed to EPA for 24h at the concentrations 0.6-600μM. Error bars indicate SD of 2 
experiments each measured in sixfold. D: Noncytotoxic concentrations in each of the 4 cell lines, as used 
in further incubation experiments, are defined as the highest concentration with maximum cell survival 
deducted from the cell survival curves.
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Figure 2. Glutathione S-transferase (GST) enzyme activities of HT-29, HuTu 80, Caco-2, and LT97 cells 
before and after incubation with curcumin, quercetin, or eicosapentaenoic acid (EPA). Error bars indicate 
SD of 5 experiments. Enzyme activities of untreated cells are set to 100%. *p<0.05 compared to control.
Figure 3. Glutathione S-transferase (GST) and UDP-glucuronosyltransferase 1 (UGT1) protein expression 
in HT-29, HuTu 80, Caco-2, and LT97 cells before and after incubation with curcumin, quercetin, or 
eicosapentaenoic acid (EPA). Western blots were quantitatively analyzed. Protein expression of untreated 
cells are set to 100%. Error bars indicate SD of 5 experiments. A: HT-29 cells express GSTP, GSTT, and UGT1. 
B: HuTu 80 cells express GSTP and GSTT. C: Caco-2 is the only cell line that expresses GSTA and GSTP. D: 
LT97 shows the same expression pattern as HT-29 cells. GSTM is not expressed in any of the 4 tested cell 
lines. *p<0.05 compared to control.
quercetin (1-1,000μM), or EPA (0.6-600μM). The resulting curves show a concentration-
dependent inhibitory effect on cell growth for all 3 compounds (Figure 1A-1C). From these 
curves, noncytotoxic concentrations were determined (Figure 1D). In subsequent experiments, 
cells were incubated for 24h using these noncytotoxic concentrations.
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Results of GST enzyme activity measurements are shown in Figure 2. In untreated cells, the 
highest GST activity is measured in Caco-2 cells with an average activity of 1871±396nmol/min.
mg protein, HuTu 80 cells show the lowest activity (264±57nmol/min.mg protein) and HT-29 
and LT97 cells showed intermediate GST activity of 537±174 and 455±174nmol/min.mg protein, 
respectively.
After incubation with the test compounds, no significant change in GST enzyme activity was 
found in HT-29 and Caco-2 cells. Of all 3 substances investigated, only quercetin significantly 
induces GST enzyme activity in the HuTu 80 cells, whereas it reduces activity in LT97 cells 
(both p<0.05). To determine which GST classes are affected, Western blot analyses for GSTA1, 
GSTP1, GSTT1, and GSTM1 were performed (Figure 3). GSTM1 is not expressed in any of the cell 
lines, GSTA is detected only in Caco-2 cells, whereas GSTP1 is detected in all 4 cell lines. In 
Caco-2 cells, curcumin significantly affected GSTP1 expression. In addition, expression of all 
UGT1 family enzymes was determined by Western blotting (Figure 3). Significant effects on GST 
and UGT expression were mostly observed in LT97 cells. In these cells, curcumin reduces GSTP1 
expression whereas UGT1 expression is induced. Quercetin significantly reduces the expression 
of GSTT1 and, like curcumin, shows an inducing effect on UGT1 expression. In contrast, EPA 
decreases both UGT1 and GSTP1 expression.
Results on GSH concentrations are shown in Figure 4. The highest GSH concentration was 
seen in Caco-2 cells with an average level of 10.1±2.7nmol/mg protein, followed by HT-29 and 
HuTu 80 cells with average concentrations of 8.2±1.7 and 7.5±2.9nmol/mg protein, respectively. 
LT97 cells showed a very low cytosolic GSH concentration of 0.26±0.15nmol/mg protein. 
Quercetin and EPA significantly reduce GSH concentration in HT-29 cells, whereas curcumin 
significantly induces GSH levels in Caco-2 cells.
DISCUSSIOn
Curcumin, quercetin, and EPA have been found to reduce cell growth in cancer cell lines8-10, 
reduce adenomas/carcinomas numbers in animal models of colon carcinogenesis14-17, and, most 
importantly, reduce number and size of colorectal adenomas in patients with FAP12,18. In the 
Figure 4. Glutathione (GSH) levels in HT-29, HuTu 80, Caco-2, and LT97 cells before and after incubation 
with curcumin, quercetin or eicosapentaenoic acid (EPA). Error bars indicate SD of 4 experiments. GSH 
concentration of untreated cells are set to 100%. *p<0.05 compared to control.
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present study we used four (pre)cancerous intestinal cell line models to analyze the in vitro 
effects of low-dose curcumin, quercetin, and EPA on the detoxification enzymes GST and UGT 
to investigate whether the protective effects attributed to these three naturally occurring 
substances have a mechanistic basis in modulating detoxification enzyme processes.
The hypothesis that elevated levels of UGTs, GSTs, and GSH have a protective role in 
carcinogenesis is firmly established.24-27 It was shown that low GST activity in the gastrointestinal 
tract correlates with an increased tumor risk and vice versa.36 Furthermore, knockout of GSTP 
in APCMin mice resulted in a sixfold increase in colon adenoma incidence compared to wild type 
APCMin mice.37 Transgenic rats containing an extra GSTP gene were shown to be less sensitive to 
liver carcinogenesis than wild-type rats.38 On the other hand, recent studies analyzing genetic 
polymorphisms in GSTA1, GSTM1, GSTT1, GSTP1, and UGT1A1, which are hypothesized to be 
related to reduced in vivo enzyme activity, have failed to find an association with tumor risk in 
patients with FAP or sporadic CRC.39,40 It is noteworthy however, that patient numbers in these 
studies were low.
Once a (pre)malignancy has developed, GSTP1 is commonly found overexpressed and 
high levels of GSH have been detected in many human tumors including colon cancer.24,41 This 
elevated state, which is present in many different tumor types, might protect cancer cells from 
chemo- and radiotherapy or oxidative stress-induced apoptosis.24
In nonmalignant healthy cells, high levels of GST, UGT, and GSH may be beneficial to protect 
the cells from oxidative stress and the influence of (pre)carcinogens. Moreover, compounds 
that increase levels of the phase II enzymes UGT and GST, as well as cytosolic GSH, could act as 
anticarcinogenic. In the present in vitro study only incidental effects of curcumin, quercetin, 
or EPA on the phase II enzymes were found and effects varied between the cell lines used. For 
instance, quercetin induced the GST enzyme activity in HuTu 80 cells but reduced it in LT97 
cells. Inducing effects were seen only in HuTu 80 and Caco-2 cells. HT-29 cells showed only a 
lowering effect on GSH, whereas most effects, both enhanced and reduced expression, were 
seen in the LT97 cells.
Of all three compounds, various effects have been described on colorectal carcinoma 
cells after at least 6h of incubation at concentrations comparable to those used in the present 
study.9,42,43 Effects were found to be strongly dependent on the duration of incubation.42 The 
majority of studies on curcumin, quercetin, or EPA in gastrointestinal cell-line models were 
performed using HT-29 and Caco-2 cells, whereas no studies analyzing GST, UGT, or GSH 
in HuTu 80 or LT97 cells were previously performed. However, because of differences in 
concentrations and duration of incubations applied in these studies, comparing the results is 
not straightforward.
Compared to GST and UGT expression, effects on GSH levels were subject of investigation 
more often. In our study, Caco-2 cells responded to quercetin by increasing the cytosolic 
GSH level, supporting the results of a previous study.44 In HT-29 cells, curcumin was found to 
significantly increase GSH content after no more than 3h45, and two studies indicated a raised 
GSH level after treatment with quercetin at a concentration of 10μM.44,46 In contrast to curcumin 
and quercetin, EPA was found to cause a 20% reduction of GSH after 24h of treatment.47 Our 
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results are in line with these previous findings on curcumin and EPA, but we found quercetin to 
reduce GSH in HT-29 cells.
Two studies on UGT effects of quercetin in differentiated Caco-2 cells found an induction in 
experimental settings with 2h and 5wk incubation periods, respectively.48,49 We did not detect 
any protein UGT1 expression in Caco-2 cells. However, we used undifferentiated cells in the log 
phase, which might explain the difference, because cell characteristics do change dramatically 
after differentiation and their characteristics are known to be diverged significantly in different 
laboratories.50,51
LT97 cells showed no effect on UGT1A1 mRNA levels after 24h treatment with 50μM EPA52, 
whereas we found a significant reduction in total UGT1 protein expression after 24h treatment 
with 10μM EPA. Since we did not discriminate between the various UGT1 family enzymes that 
might be expressed in LT97 cells, this finding represents a net overall downregulation of UGT1 
protein and may obscure differences between the various UGT1 subtypes.
Only three reports exist on GST expression/activity in the cell lines we used. The first 
reported an induction of GST enzyme activity in HT-29 cells treated with 10-30μM curcumin.45 
In the present study, we did not find any difference in GST enzyme activity after curcumin 
treatment at 10μM. Secondly, quercetin was found to reduce GSTA1 mRNA expression after 2h of 
incubation of differentiated Caco-2 cells at concentrations of 25μM48, whereas in our study 50μM 
of quercetin showed a nonsignificant increase of GSTA1 protein expression in nondifferentiated 
cells after 24h incubation period. Lastly, we found a decrease in GSTP1 expression in LT97 cells 
after incubation with 10μM EPA, whereas in a recent study analyzing the gene expression of 
LT97 cells under the influence of 50μM EPA, a modulation of the GSTP1 gene was not reported.52 
However, a time-dependent effect of EPA on this colorectal adenoma cell line was clearly 
present, with more upregulated genes after 24h, as compared to 10h of incubation.
Long term in vitro incubation with curcumin in HT-29 cells was performed by Lev-Ari et 
al.8 and Goel et al.53, resulting in considerable increase of cytotoxicity, when incubating longer 
than 24h and using concentrations higher than 25μM, which is in agreement with our results on 
culturing with 10μM curcumin for 24h.
Additional evidence for a time-dependent effect was found in quercetin-treated human 
leukemic monocyte lymphoma cells.54 Long-term treatment (12-24h) resulted in decreased 
levels of GSH leading to an prooxidative and proapoptotic effect, whereas short-term 
treatment of up to 6h had antioxidative and antiapoptotic effects. Moreover, a rat study 
indicated effects of curcumin or quercetin as well, with enhanced GST activity in the intestine 
after 2wk supplementation, whereas glutathione levels were higher in the large intestine only 
for quercetin.19 Although the data on long-term treatment are still scarce, one can hypothesize 
that long-term in vivo treatment results in more clear effects on biotransformation systems and 
leads to increased cytotoxicity, whereas long-term in vivo treatment in rats with curcumin or 
quercetin did reveal no signs of toxicity.19 However, both in vivo and in vitro dose-dependent 
effects are also demonstrated.
These time- and dose-dependent effects might explain the seemingly inconsistent effects 
on detoxifications enzymes of treatment with fixed doses of curcumin, quercetin, and EPA, at 
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fixed incubation periods in the 4 cell lines investigated here. Moreover, the time- and dose-
dependent effects make proper comparison between various studies with different study 
designs difficult.
In summary, some enhancing effects on detoxification enzymes of low-dose curcumin, 
quercetin, and EPA are found in the Caco-2 and HuTu 80 cell lines, whereas variable effects were 
detected in HT-29 and LT97 cells. Overall however, enhancement of the detoxification enzymes 
does not seem to be an important mechanism explaining the promising results obtained in 
inhibiting or preventing adenoma formation in patients with FAP.
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ABSTRACT
Chemoprevention would be a desirable strategy to avoid duodenectomy in patients with 
familial adenomatous polyposis (FAP) suffering from duodenal adenomatosis. We investigated 
the in vitro effects on cell proliferation, apoptosis, and COX-2 expression of the potential 
chemopreventives celecoxib and tauro-ursodeoxycholic acid (UDCA). HT-29 colon cancer 
cells and LT97 colorectal micro-adenoma cells derived from a patient with FAP, were exposed 
to low dose celecoxib and UDCA alone or in combination with tauro-cholic acid (CA) and 
tauro-chenodeoxycholic acid (CDCA), mimicking bile of patients with FAP treated with UDCA. 
In HT-29 cells, co-treatment with low dose celecoxib and UDCA resulted in a decreased cell 
growth (14-17%, p<0.01). A more pronounced decrease (23-27%, p<0.01) was observed in LT97 
cells. Cell growth of HT-29 cells exposed to ‘artificial bile’ enriched with UDCA, was decreased 
(p<0.001), either in the absence or presence of celecoxib. In LT97 cells incubated with ‘artificial 
bile’ enriched with UDCA, cell growth was decreased only in the presence of celecoxib (p<0.05). 
No clear evidence was found for involvement of proliferating cell nuclear antigen, caspase-3, or 
COX-2 in the cellular processes leading to the observed changes in cell growth. In conclusion, 
co-treatment with low dose celecoxib and UDCA has growth inhibitory effects on colorectal 
adenoma cells derived from a patient with FAP, and further research on this combination as 
promising chemopreventive strategy is desired.
Keywords: familial adenomatous polyposis, HT-29, LT97, celecoxib, ursodeoxycholic acid
Abbreviations: APC, adenomatous polyposis coli; β2M, beta-2 microglobulin; CA, tauro-cholic acid; 
CDCA, tauro-chenodeoxycholic acid; COX, cyclooxygenase; DMEM, Dulbecco’s modified eagle medium; 
DMSO, dimethylsulfoxide; FAP, familial adenomatous polyposis; FBS, fetal bovine serum; NSAIDs, non-
steroidal anti-inflammatory drugs; PCNA, proliferating cell nuclear antigen; PGE2, prostaglandin E2; qPCR, 
real-time quantitative polymerase chain reaction; SDS-PAGE, SDS-polyacrylamide gel electrophoresis; 
UDCA, tauro-ursodeoxycholic acid
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Familial adenomatous polyposis (FAP) is characterized by the development of numerous 
premalignant colorectal adenomatous polyps and caused by a germline mutation in the 
tumor suppressor adenomatous polyposis coli (APC) gene.1 Prophylactic colectomy, as 
preventive measurement for the inevitable development of colorectal cancer in these patients, 
substantially improved prognosis in the past decades.2 As a result, the mortality pattern has 
changed with duodenal cancer now being one of the main cancer-related causes of death.3,4 
Lifetime risk of duodenal adenomas approaches 100% in patients with FAP, and approximately 
3-4% of patients eventually develop duodenal cancer.5,6 As duodenal cancer in patients with 
FAP has been associated with a poor prognosis7,8, the clinical challenge is to identify high-risk 
patients with duodenal adenomas and intervene before progression to cancer occurs. To 
date, prophylactic duodenectomy offers the only chance of a prolonged disease-free interval 
in patients with FAP with advanced duodenal adenomatosis, but this type of intervention is 
associated with substantial morbidity and mortality.9 Chemopreventive treatments would be 
highly desirable to postpone or even avoid the necessity for radical prophylactic surgery.
In this respect, cyclooxygenase (COX) inhibiting non-steroidal anti-inflammatory 
drugs (NSAIDs) have been subject to much investigation. Whereas the COX-1 isoenzyme is 
constitutively expressed in a wide range of tissues and is considered a housekeeping enzyme, 
the COX-2 isoenzyme is an inducible enzyme that produces prostaglandins in inflammatory and 
tumorigenic settings.10 Overexpression of COX-2 is linked to evasion of apoptosis, enhanced 
cell growth, tumor angiogenesis, and tissue invasion and metastasis through several signalling 
pathways.10 Subsequently, studies in which the COX-2 enzyme was targeted by administration 
of the selective COX-2 inhibitor celecoxib, showed significant decrease in the occurrence of 
sporadic colorectal adenomas, not only by suppressing the growth of existing adenomas, but 
also by preventing the formation of new adenomas.11,12 COX-2 inhibition in a murine model of 
intestinal polyposis resulted in a substantial decrease in adenoma size and number.13 Confirming 
the findings from animal studies, administration of celecoxib was associated with regression of 
adenomas of both the colon and rectum in patients with FAP.14 The value of COX inhibiting 
agents for regression of duodenal polyposis however, is not well established. Sulindac was 
found to regress small duodenal polyps, but this effect was limited, despite larger effects on 
colorectal polyposis.15 Celecoxib was found to significantly reduce duodenal adenomatosis 
in patients with FAP after 6 months of treatment with high dosage of 400mg twice daily.16 
Unfortunately, clinical trials involving selective COX-2 inhibitors as chemopreventive agents for 
colorectal cancer have cast doubt on the suitability of these agents for long-term use, due to 
increased risks of adverse cardiovascular events.11,12
A promising strategy is the combination of low dose celecoxib, in order to minimize toxicity, 
with other substances. A candidate for such a combination regimen is ursodeoxycholic acid. In 
in vitro models of human colonic epithelial cells, ursodeoxycholic acid and taurine-conjugated 
ursodeoxycholic acid (UDCA) in particular, significantly reduced cytotoxicity of secondary bile 
acids.17 Data from clinical studies support the notion of a possible chemopreventive effect of 
UDCA on development of colorectal neoplasms, in patients with sporadic colorectal adenomas, 
and patients with ulcerative colitis and primary sclerosing cholangitis.18-20 UDCA was found to 
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reduce COX-2 expression in a rat model of colon carcinogenesis, suggesting an alternative and 
possibly complimentary pathway for inhibition of COX-2.21,22. Interestingly, a synergistic effect of 
sulindac and UDCA in the prevention of intestinal adenomas was found in a murine model of FAP.23
To explore the chemopreventive potential of low dose celecoxib in combination with 
UDCA for (duodenal) adenomatosis in patients with FAP, we aimed to investigate the in vitro 
effects on cell growth and COX-2 expression of both substances, in single treatment and in 
combination. As a model, we used the human epithelial cell line LT97 derived from colorectal 
micro-adenomas of a patient with FAP. For comparison, we used the well-established HT-29 
adenocarcinoma cell line, also derived from human colon. We hypothesize that the growth 
inhibitory effect of low dose celecoxib is further potentiated by UDCA.
MATeRIAL AnD MeTHODS
cell culture and reagents
The human colon adenocarcinoma cell line HT-29 was obtained from the American Type 
Culture Collection (Rockville, MD, USA). Additionally, we used the human epithelial cell line 
LT97, derived from colorectal micro-adenomas of a patient with FAP as previously described.24 
The following reagents were used: celecoxib (99.4% purity) from Kemprotec (Middlesbrough, 
UK), tauroursodeoxycholic acid (UDCA; >98.0% purity) from TCI Europe (Zwijndrecht, Belgium) 
and the sodium salts of tauro-cholic acid (CA; ≥97.0% purity) and tauro-chenodeoxycholic 
acid (CDCA; 98.0% purity) from Sigma-Aldrich (St. Louis, MO, USA). The cells were grown 
and maintained in ‘PC-1 Chemically defined, Serum-free Medium’, supplemented with 2mM 
L-glutamine (Lonza Walkersville, MD, USA) in a humidified incubator at 37°C and 5% CO2.
cell survival assays
Cells (15,000 cells/well) were incubated in 96-wells plates (Corning Inc., NY, USA) in 100μl PC-1 
medium. After 24h, medium was removed and PC-1 medium containing 0.1% dimethylsulfoxide 
Table 1. Incubation conditions used in the experimental design. HT-29 and LT97 cells were treated for 48 
and 72 hours with selected concentrations of celecoxib and/or taurine-conjugated bile acids. Selected 
concentrations were non-lethal dose substracted from cell survival curves (see Figure 1).
Condition Incubation condition
Selected concentrations (μM)
Celecoxib UDCA CA CDCA
1 Control - - - -
2 Celecoxib 10 - - -
3 UDCA - 1000 - -
4 Celecoxib + UDCA 10 1000 - -
5 BA/UDCA50% - 500 100 100
6 BA/UDCA50%+Celecoxib 10 500 100 100
Abbreviations: UDCA, tauro-ursodeoxycholic acid; CA, tauro-cholic acid; CDCA, tauro-chenodeoxycholic acid; 
BA, bile acids CA and CDCA.
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(DMSO, drug vehicle) and celecoxib in a concentration range of 1.5-100μM, or UDCA, CA, 
CDCA, and CA/CDCA in a concentration range of 3.1-3200μM were applied. Each concentration 
was applied in triplicate. After 24h, medium was removed and the cells were incubated with 
10% (v/v) WST-1 (Roche Diagnostics, Mannheim, Germany) in PC-1 medium for 2h, after which 
the absorbance was measured at a wavelength of 450nm, with a background correction read 
at 620nm, according the manufacturer’s instructions. At least four independent experiments 
were performed.
Based on the resulting cell survival curves, the highest non-cytotoxic concentrations of 
celecoxib and the conjugated bile acids were selected for the experiments as described below.
experimental design: incubation conditions
All incubation conditions are shown in Table 1. Three conditions were designed to evaluate 
the effect of treating cells with celecoxib, UDCA, and their combination at selected 
concentrations (conditions 2, 3 and 4) for 48 and 72h. Two additional incubation conditions 
were added to the experimental design. Because gallbladder and duodenal bile in patients 
with FAP after prophylactic colectomy was found to consist mostly of glycine or taurine 
conjugated CA and CDCA in equivalent amounts25, we used a combination of 50% CA and 
50% CDCA to mimic the in vivo duodenal bile fluid in patients with FAP (‘artificial bile’). 
In all experiments only taurine-conjugated bile acids were used. An earlier intervention 
study in patients with FAP showed that supplementation with UDCA resulted in duodenal 
bile that was enriched with UDCA to up to 50% of the total amount of bile acids.26 To mimic 
this situation in vitro, we exposed cells to UDCA enriched ‘artificial bile’, with and without 
celecoxib (conditions 5 and 6). PC-1 medium with 0.1% DMSO (drug vehicle) was used as 
control condition (condition 1). Cells (4,000 cells/well for cell growth assays, 300,000 
cells/well for protein and RNA analysis) were grown for 24h in 96-wells and 6-wells plates 
(Corning Inc.), respectively. Thereafter, medium was removed and medium with 0.1% DMSO 
containing celecoxib, UDCA, CA, CDCA and their combinations at selected concentrations 
as shown in Table 1, was applied for either 48 or 72h. Every 24h, the medium with additives 
was refreshed. After the 48 and 72h incubation periods, WST-1 assessment was performed 
as described above. At least six independent incubation experiments were performed. For 
protein concentration and Western blot analysis, cells were washed with PBS three times and 
homogenized in 0.25M saccharose/20mM Tris buffer pH 7.4 containing 1mM dithiothreitol 
(DTT) and 0.1% Triton X-100 and stored at -20°C. At least three independent incubation 
experiments were performed for protein analyses. For mRNA analysis, cells were harvested 
in TRIzol (Invitrogen, Carlsbad, CA, USA) and stored at -80°C. Two independent incubation 
experiments were performed for mRNA analysis.
measurement of protein concentrations and sds-page Western blotting
The cell proliferation marker ‘proliferating cell nuclear antigen’ (PCNA) and the apoptosis 
marker ‘caspase-3’ were assessed. Protein concentrations were determined according to the 
method of Lowry using bovine serum albumin as standard.27 Equal quantities of protein (10μg 
and 50μg for PCNA and caspase-3 respectively) were subjected to 15% SDS-polyacrylamide 
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gel electrophoresis (SDS-PAGE). Simultaneously, a molecular weight marker was loaded 
(Precision Plus Protein Kaleidoscope Standards, Bio-Rad Laboratories, Hercules, CA, USA). 
After electrophoresis, proteins were transferred (90min at 0.8mA/cm2) to nitrocellulose 
transfer membranes (Protan BA 85, Whatman, Dassel, Germany). Membranes were blocked 
with 2% non-fat dry milk and 0.5% bovine serum albumin in PBS containing 0.05% Tween-20. 
Immunodetection was performed with the monoclonal mouse anti-PCNA or anticaspase-3 
(both from Cell Signaling Technology, Beverly, MA, USA) and the anti-actin antibody (Sigma-
Aldrich), the latter as a control to ensure equal protein loading. Detection was performed 
by incubation with rabbit anti-mouse horseradish peroxidase conjugated antibody 
(DAKOCytomation, Glostrup, Denmark) and enhanced chemiluminescence by using the GE 
Healthcare detection system (GE Healthcare, UK). Intensities of the bands were quantified 
using TotalLab Quant Software (TotalLab Ltd, Newcastle upon Tyne, UK). The mean of the 
quantification by two independent observers (BvH, HR) was used to calculate overall means 
per incubation condition.
rna isolation and real-time quantitative polymerase chain reaction
Total RNA was isolated using TRIzol reagent (Invitrogen) and 1 μg RNA was converted into 
cDNA according to the instructions provided by the Roche Transcriptor High Fidelity 
cDNA synthesis kit (Roche Diagnostics). Detection and quantification of COX-2 messenger 
RNA was performed via real-time quantitative PCR (qPCR) using the CFX96 Real-Time PCR 
Detection System (Bio-Rad Laboratories). Analysis of COX-2 expression was performed 
using the primers 5’-CCGGGTACAATCGCACTTAT-3’ and 5’-GGCGCTCAGCCATACAG- 3’ 
(Isogen Life Science, Maarssen, The Netherlands) and SYBR Green (Molecular Probes, 
Eugene, OR, USA). Specificity of PCR products for COX-2 was confirmed using melting 
curve analysis and agarose gel electrophoresis. β-2 microglobulin (β2M) was used as a 
normalizing control (ΔΔCt method). Analysis of β2M was performed with the primers 
5’-ATGAGTATGCCTGCCGTGTG- 3’ and 5’-CCAAATGCGGCATCTTCAAAC-3’ with a specific 
probe 5’-FAMCGCGTCGTGGGATGGAGACATGTAAGCAGACGCGDabcyl- 3’ (Biolegio, Nijmegen, 
The Netherlands). The β2M product was specified by agarose gel electrophoresis. The 
PCR procedure was performed in triplicate on each sample from the two independent 
incubation experiments and the mean of the triplets was used to calculate overall mean of the 
two experiments.
statistical analyses
Results are expressed as mean with standard error of mean (SEM). To evaluate differences 
between the six incubation conditions, the one-way ANOVA-test was performed. When the 
ANOVA-test was statistically significant (P-value of <0.05, two-sided), statistical significance 
between different incubation conditions was evaluated using the post hoc Tukey’s pairwise 
comparison. Statistical analyses were performed using GraphPad Prism, version 4.00 (GraphPad 
Software Inc., San Diego, CA, USA). 
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Figure 1. A: Cell survival curves: HT-29 and LT97 cells after treatment with celecoxib. HT-29 cells (B) and 
LT97 cells (C) after 24h treatment with taurine-conjugated bile acids cholic acid (CA), chenodeoxycholic 
acid (CDCA), ursodeoxycholic acid (UDCA) and ‘artificial bile’ composed of 50% CA and 50% CDCA. 
Cell survival was measured with WST-1 assay after treatment of the cells at selected concentration 
ranges of 1.5-100μM for celecoxib and 3.1-3200μM for UDCA, CA, CDCA, or CA/CDCA. The highest non-
cytotoxic concentrations of celecoxib and the taurine-conjugated bile acids, represented by the highest 
concentrations at the plateau of the cell survival curves, were selected for further experiments (for exact 
concentrations, see Table 1). Note that the X-axis represents a logarithmic scale. Abbreviations: CA, tauro-
cholic acid; CDCA, tauro-chenodeoxycholic acid; UDCA, tauro-ursodeoxycholic acid.
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ReSULTS
cell survival assays
Cell survival curves of HT-29 and LT97 cells after 24h of incubation with celecoxib and the 
taurine-conjugated bile acids are shown in Figure 1. Based on these curves, we subtracted non-
cytotoxic dosages of celecoxib and bile acids for the incubation experiments (see Table 1).
cell growth assays
Results of the cell growth experiments are shown in Figure 2. In HT-29 cells, incubation with 
either celecoxib or UDCA alone had no significant effect on cell growth after either 48 or 
72h of incubation. However, the combination of celecoxib and UDCA resulted in a decrease 
in cell growth of 14 and 17% after 48 and 72h, respectively. A more pronounced effect of the 
Figure 2. Cell growth of HT-29 and LT97 cells after 48 and 72 hours of treatment with specified substances. 
Cell viability was assessed by WST-1 assay. Control condition, cells without additives, was taken as reference. 
One-way ANOVA was statistically significant with p<0.0001 in A-D; test results of post hoc tests comparing 
treatment conditions with control condition: * statistically significant p<0.05, ** statistically significant 
p<0.01, *** statistically significant p<0.001. Abbreviations: Coxib, celecoxib; UDCA, tauro-ursodeoxycholic 
acid; BA, bile acids tauro-cholic acid and tauro-chenodeoxycholic acid.
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combination was observed in LT97 cells, namely 23 and 27% decrease after 48 and 72h of 
incubation, respectively. When cells were exposed to UDCA enriched ‘artificial bile’, cell growth 
decreased significantly in HT-29 cells, either in absence or presence of celecoxib. In LT97 
cells incubated with enriched ‘artificial bile’, a significant decrease in cell growth was found 
only in the presence of celecoxib. Post hoc comparison of the condition with UDCA enriched 
‘artificial bile’ without celecoxib (condition 5) vs. UDCA enriched ‘artificial bile’ with celecoxib 
(condition 6), revealed no differences in cell growth in both cell line models.
cell proliferation (pcna) and apoptosis (caspase-3) by Western blot assay
Results of Western blot analyses of the cell proliferation marker PCNA and the apoptosis marker 
caspase-3 are shown in Figures 3 and 4, respectively. No significant changes in levels of PCNA 
or caspase-3 were found in any of the tested incubation conditions. 
Figure 3. Western blot analyses of PCNA protein in HT-29 and LT97 cells after 48 and 72 hours of treatment 
with specified substances. Control condition, cells without additives, was taken as reference. One-way 
ANOVA was not statistically significant with p>0.05 in A-D; post hoc tests were therefore not performed. 
Abbreviations: Coxib, celecoxib; UDCA, tauro-ursodeoxycholic acid; BA, bile acids tauro-cholic acid and 
tauro-chenodeoxycholic acid.
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coX-2 expression by qpcr
To determine whether the observed effects on cell growth were associated with down-
regulation of COX-2, we assessed COX-2 mRNA expression by qPCR. Results are shown in 
Figure 5. Note that an increase in mean ΔΔCt values indicates a decrease in COX-2 mRNA 
expression relative to the control condition. Although effects on mRNA expression seem 
apparent after 72h of incubation in both HT-29 and LT97 cells, a statistically significant 
difference was only observed in LT97 cells after 72h of incubation (p<0.05). Post hoc tests 
showed a significant increase in COX-2 mRNA expression after incubation with UDCA 
enriched ‘artificial bile’ in the presence of celecoxib (p<0.05). Other pairwise comparisons 
were not statistically significant.
Figure 4. Western blot analyses of caspase-3 protein in HT-29 and LT97 cells after 48 and 72 hours of 
treatment with specified substances. Control condition, cells without additives, was taken as reference. 
One-way ANOVA was not statistically significant with p>0.05 in A-D; post hoc tests were therefore not 
performed; Abbreviations: Coxib, celecoxib; UDCA, tauro-ursodeoxycholic acid; BA, bile acids tauro-
cholic acid and tauro-chenodeoxycholic acid.
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DISCUSSIOn
The aim of the present study was to explore the chemopreventive potential of celecoxib in 
combination with taurine-conjugated UDCA with respect to (duodenal) adenomatosis in 
patients with FAP. Therefore, effects on cell growth and COX-2 expression were investigated 
in LT97 human colorectal micro-adenoma cells derived from a patient with FAP in comparison 
with the well-established HT-29 colon adenocarcinoma cells.
We observed that combination treatment with low dose (10μM) of the selective COX-2 
inhibitor celecoxib and the tertiary bile acid UDCA (1mM) has a modest growth inhibitory effect 
on HT-29 cells. This effect was even more pronounced in LT97 colorectal micro-adenoma cells, 
derived from a patient with FAP. We found no evidence of a growth inhibiting effect of low dose 
Figure 5. COX-2 mRNA expression in HT-29 and LT97 cells after 48 and 72 hours of treatment with specified 
substances, assessed by real-time quantative PCR. Control condition, cells without additives, was taken 
as reference. Results are expressed as value of ΔΔCt. One-way ANOVA was not statistically signifant with 
p>0.05 in A-C, but statistically significant with p<0.05 in D, post hoc test were therefore only performed 
in D: * statistically significant with p<0.05; Abbreviations: Coxib, celecoxib; UDCA, tauro-ursodeoxycholic 
acid; BA, bile acids tauro-cholic acid and tauro-chenodeoxycholic acid.
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celecoxib (10μM) alone in either HT-29 or LT97 cells, which is in line with results from previous 
studies in several gastrointestinal tumor cell lines.28-31 However, considerable antiproliferative 
effects in HT-29 cells, as well as in other colorectal carcinoma cell lines, were previously 
described for higher (>25μM) concentrations of celecoxib.28-30
Two important differences between the present study and most other studies are to be 
noted. Firstly, we used serum-free chemically defined PC-1 cell culture medium without fetal 
bovine serum (FBS). FBS is commonly used in many in vitro studies, but the composition varies 
due to batch-to-batch differences, which may influence results.32 For example, expression of 
COX-2 and resistance to apoptosis in HT-29 cells were found to be influenced by culturing in the 
presence or absence of fetal bovine serum.33 Secondly, we used low doses of celecoxib (10μM), 
in contrast to higher doses used in most other in vitro studies. As high in vivo doses of celecoxib 
are undesirable because of associated cardiotoxicity11,12, we applied a near-physiological 
concentration of celecoxib, close to serum concentrations that were achieved in patients with 
FAP treated with celecoxib.34 However, concentrations of celecoxib applied in most in vitro cell 
culture experiments were much higher (>40μM).
After prophylactic colectomy in patients with FAP, the composition of the circulating 
bile acid pool changes and duodenal bile largely contains glycine- or taurine-conjugated 
CA and CDCA in nearly equal amounts.25 In in vitro models of human colon cancer cells, 
non-conjugated UDCA, but more in particular taurine-conjugated UDCA, significantly 
reduced cytotoxicity of secondary bile acids.17 By supplementing patients with FAP with 
high dosage of UDCA, up to 50% enrichment of duodenal bile with UDCA was reached, 
with a large reduction in concentration of the cytotoxic bile acid CDCA.26 In addition, a 
non-significant reduction of COX-2 expression in the duodenal mucosa of these patients 
was noted immunohistochemically.26 Because of this reduction in biliary concentrations of 
CDCA and mucosal COX-2, an inhibition of cell proliferation can be expected after UDCA 
supplementation. UDCA was also found to have a suppressing effect on COX-2 in a rat model 
of colon carcinogenesis, suggesting an alternative and possibly complimentary pathway for 
COX-2-enzyme inhibition.21,22
Therefore, we performed our in vitro experiments using an adenoma cell line derived from a 
patient with FAP, and mimicked the in vivo situation as studied before26, in which bile of patients 
with FAP was enriched with the less cytotoxic UDCA, partly replacing the more cytotoxic CDCA. 
In addition, we tested whether a synergistic effect of low dose celecoxib and UDCA exists.
In our experiments, cell growth decreased significantly in HT-29 cells exposed to UDCA 
enriched ‘artificial bile’, mimicking in vivo bile exposure in patients with FAP treated with 
UDCA, either in absence or presence of celecoxib. In LT97 cells incubated with UDCA enriched 
‘artificial bile’, a significant decrease in cell growth was found only in the presence of celecoxib. 
These findings suggest that celecoxib exerts additional beneficial growth inhibiting effects in 
FAP-derived adenoma cells and not in carcinoma cells.
Both LT97 and HT-29 cells were characterized as having mutations in the tumor suppressor 
gene APC.24,35 Previous studies have demonstrated high levels of COX-2 expression in HT-29 
cells36 and low basal COX-2 expression in LT97 cells37. The difference we observed in effects on 
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cell growth between HT-29 and LT97 after incubation with UDCA enriched ‘artificial bile’ with/
without celecoxib, might be explained mainly by the low levels of COX-2 present in LT97 cells, 
which may be more efficiently inhibited by low dose celecoxib, as compared to HT-29 cells, with 
high basal levels of COX-2. The relative insensitivity of LT97 cells towards bile acids alone, as 
noticed in our study, was previously reported.37 In general, LT97 cells seem to be more resistant 
to bile acids alone, whereas the combination of low dose celecoxib and bile acids exerts more 
inhibition of cell proliferation, in comparison to HT-29 cells.
Multiple lines of evidence, including results from in vitro studies, animal studies, as well 
as clinical studies, indicate that inhibition of the increased COX-2 expression, often noticed 
in carcinogenic processes, at least in part accounts for the anti-proliferative activity of 
celecoxib.38 In addition, COX-2 independent pathways have been suggested to be involved in 
the anti-proliferative effect of celecoxib.38,39 Anti-proliferative effects with low concentrations 
of celecoxib, were achieved in vitro in COX-2 deficient prostate cancer cells.40 Furthermore, it 
was clearly demonstrated that high doses of celecoxib (>50μM) are able to induce apoptosis, 
but low doses, including the dose we used (10μM), did not induce apoptosis in three colon 
tumor cells lines, including HT-29.38 In our study, no significant changes in the levels of PCNA 
or caspase-3 were found, indicating that the involvement of these pathways in the growth 
inhibition by celecoxib and UDCA at the concentrations used in our experiments seems 
modest. We found a significant increase in COX-2 mRNA expression in LT97 cells only after 
72h of treatment with UDCA enriched ‘artificial bile’ in the presence of celecoxib. However, 
after 72h of incubation with celecoxib, either in the presence of absence of bile acids, in 
both cell lines a general tendency of increased COX-2 mRNA levels seems to be apparent, 
which may be explained as resulting from an overshoot mechanism. As a reaction to an 
initial inhibition of COX-2, transcription may be stimulated by a feedback mechanism, and 
mRNA levels may be up-regulated, resulting in higher levels after longer incubation periods. 
The limited effects on COX-2 mRNA levels however, may also further support the concept 
of involvement of COX-2 independent pathways. Experiments that specifically focus on 
any of the COX-2 dependent and independent pathways will be required to elucidate the 
precise mechanism of the growth reduction achieved by combination treatment of low dose 
celecoxib and UDCA.
In conclusion, in vitro incubation with a combination of low dose celecoxib and UDCA 
exerts growth inhibitory effects in colorectal micro-adenoma cells derived from a patient with 
FAP, whereas incubation with celecoxib or UDCA alone did not show such an effect. Our in vitro 
results should encourage further research on the low dose celecoxib and UDCA combination 
therapy as promising chemopreventive strategy for patients with FAP, who have a high-risk of 
developing gastrointestinal neoplasms.
90
ReFeRenCeS
1. Bodmer WF, Bailey CJ, Bodmer J, Bussey HJ, 
Ellis A, Gorman P, Lucibello FC, Murday VA, 
Rider SH, Scambler P, Sheer D, Solomon E, 
Spurr NK. Localization of the gene for familial 
adenomatous polyposis on chromosome 5. 
Nature 1987;328:614-6.
2. Bulow S. Results of national registration 
of familial adenomatous polyposis. Gut 
2003;52:742-6.
3. Belchetz LA, Berk T, Bapat BV, Cohen Z, 
Gallinger S. Changing causes of mortality in 
patients with familial adenomatous polyposis. 
Dis Colon Rectum 1996;39:384-7.
4. De Campos FG, Perez RO, Imperiale AR, Seid 
VE, Nahas SC, Cecconello I. Evaluating causes 
of death in familial adenomatous polyposis. J 
Gastrointest Surg 2010;14:1943-9.
5. Bulow S, Bjork J, Christensen IJ, Fausa O, 
Jarvinen H, Moesgaard F, Vasen HF. Duodenal 
adenomatosis in familial adenomatous 
polyposis. Gut 2004;53: 381-6.
6. Vasen HF, Bulow S, Myrhoj T, Mathus-Vliegen 
L, Griffioen G, Buskens E, Taal BG, Nagengast 
F, Slors JF, de Ruiter P. Decision analysis in 
the management of duodenal adenomatosis 
in familial adenomatous polyposis. Gut 
1997;40:716-9.
7. De Vos tot Nederveen Cappel WH, Järvinen 
HJ, Björk J, Berk T, Griffioen G, Vasen HF. 
Worldwide survey among polyposis registries 
of surgical management of severe duodenal 
adenomatosis in familial adenomatous 
polyposis. Br J Surg 2003;90:705-10.
8. Latchford AR, Neale KF, Spigelman AD, Phillips 
RK, Clark SK. Features of duodenal cancer in 
patients with familial adenomatous polyposis. 
Clin Gastroenterol Hepatol 2009;7:659-63.
9. De Castro SM, van Eijck CH, Rutten JP, 
Dejong CH, van Goor H, Busch OR, Gouma 
DJ. Pancreas-preserving total duodenectomy 
versus standard pancreatoduodenectomy for 
patients with familial adenomatous polyposis 
and polyps in the duodenum. Br J Surg 
2008;95:1380-6.
10. Greenhough A, Smartt HJ, Moore AE, 
Roberts HR, Williams AC, Paraskeva C, Kaidi 
A. The COX-2/PGE2 pathway: key roles in the 
hallmarks of cancer and adaptation to the 
tumour microenvironment. Carcinogenesis 
2009;30:377-86.
11. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, 
Hajer J, Zavoral M, Lechuga MJ, Gerletti P, 
Tang J, Rosenstein RB, Macdonald K, Bhadra 
P, Fowler R, Wittes J, Zauber AG, Solomon 
SD, Levin B. Celecoxib for the prevention of 
colorectal adenomatous polyps. N Engl J Med 
2006;355:885-95.
12. Bertagnolli MM, Eagle CJ, Zauber AG, Redston 
M, Solomon SD, Kim K, Tang J, Rosenstein 
RB, Wittes J, Corle D, Hess TM, Woloj GM, 
Boisserie F, Anderson WF, Viner JL, Bagheri 
D, Burn J, Chung DC, Dewar T, Foley TR, 
Hoffman N, Macrae F, Pruitt RE, Saltzman 
JR, Salzberg B, Sylwestrowicz T, Gordon GB, 
Hawk ET. Celecoxib for the prevention of 
sporadic colorectal adenomas. N Engl J Med 
2006;355:873-84.
13. Oshima M, Dinchuk JE, Kargman SL, Oshima 
H, Hancock B, Kwong E, Trzaskos JM, Evans 
JF, Taketo MM. Suppression of intestinal 
polyposis in Apc delta716 knockout mice by 
inhibition of cyclooxygenase 2 (COX-2). Cell 
1996;87:803-9.
14. Steinbach G, Lynch PM, Phillips RK, Wallace 
MH, Hawk E, Gordon GB, Wakabayashi N, 
Saunders B, Shen Y, Fujimura T, Su LK, Levin B. 
The effect of celecoxib, a cyclooxygenase-2 
inhibitor, in familial adenomatous polyposis. N 
Engl J Med 2000;342:1946-52.
15. Debinski HS, Trojan J, Nugent KP, Spigelman 
AD, Phillips RK. Effect of sulindac on small 
polyps in familial adenomatous polyposis. 
Lancet 1995;345:855-6.
16. Phillips RK, Wallace MH, Lynch PM, Hawk E, 
Gordon GB, Saunders BP, Wakabayashi N, Shen 
Y, Zimmerman S, Godio L, Rodrigues-Bigas M, 
Su LK, Sherman J, Kelloff G, Levin B, Steinbach 
G. A randomised, double blind, placebo 
controlled study of celecoxib, a selective 
cyclooxygenase 2 inhibitor, on duodenal 
polyposis in familial adenomatous polyposis. 
Gut 2002;50:857-60.
17. Shekels LL, Beste JE, Ho SB. 
Tauroursodeoxycholic acid protects in vitro 
models of human colonic cancer cells from 
cytotoxic effects of hydrophobic bile acids. J 
Lab Clin Med 1996;127:57-66.
18. Alberts DS, Martinez ME, Hess LM, Einspahr 
JG, Green SB, Bhattacharyya AK, Guillen J, 
Krutzsch M, Batta AK, Salen G, Fales L, Koonce 
K, Parish D, Clouser M, Roe D, Lance P. Phase 
III trial of ursodeoxycholic acid to prevent 
23
4
91
1
7
8
9
6
&
5
Celecoxib & UDCA co-treatment in intestinal tumor cell lines
colorectal adenoma recurrence. J Natl Cancer 
Inst 2005;97:846-53.
19. Tung BY, Emond MJ, Haggitt RC, Bronner 
MP, Kimmey MB, Kowdley KV, Brentnall 
TA. Ursodiol use is associated with lower 
prevalence of colonic neoplasia in patients 
with ulcerative colitis and primary sclerosing 
cholangitis. Ann Intern Med 2001;134:89-95.
20. Pardi DS, Loftus EV Jr, Kremers WK, Keach 
J, Lindor KD. Ursodeoxycholic acid as a 
chemopreventive agent in patients with 
ulcerative colitis and primary sclerosing 
cholangitis. Gastroenterology 2003;124:889-
93.
21. Wali RK, Khare S, Tretiakova M, Cohen G, 
Nguyen L, Hart J, Wang J, Wen M, Ramaswamy 
A, Joseph L, Sitrin M, Brasitus T, Bissonnette 
M. Ursodeoxycholic acid and F(6)-D(3) 
inhibit aberrant crypt proliferation in the rat 
azoxymethane model of colon cancer: roles 
of cyclin D1 and E-cadherin. Cancer Epidemiol 
Biomarkers Prev 2002;11:1653-62.
22. Khare S, Mustafi R, Cerda S, Yuan W, 
Jagadeeswaran S, Dougherty U, Tretiakova 
M, Samarel A, Cohen G, Wang J, Moore C, 
Wali R, Holgren C, Joseph L, Fichera A, Li 
YC, Bissonnette M. Ursodeoxycholic acid 
suppresses Cox-2 expression in colon cancer: 
roles of Ras, p38, and CCAAT/enhancer-
binding protein. Nutr Cancer 2008;60:389-
400.
23. Jacoby RF, Cole CE, Hawk ET, Lubet RA. 
Ursodeoxycholate/Sulindac combination 
treatment effectively prevents intestinal 
adenomas in a mouse model of polyposis. 
Gastroenterology 2004;127:838-44.
24. Richter M, Jurek D, Wrba F, Kaserer K, Wurzer 
G, Karner-Hanusch J, Marian B. Cells obtained 
from colorectal micro-adenomas mirror early 
premalignant growth patterns in vitro. Eur J 
Cancer 2002;38:1937-45.
25. Barker GM, Radley S, Bain I, Davis A, Lawson 
AM, Keighley MR, Neoptolemos JP. Biliary 
bile acid profiles in patients with familial 
adenomatous polyposis before and after 
colectomy. Br J Surg 1994;81:441-4.
26. Berkhout M, Roelofs HM, Friederich P, van 
Schaik A, Gosens MJ, Marian B, Pool-Zobel BL, 
van Krieken JH, Peters WH, Nagengast FM. 
Ursodeoxycholic acid intervention in patients 
with familial adenomatous polyposis: a pilot 
study. Transl Res 2007;150:147-9.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 
Protein measurement with the Folin phenol 
reagent. J Biol Chem 1951;193:265-75.
28. Lev-Ari S, Strier L, Kazanov D, Madar-
Shapiro L, Dvory-Sobol H, Pinchuk I, Marian 
B, Lichtenberg D, Arber N. Celecoxib and 
curcumin synergistically inhibit the growth 
of colorectal cancer cells. Clin Cancer Res 
2005;11:6738-44.
29. Grösch S, Tegeder I, Niederberger E, Bräutigam 
L, Geisslinger G. COX-2 independent induction 
of cell cycle arrest and apoptosis in colon 
cancer cells by the selective COX-2 inhibitor 
celecoxib. FASEB J 2001;15:2742-4.
30. Schiffmann S, Maier TJ, Wobst I, Janssen A, 
Corban-Wilhelm H, Angioni C, Geisslinger 
G, Grosch S. The anti-proliferative potency 
of celecoxib is not a class effect of coxibs. 
Biochem Pharmacol 2008;76:179-87.
31. Lev-Ari S, Kazanov D, Liberman E, Ben-Yosef 
R, Arber N. Down-regulation of PGE2 by 
physiologic levels of celecoxib is not sufficient 
to induce apoptosis or inhibit cell proliferation 
in human colon carcinoma cell lines. Dig Dis 
Sci 2007;52:1128-33.
32. van der Valk J, Brunner D, de Smet K, Fex SA, 
Honegger P, Knudsen LE, Lindl T, Noraberg 
J, Price A, Scarino ML, Gstraunthaler G. 
Optimization of chemically defined cell 
culture media--replacing fetal bovine serum 
in mammalian in vitro methods. Toxicol In 
Vitro 2010;24:1053-63.
33. Battu S, Rigaud M, Beneytout JL. Resistance to 
apoptosis and cyclooxygenase-2 expression 
in a human adenocarcinoma cell line HT29 
CL.19A. Anticancer Res 1998;18:3579-83.
34. Davies NM, McLachlan AJ, Day RO, 
Williams KM. Clinical pharmacokinetics 
and pharmacodynamics of celecoxib: a 
selective cyclo-oxygenase-2 inhibitor. Clin 
Pharmacokinet 2000;38:225-42.
35. Huang F, Hsu S, Yan Z, Winawer S, Friedman 
E. The capacity for growth stimulation by TGF 
beta 1 seen only in advanced colon cancers 
cannot be ascribed to mutations in APC, DCC, 
p53 or ras. Oncogene 1994;9:3701-6.
36. Shao J, Sheng H, Inoue H, Morrow JD, 
DuBois RN. Regulation of constitutive 
cyclooxygenase-2 expression in colon 
carcinoma cells. J Biol Chem 2000;275:33951-6.
37. Jurek D, Fleckl E, Marian B. Bile acid induced 
gene expression in LT97 colonic adenoma 
cells. Food Chem Toxicol 2005;43:87-93.
92
38. Maier TJ, Schilling K, Schmidt R, Geisslinger 
G, Grösch S. Cyclooxygenase-2 (COX-
2)-dependent and -independent 
anticarcinogenic effects of celecoxib in human 
colon carcinoma cells. Biochem Pharmacol 
2004;67:1469-78.
39. Grösch S, Maier TJ, Schiffmann S, Geisslinger 
G. Cyclooxygenase-2 (COX-2)-independent 
anticarcinogenic effects of selective COX-2 
inhibitors. J Natl Cancer Inst 2006;98:736-47.
40. Patel MI, Subbaramaiah K, Du B, Chang M, Yang 
P, Newman RA, Cordon-Cardo C, Thaler HT, 
Dannenberg AJ. Celecoxib inhibits prostate 
cancer growth: evidence of a cyclooxygenase-
2-independent mechanism. Clin Cancer Res 
2005;11:1999-2007.


Clinical chemoprevention trial
section c

Ursodeoxycholic acid counteracts 
celecoxib in reduction of duodenal 
polyps in patients with familial 
adenomatous polyposis: A multicentre, 
randomized controlled trial
chapter 6
Bjorn WH van Heumen1, Hennie MJ Roelofs1, M Elisa Vink-Börger2, Evelien Dekker3, 
E (Lisbeth) MH Mathus-Vliegen3, Jan Dees4, Jan J Koornstra5, Alexandra MJ Langers6, 
Iris D Nagtegaal2, Ellen Kampman7, Wilbert HM Peters1, Fokko M Nagengast1 
Departments of Gastroenterology & Hepatology1, Pathology2, and Health Evidence7, Radboud University 
Nijmegen Medical Centre; Department of Gastroenterology & Hepatology, Academic Medical Centre, 
Amsterdam3; Erasmus Medical Centre, Rotterdam4; University Medical Centre Groningen5 and Leiden 
University Medical Centre6, The Netherlands.
Acknowledgements: The authors thank Dr W Kievit for statistical assistance, MWJ van Vugt-van 
Pinxteren, CC Cohen, AC de Groot, M de Ley, A Beneken-Kolmer, BM de Klerk, and Dr JW Poley for 
logistic support, and Drs RPR Adang, LGJB Engels, P Friederich, BE Schenk, NC Talstra, JR Vermeijden, 
WH de Vos tot Nederveen Cappel, PJ Wahab, BJM Witteman, and FL Wolters for their efforts to refer 
patients with FAP to our clinic. Dr Falk Pharma (Freiburg, Germany) provided ursodeoxycholic acid and 
placebo tablets without involvement in study design, collection, analysis and interpretation of data, 
in the writing of the paper or in the decision to submit it for publication.
PUBLISHED IN: ORPHANET JOURNAL OF RARE DISEASES, 2013, 8:118.
98
ABSTRACT
Due to prophylactic colectomy, mortality in patients with familial adenomatous polyposis (FAP) 
has changed, with duodenal cancer currently being the main cause of death. Although celecoxib 
reduces duodenal polyp density in patients with FAP, its long-term use may increase the risk of 
cardiovascular events and alternatives need to be explored. Preclinical studies suggest that the 
combination of celecoxib with ursodeoxycholic acid (UDCA) is a potentially effective strategy. 
We performed a randomized, double-blind, placebo-controlled trial to investigate the effect of 
celecoxib and UDCA co-treatment on duodenal adenomatosis in patients with FAP. Patients with 
FAP received celecoxib (400mg twice daily) and UDCA (1000-2000mg daily, 20-30mg/kg/day, 
n=19) or celecoxib and placebo (n=18) orally for 6 months. Primary outcome was drug efficacy, 
assessed by comparing pre- and post-intervention duodenal polyp density by blinded review 
of endoscopic recordings. As secondary outcomes, cell proliferation, apoptosis, and COX-2 
levels in normal duodenal mucosa were assessed by immunohistochemistry or real-time 
quantitative polymerase chain reaction. In intention-to-treat analysis, decreased polyp 
density was observed after celecoxib/placebo treatment (p=0.029), whereas increased polyp 
density was observed after celecoxib/UDCA treatment (p=0.014). The difference in change in 
duodenal polyp density was statistically significant between the groups (p=0.011). No changes 
in secondary outcomes were observed. Thirty patients (81%) reported one or more adverse 
events, 16 patients (84%, Common Toxicity Criteria for Adverse Events version  3.0 (CTCAE) 
grade 1-3) treated with celecoxib/UDCA and 14 patients (78%, CTCAE grade 1-2) treated with 
celecoxib/placebo. Nine patients (24%) discontinued intervention prematurely, 5 patients 
(26%) treated with celecoxib/UDCA and 4 patients (22%) treated with celecoxib/placebo. In 
conclusion, celecoxib reduces duodenal polyp density in patients with FAP, and unexpectedly, 
high dose UDCA co-treatment counteracts this effect. The benefit of long term use of celecoxib 
for duodenal cancer prevention needs to be weighed against the (risk of) adverse events.
Keywords: familial adenomatous polyposis; chemoprevention; celecoxib; ursodeoxycholic acid; duodenal 
adenomatosis; cell proliferation; apoptosis; cyclooxygenase-2
Abbreviations: AEs, adverse events; AMC, Academic Medical Centre Amsterdam; APC, adenomatous 
polyposis coli; β2M, beta-2 microglobulin; CA, cholic acid; CDCA, chenodeoxycholic acid; COX-2, 
cyclooxygenase-2; CTCAE, Common Toxicity Criteria for Adverse Events; EMC, Erasmus Medical Centre 
Rotterdam; FAP, familial adenomatous polyposis; H&E, hematoxylin&eosin; LUMC, Leiden University 
Medical Centre; NSAIDs, non-steroidal anti-inflammatory drugs; PSC: primary sclerosing cholangitis; 
qPCR, real-time quantitative polymerase chain reaction; RUNMC, Radboud University Nijmegen Medical 
Centre; UC: ulcerative colitis; UDCA, ursodeoxycholic acid; UMCG, University Medical Centre Groningen
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In the past decades, prophylactic colectomy to prevent development of colorectal cancer 
substantially improved prognosis in patients with familial adenomatous polyposis (FAP).1 The 
mortality pattern has changed and duodenal cancer now is the main cancer-related cause 
of death.2,3 Lifetime risk of duodenal adenomas approaches 100% 4, and approximately 3-7% 
of patients develop duodenal cancer.5,6 As duodenal cancer in patients with FAP has a poor 
prognosis7,8, the clinical challenge is to identify patients with high-risk duodenal adenomas 
and intervene before progression to cancer occurs. Prophylactic duodenectomy may offer a 
prolonged disease-free interval, but is associated with substantial morbidity and mortality.9,10 
Therefore, chemoprevention would be highly desirable to postpone or even avoid the necessity 
for radical surgery.
Cyclooxygenase (COX) inhibiting non-steroidal anti-inflammatory drugs (NSAIDs) have 
been investigated extensively as potential chemopreventive drugs. COX-2 is induced in 
inflammatory and tumorigenic settings.11 Overexpression of COX-2, as found in colorectal 
adenomas and carcinomas, was linked to reduced apoptosis, enhanced cell growth, tumour 
angiogenesis, tissue invasion, and metastasis.11 Treatment with the COX-2 inhibitor celecoxib 
resulted in regression of colorectal adenomas in patients with FAP12, as well as in significant 
decrease in sporadic colorectal adenomas.13,14
For duodenal polyposis, the value of COX inhibiting agents is not yet established.15 Sulindac 
showed regression of small duodenal polyps in patients with FAP16,17, but had no benefit in 
controlling periampullary polyposis.18 The significant reduction in duodenal polyp density after 
6 months of treatment with high dose celecoxib in patients with FAP with clinically significant 
disease was promising.19
Unfortunately, suitability of COX-2 inhibitors for long-term use is subject of discussion, 
due to increased risks of adverse cardiovascular events.13,14,20 Combining celecoxib with 
other potentially effective drugs could be a more effective strategy. A candidate drug is 
ursodeoxycholic acid (UDCA), for a number of reasons. First, the clustering of adenomas 
around the ampulla of Vater suggests that bile plays a role in duodenal adenomatosis.21 In 
in vitro models of human colorectal cancer cells, UDCA significantly reduced cytotoxicity 
of secondary bile acids22, and celecoxib and UDCA co-treatment inhibited cell growth 
in colorectal adenoma cells from a patient with FAP.23 Second, clinical studies showed 
chemopreventive effects of UDCA on development of colorectal neoplasms, in patients 
with sporadic colorectal adenomas, and in patients with ulcerative colitis (UC) and primary 
sclerosing cholangitis (PSC).24-26 Third, UDCA was found to suppress COX-2 levels in a rat 
model of colonic carcinogenesis27, suggesting an alternative pathway for COX-2 inhibition.28 
Finally, in a mouse model of FAP, sulindac and UDCA co-treatment showed synergistic effects 
in the prevention of intestinal adenomas.29
Based on these findings, the aim of the present randomized controlled trial was to examine 
the effect of celecoxib plus UDCA co-treatment, in comparison to celecoxib plus placebo, 
on duodenal adenomatosis in patients with FAP. We hypothesized that adding UDCA to the 
treatment with celecoxib results in a further reduction of duodenal polyp density. 
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PATIenTS AnD MeTHODS
This clinical trial (http://ClinicalTrials.gov number NCT00808743) was conducted according to 
ICH Good Clinical Practice and complied with the principles of the amended Declaration of 
Helsinki and Dutch legislation. Ethical approval was obtained at the initiating centre Radboud 
University Nijmegen Medical Centre (RUNMC; Protocol approval number 2008/148; CCMO 
number NL23569.091.08). In the other participating centres, feasibility was approved by the 
local Medical Ethics Committees. All study participants provided written informed consent. 
The study was monitored by a RUNMC Safety Monitoring Board.
study participants
The study population consisted of patients with FAP recruited from the cohort under regular 
surveillance at the RUNMC, Academic Medical Centre Amsterdam (AMC), Erasmus Medical 
Centre Rotterdam (EMC), University Medical Centre Groningen (UMCG), and Leiden University 
Medical Centre (LUMC). The study was conducted between June 2009 and June 2011.
The diagnosis FAP was established either clinically, by the presence of >100 colorectal 
polyps, or genetically, by the presence of adenomatous polyposis coli (APC) gene mutations. 
Eligible patients were between 18 and 70 years of age, capable of informed consent, had 
Spigelman stage II or III duodenal adenomatosis at last surveillance duodenoscopy, and had 
no history of surgical duodenal resection. Exclusion criteria included peptic ulcer disease, 
inflammatory bowel disease, cardiovascular disease (congestive cardiac failure with New 
York Heart Association class ≥II; history of ischemic heart disease and/or cerebrovascular 
disease) or significant cardiovascular risk (at least two of the following risk factors: 
hypertension, hypercholesterolaemia, diabetes mellitus, ≥2 first degree relatives with 
cardiovascular event below the age of 55 years), abnormal results on a full blood count 
or abnormal liver or renal function tests, known intolerability of NSAIDs, sulfonamids, or 
UDCA, use of NSAIDs or UDCA for >1 week during 6 months prior to study entry, use of 
lithium, and pregnancy or lactation.
study procedures
Evaluation at baseline included history taking, physical examination, and clinical laboratory 
evaluation (full blood count, liver and renal function, cholesterol). Endoscopic procedures 
were performed using a side-viewing endoscope (Olympus TJF-160, Olympus Medical Systems 
Europe, Hamburg, Germany) and a forward-viewing endoscope (Olympus GIF-1T-Q160) 
successively. Endoscopic procedures were recorded digitally. After completion of the recording 
procedures, six random biopsies of normal appearing mucosa were taken in the second (D2) 
portion of the duodenum. Two biopsies were fixed in formalin and embedded in paraffin, four 
biopsies were snap frozen in liquid nitrogen and stored at -80°C. Biopsies were taken using 
an Olympus Endojaw FB-232U with open forceps diameter 9mm, or a Boston Scientific Radial 
Jaw 3 with open forceps diameter 8mm (Boston Scientific, Natick, MA, USA). Procedures were 
repeated after 6 months. At baseline, no biopsies of adenomatous lesions were taken, as this 
could influence primary outcome.
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After completion of pre-intervention duodenoscopy, patients were randomly assigned to 
one of two treatment groups in an 1:1 ratio. Randomization was performed at the Department 
of Clinical Pharmacy RUNMC, by a computer-generated schedule, to assign sequentially 
numbered treatment packs in randomized blocks of four. Patients, physicians, and investigators 
were blinded to treatment allocation. Patients in group A received orally for 6 months: 
celecoxib (Celebrex, Pfizer, New York, NY, USA) 400mg twice daily (once daily during the first 
2 weeks), in combination with UDCA (Ursofalk, Dr Falk Pharma, Freiburg, Germany). Patients 
in study group B received orally for 6 months: celecoxib 400mg twice daily (once daily during 
the first 2 weeks), in combination with an UDCA identical-appearing placebo (Dr Falk Pharma). 
UDCA/placebo was given in two daily doses, with total daily UDCA dose based on body weight: 
≤50kg: 1000mg, 50-70kg: 1500mg, >70kg: 2000mg (20-30mg/kg/day). UDCA starting dose was 
500mg, which was raised with 500mg every 2 weeks until maximum dose was reached. The 
placebo contained lactose and cellulose.
Information on adverse events (AEs) was obtained during patient contacts by telephone 
at 1 and 3 months, and prior to post-intervention duodenoscopy at 6 months. Monitoring of 
blood pressure and clinical laboratory parameters was performed at 1 and 6 months. AEs were 
graded as defined by the Common Toxicity Criteria for Adverse Events version 3.0 (CTCAE 
v3.0).30 Compliance was monitored by means of pill counts and review of diaries completed by 
the patients.
Disclosure of randomization was performed by the Department of Clinical Pharmacy 
RUNMC on December 10th 2012, after completion of assessment of recorded duodenoscopies 
and all tissue analyses.
assessment of recorded endoscopic procedures
Endoscopic recordings were analyzed using qualitative assessment of duodenal polyp density, 
as previously described in patients with FAP for the colorectum12 and duodenum19. In short, 
five gastroenterologists experienced in management of FAP (ED, JD, JJK, AMJL, FMN), 
independently scored the blinded pairs of pre- and post-intervention videos of each patient, 
shown in random order. Pairs were scored as no change (scored as 0), clinical improvement 
(scored as +1), or clinical deterioration (scored as -1) in polyp density. Based on the scores of the 
five gastroenterologists, mean scores of change in duodenal polyp density were calculated for 
each patient. Patients that discontinued intervention prematurely were included in intention-
to-treat analysis with a score of change in duodenal polyp density of -0.5.
immunohistochemical staining for cell proliferation, apoptosis, and coX-2
Tissue sections of 4μm were cut from paraffin blocks, mounted on electrostatic slides (Super 
Frost Plus, Menzel-Gläser, Baunschweig, Germany) and stained with Hematoxylin & Eosin 
(H&E). Only samples with normal histology (non-dysplastic and non-adenomatous mucosa), as 
verified by an expert pathologist (IDN), were used for further analyses. 
Tissue sections were deparaffinized and dehydrated. Endogenous peroxidase was blocked 
with 3% hydrogen peroxide. Subsequently, heat-induced antigen retrieval was performed 
in sodium citrate buffer (10mmol/L, pH=6). Cell proliferation activity was assessed after 
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staining for 1 hour at room temperature with mouse anti-human MIB-1 monoclonal antibody 
(Dako A/S, Glostrup, Denmark) at dilution 1:200. MIB-1 recognizes the Ki-67 nuclear antigen 
of dividing cells.31 Apoptosis was assessed by staining overnight at 4°C with mouse anti-
human M30 CytoDEATH monoclonal antibody (Roche Diagnostics, Mannheim, Germany) 
at dilution 1:400. M30 recognizes cleaved cytokeratin 18, expressed in epithelial cells during 
early apoptosis.32 COX-2 was assessed by staining overnight at 4°C with mouse anti-human 
COX-2 monoclonal antibody (Cayman Chemical, Ann Arbor, MI, USA) at dilution 1:100. 
Visualization of MIB-1 was achieved using the Brightvision (1:1)/BrightDab detection system 
(Immunologic, Duiven, The Netherlands), whereas M30 and COX-2 were visualized using the 
avidin-biotin peroxidase complex method (Vector Laboratories, Burlingame, CA, USA). Mayer 
hematoxylin counterstaining was applied. Tissue sections of colorectal carcinomas were used 
as positive controls.
evaluation of immunohistochemical staining and scoring
Tissue samples were independently evaluated by light microscopy (Leica Microsystems, 
Rijswijk, The Netherlands) by two investigators (BWHvH, MEV-B). If scores differed, a consensus 
agreement was reached during re-evaluation. A random selection of 10% of scores were re-
evaluated and verified by an expert pathologist (IDN). Cell proliferation index was expressed as 
percentage of MIB-1 positive epithelial cells in areas of the tissue section with well-orientated 
crypt-villi architecture. Apoptotic index was expressed as number of M30 positive epithelial 
cells per mm2 tissue area. COX-2 staining in epithelial cells was scored as previously described33: 
0, no staining; 1, weak cytoplasmatic and membranous staining (may contain strong staining in 
<10% of cells); 2, moderate-to-strong staining in 10-90% of cells; and 3, strong staining in >90% 
of cells.
rna isolation and real-time quantitative polymerase chain reaction (qpcr) for 
coX-2
One biopsy sample of each location was weighed and taken up in 200μl TRIzol (Life Technologies, 
Pailey, UK). Tissue was homogenized by 10 strokes with a Teflon pestle. After homogenization, 
another 600μl TRIzol was added. Total RNA was extracted according to the manufacturer’s 
instructions (Life Technologies) with a slight modification: prior to precipitating the RNA with 
isopropyl alcohol, 7.5μg RNAse-free glycogen was added to the aqueous phase. Approximately 
1 μg RNA was converted into cDNA according to the instructions provided by the Roche 
Transcriptor High Fidelity cDNA synthesis kit (Roche Diagnostics). Detection and quantification 
of COX-2 messenger RNA was performed by qPCR using the CFX96 Real-Time PCR Detection 
System (Bio-Rad Laboratories, Hercules, CA, USA). Analysis of COX-2 expression was performed 
using two different COX-2 specific primer sets: forward 5’-GGCGCTCAGCCATACAG-3’(exon 1) 
with reverse 5’-CCGGGTACAACTGCACTTAT-3’(exon 2) and forward 5’-GGCGCTCAGCCATACAG-
3’(exon 1) with reverse 5’-TCTTGTCAAAAATTCCGGTG-3’ (exons 2 and 3) (Isogen Life Science, 
Maarssen, The Netherlands). PCR products were detected with SYBR Green (Molecular 
Probes, Eugene, OR, USA). Specificity of COX-2 PCR products was checked using melting 
curve analysis and agarose gel electrophoresis. Levels of β-2 microglobulin (β2M) mRNA 
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were used as a normalizing control. Analysis of β2M was performed with the primers 
5’-ATGAGTATGCCTGCCGTGTG- 3’ and 5’-CCAAATGCGGCATCTTCAAAC-3’ with a specific probe 
5’-FAMCGCGTCGTGGGATGGAGACATGTAAGCAGACGCGDabcyl- 3’ (Biolegio, Nijmegen, The 
Netherlands). The β2M product was checked by agarose gel electrophoresis. PCR procedures 
were performed in triplicate or quadruplicate and mean Ct values were calculated.
statistical analysis
Baseline characteristics were expressed as percentage or medians with range when appropriate. 
Continuous variables were considered to be not normally distributed. Differences between 
treatment groups on continuous variables were tested using Mann-Whitney U test, and 
differences on discrete variables were examined using Chi-square test, or Fisher’s exact test 
when appropriate. Differences on continuous and ordinal variables within treatment groups, 
comparing pre- and post-intervention measurements, were examined using Wilcoxon Signed 
Rank test and McNemar’s test, respectively. Analyses of primary outcome were performed 
on an intention-to-treat basis, with a per-protocol analysis as sensitivity analysis. Based on an 
assumed relevant and detectable reduction of 20% in polyp size as primary outcome, sample 
size was set at 40 patients per treatment group to demonstrate a significant difference at the 
5% significance level with a statistical power of 80%. A p-value of <0.05 (2-sided) was considered 
statistically significant. Statistical analysis was performed using SPSS statistical software version 
21 (IBM SPSS, Chicago, IL, USA).
ReSULTS
patient characteristics
The CONSORT diagram of the study is depicted in Figure 1. Of all patients with FAP that were 
under regular surveillance in the five participating University hospitals, 94 patients were eligible 
for inclusion. Twenty-three patients were excluded based on exclusion criteria and 29 patients 
declined informed constent. Forty-two patients underwent initial duodenoscopy, of which five 
patients were not randomized: four had insufficient polyps and one patient required treatment 
because of advanced duodenal adenomatosis. Thirty-seven patients were randomized: 
19 patients received celecoxib & UDCA (group A) and 18 patients received celecoxib & placebo 
(group B). Patient characteristics are depicted in Table 1. Due to technical failure, either pre- or 
post-intervention recordings could not be analysed in five patients. Consequently, thirty-two 
patients (group A, n=17; group B, n=15) were analysed on an intention-to-treat basis for the 
primary outcome. Nine patients (24.3%) discontinued intervention prior to duodenoscopy at 
six months. Consequently, per-protocol analysis was performed on 23 patients (group A, n=12; 
group B, n=11). 
primary outcome: change in duodenal polyp density
In the intention-to-treat analysis, clinical deterioration (n=17, median= -0.2, range:-0.6-
+0.4) in duodenal polyp density was observed in group A (Wilcoxon Signed Rank, p=0.014), 
receiving celecoxib & UDCA, while clinical improvement (n=15, median=0.6, range:-0.5-+1.0) 
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Figure 1. CONSORT diagram. Abbreviations: FAP, familial adenomatous polyposis; NSAID,  non-
steroidal anti-inflammatory drugs; UDCA, ursodeoxycholic acid. 
  
Figure 1. CONSORT diagram. Abbreviations: FAP, familial adenomatous polyposis; NSAID, non-steroidal 
anti-inflammatory drugs; UDCA, ursodeoxycholic acid.
was observed in group B (Wilcoxon Signed Rank, p=0.029), receiving celecoxib & placebo 
(Figure 2). The difference in mean score of change in duodenal polyp density was statistically 
significant between groups (Mann-Whitney U, p=0.011).
In the per-protocol analyses, the difference in mean score of change in duodenal polyp 
density between group A (n=12, median=-0.2, range:-0.6-+0.4) and group B (n=11, median=0.8, 
range:0.0-+1.0) was more pronounced (Mann-Whitney U, p<0.001). Clinical deterioration in 
duodenal polyp density observed in group A was not statistically significant (Wilcoxon Signed 
Rank, p=0.271), in contrast to the clinical improvement observed in group B (p=0.004).
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Table 1. Base-line characteristics of patients with FAP.
Overall 
population
Group A:
Celecoxib&UDCA
Group B:
Celecoxib&Placebo p-value
Number of patients 37 19 18
Age at study entry, median/range (yr) 42/22-67 42/22-67 41/27-64 0.964(3)
Sex (n, %) 0.618(4)
Male 18 (48.6) 10 (52.6) 8 (44.4)
Female 19 (51.4) 9 (47.4) 10 (55.6)
Participants per centre (n, %) 0.932(5)
RUNMC 18 (48.6) 10 (52.6) 8 (44.4)
AMC 10 (27.0) 4 (21.1) 6 (33.3)
EMC 4 (10.8) 2 (10.5) 2 (11.1)
UMCG 3 (8.1) 2 (10.5) 1 (5.6)
LUMC 2 (5.4) 1 (5.3) 1 (5.6)
Body Mass Index, median/range (kg/m2) 25.6/18.8-34.5 26.0/19.2-34.5 25.6/18.8-33.1 0.408(3)
Diagnosis FAP 0.660(5)
Clinical only 6 (16.2) 4 (21.2) 2 (11.1)
APC gene mutation 31 (83.8) 15 (78.9) 16 (88.9)
Age at primary CR surgery, median/range (yr) 21/7-60 22/7-60 18.5/11-48 0.298(3)
Time since primary CR surgery, median/
range (yr)
18/1-38 17/1-33 20.5/8-38 0.178(3)
Type of primary CR surgery 0.738(5)
IRA 18 (48.6)(1) 10 (52.6)(1) 8 (44.4)
IPAA 14 (37.8) 6 (31.6) 8 (44.4)
Ileostomy 5 (13.5) 3 (15.8) 2 (11.1)
Secondary CR surgery (n, %) 11 (29.7) 5 (26.3) 6 (33.3) 0.641(4)
Spigelman stage at last surveillance before 
entry
0.985(4)
II 19 (51.4)(2) 10 (52.6) 9 (50)(2)
III 17 (45.9)(2) 9 (47.4) 8 (44.4)(2)
(1) Including one patient who underwent ileosigmoid anastomosis; (2) In 1 case exact data on last previous 
surveillance duodenoscopy was missing; (3) The p-value was calculated using the Mann-Whitney U test; (4) The 
p-value was calculated using the chi-square test; (5) The p-value was calculated using the Fisher’s exact test
Abbreviations: FAP, familial adenomatous polyposis; APC, adenomatous polyposis coli; CR, colorectal; IRA, 
Ileorectal anastomosis; IPAA, Ileal pouch-anal anastomosis; Ileostomy, proctocolectomy with ileostomy; UDCA, 
ursodeoxycholic acid; AMC, Academic Medical Centre Amsterdam; EMC, Erasmus Medical Centre Rotterdam; 
LUMC, Leiden University Medical Centre; RUNMC, Radboud University Nijmegen Medical Centre; UMCG, 
University Medical Centre Groningen
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secundary outcome: cell proliferation, apoptosis, and coX-2 immunohistochemistry
Changes in cell proliferation, apoptosis, and COX-2 were evaluated in all patients that 
completed the intervention period and underwent pre- and post-intervention duodenoscopy, 
with one additional patient excluded in group B of whom post-intervention biopsies could not 
be assessed (n=27).
Median difference in cell proliferation pre- versus post-intervention was not statistically 
significant between both treatment groups (group A: n=14, median difference =-5.0%, 
range=-20.0%-10.0%; group B: n=13, median difference=0.0%, range:-15.0%-20.0%; Mann-
Whitney U, p=0.141). The median decrease in cell proliferation of 5.0% observed in group A was 
not statistically significant (Wilcoxon Signed Rank, p=0.057).
No M30 positive apoptotic epithelial cells were scored in any of the evaluated samples, 
except for positive control samples.
COX-2 staining was scored as either moderate-to-strong or strong staining in all evaluated 
samples. No difference in COX-2 staining was seen comparing pre- and post-intervention: in 
group A, a decreased score was observed in 2 patients, an equal score in 8 patients, and an 
Celecoxib & UDCA co-treatment for duodenal adenomatosis in FAP 
density observed in group A was not statistically significant (Wilcoxon Signed Rank, p=0.271), in 
contrast to the clinical improvement observed in group B (p=0.004). 
 
 
Figure 2: Box-Whisker plots of intention-to-treat and per-protocol analysis. Intention-to-treat analysis 
of mean score of change in duodenal polyp density comparing duodenoscopic recordings pre- and 
post-intervention with either celecoxib & UDCA (group A) or celecoxib & placebo (group B): clinical 
deterioration in group A (n=17, Wilcoxon Signed Rank, p=0.014), clinical improvement in group B 
(n=15, Wilcoxon Signed Rank, p=0.029); difference in mean score between groups statistically 
significant (Mann-Whitney U, p=0.011). Per-protocol analysis: clinical deterioration in group A (n=12, 
Wilcoxon Signed Rank, p=0.271), clinical improvement in group B (n=11, Wilcoxon Signed Rank, 
p=0.004); difference in mean score between groups statistically significant (Mann-Whitney U, 
p<0.001); Abbreviation: UDCA, ursodeoxycholic acid. 
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positive control samples. 
Figure 2. Box-Whisker plots of intention-to-treat and per-protocol analysis. Intention-to-treat analysis of 
mean score of change in duodenal polyp density comparing duodenoscopic recordings pre- and post-
intervention with either celecoxib & UDCA (group A) or celecoxib & placebo (group B): clinical deterioration 
in group A (n=17, Wilcoxon Signed Rank, p=0.014), clinical improvement in group B (n=15, Wilcoxon Sig ed 
Rank, p=0.029); difference in mean score between groups statistically significant (Mann-Whitney U, 
p=0.011). Per-protocol alysis: clinical deterioration in group A ( =12, Wil oxon Sign d R nk, p=0.271), 
clinical improvement i  group B (n=11, Wilcoxon Signed Rank, p=0.004); difference in mean sc re between 
groups statistically significant (Mann-Whitney U, p<0.001); Abbreviation: UDCA, ursodeoxycholic acid.
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increased score in 3 patients (McNemar, p=1.000). In group B, a decreased score was observed in 
4 patients, an equal score in 6 patients, and an increased score in 2 patients (McNemar, p=0.688).
secondary outcome: coX-2 mrna analyses
COX-2 mRNA expression was also evaluated in all patients that completed the intervention 
period, with the noted one additional patient excluded in group B (n=27).
In 12 patients (group A: n=6, group B: n=6), no measurable COX-2 mRNA levels were present 
in either pre- or post-intervention sample. In all other cases, low COX-2 mRNA levels seemed 
present, but specificity of PCR products could not be confirmed by melting curve analyses and 
agarose gel electrophoresis. Experiments in which the second set of specific COX-2 primers 
were used, showed the same results. Simultaneous qPCR analyses on colorectal cancer tissue 
samples showed high levels of COX-2 specific qPCR products.
adverse events and compliance 
AEs were analysed for all randomized patients (n=37). An overview of all 58 AEs reported by 
30 patients (81.1%) is shown in Table 2. In group A (n=19), 10 grade 1, 18 grade 2, and 6 grade 3 
AEs were reported by 16 patients (84.2%), whereas in group B (n=18), 9 grade 1, and 15 grade 
2 AEs were reported by 14 patients (77.8%) (Fisher’s exact, p=0.114). Five patients (26.3%) 
discontinued intervention in group A, due to complaints of abdominal pain and diarrhea (n=1), 
diarrhea (n=1), mood alteration/depression (n=1), fatigue and anal/perianal pain (n=1), and skin 
rash (n=1). Four patients (22.2%) discontinued intervention in group B, due to complaints of 
skin rash (n=1), chest pain, palpitations, and dyspnea (n=1), dyspnea (n=1), and dyspepsia (n=1) 
(Fisher’s exact, p=1.000). Two patients in group A reported insomnia and edema of the lower 
limbs respectively, which resolved after reducing the celecoxib dose to halve the standard trial 
dose. Both patients completed the intervention period and were included in the analyses.
Compliance was evaluated in all patients that completed the 6 months intervention period 
(n=28). In group A, the median compliance for celecoxib and UDCA was 98.4% (range: 82.4-
100%) and 96.8% (range: 42.2-100%), respectively. In group B, the median compliance for 
celecoxib and placebo was 99.4% (range: 79.1-100%) and 97.0% (range: 80.3-100%), respectively.
Table 2. Adverse Events in patients with FAP treated with either celecoxib & ursodeoxycholic acid or 
celecoxib & placebo. (Continued).
CTCAe Category name adverse event
Treatment groups
Group A
n=19
Group B
n=18
Auditory/Ear Otitis, middle ear 1 (0/1/0) 0
Blood/Bone marrow Anemia - hemoglobin 1 (1/0/0) 0
Leukopenia 1 (0/1/0) 0
Cardiac arrhythmia Palpitations 0 2 (2/0/0)
Constitutional symptoms Fatique 2 (0/1/1) 1 (0/1/0)
Insomnia 1 (0/0/1) 0
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Table 2. Adverse Events in patients with FAP treated with either celecoxib & ursodeoxycholic acid or 
celecoxib & placebo. (Continued).
CTCAe Category name adverse event
Treatment groups
Group A
n=19
Group B
n=18
Dermatology/Skin Hair loss - scalp 1 (1/0/0) 0
Rash 1 (0/1/0) 1 (0/1/0)
Gastrointestinal Constipation 2 (2/0/0) 2 (2/0/0)
Diarrhea 2 (1/1/0) 2 (2/0/0)
Heartburn/dyspepsia/nausea 4 (1/3/0) 2 (1/1/0)
Ulcera - oral 0 1 (1/0/0)
Ulcera - ileum/colon/rectum 1 (1/0/0) 0
Hepatobiliary/Pancreas Pancreas irritation(1) 0 1 (0/1/0)
Infection Infection - gastroenteritis 1 (0/1/0) 2 (0/2/0)
Infection - dental-tooth 1 (0/1/0) 1 (0/1/0)
Infection - skin 1 (0/1/0) 1 (0/1/0)
Lymphatics Edema - lower limbs 2 (1/1/0) 0
Metabolic/Laboratory Elevated AST, GGT 1 (1/0/0) 1 (1/0/0)
Hypokalemia 1 (0/0/1) 0
Neurology Dizzyness 1 (1/0/0) 0
Mood alteration - depression 1 (0/0/1) 0
Neuropathy - carpal tunnel syndrome 1 (0/1/0) 0
Pain Abdominal 1 (0/0/1) 0
Anal/perianal 4 (0/4/0) 1 (0/1/0)
Joint 0 1 (0/1/0)
Chest/thorax 0 1 (0/1/0)
Pulmonary/Upper respiratory Dyspnea 0 2 (0/2/0)
Nasal cavity/paranasal sinus reaction 0 2 (0/2/0)
Renal/Genitourinary Lower urinary tract symptoms - prostatism 1 (0/1/0) 0
Secondary malignancy Secondary malignancy - basalioma - nose 1 (0/0/1) 0
Total n of reported AE 34 (10/18/6)(2) 24 (9/15/0)(2)
Patients reporting ≥1 AE (n, %) 16 (84.2%) 14 (77.8%)
Number of specific adverse event reported during 6 month intervention in patients with FAP with either 
celecoxib & ursodeoxycholic acid (group A) or celecoxib & placebo (group B), is depicted as grade 1, 2, or 3, as 
defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grade 4 and 5 adverse 
events did not occur.
(1) Adverse event related to pre-intervention duodenoscopy; no other adverse events related to duodenoscopy 
were reported; (2) Distribution of number of adverse events grade 1, 2, or 3, was not significantly different 
between treatment groups (Fisher’s exact, p=0.114). Abbreviations: FAP, familial adenomatous polyposis; AST, 
aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; AE, Adverse Event.
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DISCUSSIOn
This randomized controlled trial confirms that celecoxib mono-treatment reduces duodenal 
polyp density in patients with FAP, whereas it demonstrates that celecoxib and UDCA co-
treatment has no beneficial effect. In contrast to our hypothesis of an expected additional 
effect of the combination, our results imply that the clinical improvement observed in patients 
treated with celecoxib alone is counteracted by co-treatment with UDCA. We found no changes 
in cell proliferation, apoptosis or COX-2 expression in normal duodenal mucosa of patients with 
FAP, that could explain the observed effects.
The clinical improvement of duodenal polyp density after treatment with celecoxib alone, 
confirms results from a previous trial with similar design.19 COX-2 overexpression was found 
in oesophageal 34, gastric 35, colorectal 36, as well as small intestinal cancer.37 Multiple lines of 
evidence, including results from in vitro, animal, and clinical studies, indicated that inhibition 
of the increased COX-2 expression, at least in part accounts for the anti-proliferative activity 
of celecoxib.38 In addition, COX-2 independent pathways were suggested to be involved in the 
anti-proliferative effect of celecoxib.38,39 To our surprise, we found a high COX-2 expression by 
immunohistochemical analyses, but detected no COX-2 mRNA expression in normal appearing 
duodenal mucosa of patients with FAP, neither pre- nor post-intervention. Consequently, 
controversy exists between assessment of COX-2 by immunohistochemistry or qPCR assay. 
We assume that results on COX-2 in immunohistochemistry could be based on aspecific 
protein staining by the COX-2 antibody. Assessment of duodenal COX-2 mRNA levels by using 
Quantigene Plex Assay, confirmed our findings with the qPCR assay: COX-2 mRNA expression 
is extremely low or even absent in normal duodenal mucosa of patients with FAP (van Heumen 
et  al., unpublished results, Chapter 7 of this thesis). Our results are in agreement with a 
previous report of undetectable COX-2 mRNA levels in human small intestinal mucosa by using 
qPCR analysis.37
After prophylactic colectomy, duodenal bile composition changes and largely consists 
of cholic acid (CA) and chenodeoxycholic acid (CDCA).40 In in vitro models of human colon 
cancer cells, UDCA significantly reduced cytotoxicity of secondary bile acids.22 By UDCA 
supplementation in patients with FAP, up to 50% enrichment of duodenal bile with UDCA 
was reached, with a large reduction in concentration of the cytotoxic CDCA.41 Based on 
these findings, an inhibition of cell proliferation was expected after UDCA supplementation. 
Although we combined celecoxib and high dose UDCA (20-30mg/kg daily), the in vitro effects 
could not be reproduced in vivo in our trial. Moreover, our hypothesis was in part based on 
clinical studies in patients with UC and PSC showing chemopreventive effects of UDCA on 
development of colorectal neoplasms.25,26 Recently however, treatment of patients with UC and 
PSC with high dose UDCA (28-30mg/kg daily) was found to be associated with an increased 
risk of colorectal neoplasms.42 This could be an explanation for the disappointing effect we 
obtained by the combination treatment of celecoxib and high dose UDCA. In contrast, a recent 
meta-analysis revealed that long-term low dose UDCA treatment (8-15mg/kg daily) reduces 
the risk of advanced colorectal neoplasms in patients with UC and PSC.43 Extrapolating these 
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results, long-term low dose UDCA treatment could be expected to be effective in patients with 
advanced duodenal adenomatosis. However, in a recent clinical trial in patients with FAP, no 
effects of low dose UDCA (10mg/kg daily) after 24 months as mono-treatment were found on 
Spigelman scores.44 Future studies that focus on the intracellular mechanisms of action may 
elucidate the ambivalent effect of UDCA as chemopreventive drug in (pre-) clinical studies.
The present study has several strenghts. First, it is the first randomized clinical trial to 
investigate a combination of two potential chemopreventive drugs for duodenal adenomatosis in 
patients with FAP. Second, the study population consists of an unique sample of patients with FAP 
from 5 out of the 8 Dutch University Medical Centres. Third, bias due to interobserver variability 
was minimized, as primary outcome was based on scores of polyp density by 5 gastroenterologists, 
who independently compared pre- and post-intervention videos shown in random order, while 
blinded to treatment allocation. The following limitations are noted. First, our study lacks a ‘true 
placebo’ group. Hence, we were not able to confirm the spontaneous reduction in duodenal 
polyps in the placebo group, that was previously described.19,44 Second, changes in duodenal 
polyp density are assessed qualitatively. In previous chemopreventive studies on colorectal 
adenomatosis, changes in polyp density were assessed by exact counting of polyp number and 
measuring polyp diameter.12,45 This method is not suitable for assessment of the plaque-like 
duodenal polyps, which are partially obscured due to folding over the mucosal folds. Moreover, 
the curved anatomy of the duodenum introduces an optic bias in the two dimensional images 
obtained during endoscopy, which further hampers reliable quantification. In clinical practice, the 
Spigelman scoring system is an established tool to assess duodenal adenomatosis and is commonly 
used to plan follow up or treatment.4,46 In clinical science however, the Spigelman score seems 
insufficiently distinctive to detect subtle changes in polyp density, and it does not account for 
peri-ampullary adenomatosis specifically.47 The applied method of assessment in our study, which 
does include visual assessment of the peri-ampullary region by side-viewing duodenoscopy, 
permits adequate comparison with previous studies in the field.12,19,45 Third, although we were able 
to detect a significant difference in change in duodenal polyp density between the two treatment 
groups, sample size requirements were not met. As the participants already were under regular 
endoscopic surveillance and a chemopreventive option to their benefit was the aim of our study, 
we expected a high willingness to participate in the trial. However, of all eligible patients with FAP 
under regular surveillance in any of the five participating centres, 31% declined informed consent. 
Reports of cardiotoxicity of celecoxib13,14,20 could have withheld patients with FAP to participate. In 
addition, because of these reports, we applied strict exclusion criteria, leaving out another 24% 
of patients. We seemingly underestimated the required dedication to participate in the strenuous 
study protocol, which included a relatively short follow-up interval of 6 months, as compared 
to regular surveillance intervals of 2-3 years for patients with Spigelman stage II and 1-2 years for 
patients with Spigelman stage III.46 Chemopreventive therapies should be well tolerated and have 
a low toxicity. During intervention period, up to 81% of patients reported at least one adverse 
event, and 24% of patients discontinued intervention due to adverse events. Altogether, it seems 
unrealistic to expect that the regimens under investigation in the present study, would be suitable 
as a life-time chemopreventive treatment.
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In conclusion, high dose UDCA co-treatment completely counteracts the positive effect 
of celecoxib, namely the reduction of duodenal polyp density in patients with FAP. It still 
needs investigation whether low dose UDCA co-treatment does have a beneficial effect in this 
respect. The benefit of long term use of celecoxib for duodenal cancer prevention in patients 
with FAP needs to be weighed against the potential risk of (cardiovascular) adverse events. The 
search for effective chemopreventive strategies is ongoing and drugs of interest for patients 
with FAP include sulindac and difluoromethylornithine48, curcumin and quercetin49, and 
eicosapentaenoic acid.45 Future research has to result in suitable chemopreventive treatment 
regimes to avoid radical duodenectomy or duodenal cancer.
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ABSTRACT
Chemoprevention would be desirable to avoid duodenectomy in patients with familial 
adenomatous polyposis (FAP). Identification of risk markers in normal duodenal mucosa could 
help identify patients at increased risk for malignant transformation. Messenger RNA (mRNA) 
levels of glutathione S-transferase A1 (GSTA1), glutathione S-transferase P1 (GSTP1), KIAA1199, 
E-cadherin, peroxisome proliferative activated receptor δ (PPARδ), caspase-3, cyclin D1, 
β-catenin, and cyclooxygenase-2 (COX-2) were measured using the QuantiGene 2.0 Plex assay. 
Levels in endoscopically normal appearing mucosa of patients with FAP (n=37) were compared 
with levels in non-FAP patient controls (n=16). In addition, levels before and after treatment 
with either celecoxib & ursodeoxycholic acid (UDCA, n=14) or celecoxib & placebo (n=13) 
were evaluated in patients with FAP. mRNA levels of glutathione S-transferase A1 (28.16% vs. 
38.24%, p=0.008) and caspase-3 (3.30% vs. 5.31%, p=0.001) were significantly lower in patients 
with FAP vs. non-FAP patient controls, respectively. Effect on E-cadherin was significantly 
different between both treatment groups (p=0.006), however, within each treatment group 
no statistically significant change in mRNA level was observed. No other statistically significant 
differences were detected.
In conclusion, protection against toxins and carcinogens (GSTA1) and apoptosis (caspase-3) 
seems lower in patients with FAP, which could contribute to increased susceptibility for 
malignant transformation of duodenal mucosa. None of the potential risk markers was 
consistently influenced by either celecoxib or celecoxib & UDCA. COX-2 mRNA levels in normal 
duodenal mucosa of patients with FAP, were found to be unexpectedly low.
Keywords: familial adenomatous polyposis (FAP); duodenal mucosa; risk markers; celecoxib; 
ursodeoxycholic acid; duodenal adenomatosis
Abbreviations: AMC, Academic Medical Centre Amsterdam; APC, adenomatous polyposis coli; β2M, 
beta-2-microglobulin; COX-2, cyclooxygenase-2; EMC, Erasmus Medical Centre Rotterdam; FAP, familial 
adenomatous polyposis; GSTA1, glutathione S-transferase A1; GSTP1, glutathione S-transferase P1; GSTs, 
glutathione S-transferases; lef, lymphoid enhancer factor family; LUMC, Leiden University Medical Centre; 
NSAIDs, non-steroidal anti-inflammatory drugs; PGE2, prostaglandin E2; PPARδ, peroxisome proliferator-
activated receptor δ; qPCR, quantitative polymerase chain reaction; RUNMC, Radboud University 
Nijmegen Medical Centre; Tcf, T cell factor; UDCA, ursodeoxycholic acid; UMCG, University Medical 
Centre Groningen
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Familial adenomatous polyposis (FAP), characterized by the development of numerous 
premalignant colorectal adenomatous polyps, is caused by a germline mutation in the 
tumor suppressor adenomatous polyposis coli (APC) gene.1 In the past decades, preventing 
development of colorectal cancer by prophylactic colectomy, substantially improved prognosis 
in patients with FAP.2 As a result, the mortality pattern has changed and duodenal cancer now 
is the leading cancer-related cause of death.3, 4 Lifetime risk of duodenal adenomas approaches 
100% in patients with FAP5, and approximately 3-7% of patients eventually develop duodenal 
cancer.6, 7 As duodenal cancer in patients with FAP has been associated with a poor prognosis8, 9, 
the clinical challenge is to identify patients with high-risk duodenal adenomas and intervene 
before progression to cancer occurs. Identification of early risk markers in normal duodenal 
epithelium could help identify patients at increased risk for malignant transformation.
Potentially useful biomarkers can be expected in cellular pathways that are linked to the 
affected APC gene and its translational product. APC is a multifunctional protein involved in 
regulation of cell proliferation, cell migration, cell adhesion, cytoskeletal reorganisation, and 
chromosomal stability.10 The role of APC in intestinal carcinogenesis is attributed largely to the 
Wnt signaling pathway, but disruption of intercellular adhesion and stability of the cytoskeleton 
seems to be involved as well.11 Loss of functional APC results in accumulation of cytosolic 
β-catenin and subsequent translocation to the nucleus, where β-catenin associates with 
members of the T cell factor (Tcf) and lymphoid enhancer factor family (lef).11 The β-catenin/
Tcf complex activates several transcriptional targets, including the G1/S-regulating cyclin D112 
and the peroxisome proliferator-activated receptor δ (PPARδ).13 In addition, β-catenin also 
functions as an essential component of epithelial intercellular adherens junctions, where it links 
the cytoplasmic tail of E-cadherin to α-catenin which binds actin and actin-associated proteins 
of the microtubule cytoskeleton.14 KIAA1199 was recently described as a novel target of the Wnt 
signaling pathway, in both colon and gastric carcinogenesis.15, 16 While disruptions in the Wnt 
signaling pathway are involved in tumor initiation17, abnormal expression of cyclooxygenase-2 
(COX-2) observed in the majority of adenomas and carcinomas, is thought to play a crucial role 
in tumor progression by increasing the levels of prostaglandin E2 (PGE2).18 Overexpression of 
COX-2 is linked to reduced apoptosis, enhanced cell growth, tumor angiogenesis, and tissue 
invasion and metastasis.19 The involvement of the COX-2/PGE2 pathway may also explain the 
observed chemopreventive effects of COX inhibiting non-steroidal anti-inflammatory drugs 
(NSAIDs), decreasing the occurrence of sporadic colorectal adenomas.20, 21 Treatment with the 
COX-2 selective inhibitor celecoxib was found associated with regression of colorectal adenomas 
in patients with FAP.22 Significant reduction in duodenal polyp density in patients with FAP with 
clinically significant disease was achieved with high-dose celecoxib23, a finding we recently 
confirmed (see Chapter 6).24 Combining celecoxib with other potentially effective drugs could 
reveal more effective strategies. Based on several preclinical and clinical studies, ursodeoxycholic 
acid (UDCA) was a candidate drug.25-29 However, combining celecoxib with UDCA was found 
ineffective in reducing duodenal polyp density in patients with FAP (see Chapter 6).24
The clustering of adenomas around the ampulla of Vater suggests that cytotoxic bile 
plays a role in duodenal adenomatosis in patients with FAP.30 Detoxification enzymes, such as 
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glutathione S-transferases (GSTs), protect the gastrointestinal mucosa against exogenous and 
endogenous toxic, mutagenic or carcinogenic compounds by catalyzing the conjugation with 
glutathione.31 In patients with FAP, a significantly lower GST activity was observed in colonic 
mucosa as compared to healthy controls.32 Distorted expression levels of detoxification enzymes 
in the duodenum, could reduce functional activity and modulate individual susceptibility for 
development of duodenal adenomas and carcinomas in patients with FAP.
Aim of the present study was to gain further insight into the cellular targets of potential 
chemopreventive treatment for duodenal adenomatosis in patients with FAP, as well as to 
define epithelial risk markers of malignant transformation. We determined messenger RNA 
(mRNA) expression levels of potential risk markers in duodenal epithelium of patients with 
FAP in comparison to non-FAP patient controls. Furthermore, we investigated the effects of 
treatment with celecoxib or celecoxib & UDCA co-treatment on mRNA expression of these 
selected biomarkers.
PATIenTS AnD MeTHODS
study participants
The study population consists of patients with FAP and non-FAP patient controls. The patients 
with FAP, recruited at the Radboud University Nijmegen Medical Centre (RUNMC), Academic 
Medical Centre Amsterdam (AMC), Erasmus Medical Centre Rotterdam (EMC), University 
Medical Centre Groningen (UMCG), and Leiden University Medical Centre (LUMC), participated 
in a double-blind randomized clinical trial (http://ClinicalTrials.gov number NCT00808743), 
which is described in detail elsewhere (see Chapter 6).24 In short, after completion of pre-
intervention gastroduodenoscopy, patients with FAP were randomly assigned to one of two 
treatment groups. Patients in group A received celecoxib (Celebrex, Pfizer, New York, NY, USA) 
400 mg twice daily for 6 months in combination with UDCA (20-30mg/kg body weight daily; 
Ursofalk, Dr Falk Pharma, Freiburg, Germany). Patients in group B received celecoxib 400 mg 
twice daily in combination with an UDCA identical-appearing placebo (Dr Falk Pharma). The 
diagnosis FAP was established either clinically, by the presence of >100 colorectal polyps, or 
genetically, by the presence of adenomatous polyposis coli (APC) gene mutations. Eligible 
patients were between 18 and 70 years of age, capable of informed consent, had Spigelman 
stages II or III at last surveillance gastroduodenoscopy, and had no history of surgical duodenal 
resection. 
Patient controls were recruited at the Department of Gastroenterology & Hepatology, 
RUNMC. All patients aged 18 to 70 years and scheduled for diagnostic gastroduodenoscopy 
because of dyspepsia, or follow-up after previous diagnosis of upper gastrointestinal dysplasia 
or Barrett’s metaplasia, were selected. With permission from the referring physician, patients 
received a study information leaflet and an informed consent form by post. They were 
contacted by telephone one week before the planned gastroduodenoscopy to inquire if 
additional information was necessary, whether they were willing to participate, and if so, 
if any of the exclusion criteria were applicable. Exclusion criteria were: use of NSAIDs or UDCA 
for >1 week during 3 months prior to study entry, history of inflammatory bowel disease, 
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upper gastrointestinal cancer, upper gastrointestinal surgery, celiac disease, pregnancy, or 
lactation. Informed consent was obtained prior to gastroduodenoscopy. Patient controls were 
compensated for participation with €100.
From all participants, four random biopsies of normal appearing mucosa were taken in 
the D2 segment of the duodenum, as well as four random biopsies in the D3/D4 segment. An 
Olympus Endojaw FB-232U with open forceps diameter 9mm, or a Boston Scientific Radial Jaw 
3 with open forceps diameter 8mm (Boston Scientific, Natick, MA, USA) was used. Biopsies 
were snap frozen in liquid nitrogen and stored at -80°C for mRNA analyses. Patients with FAP 
underwent gastroduodenoscopy twice: at baseline and after the intervention period.
The present study was conducted according to ICH Good Clinical Practice and complied 
with the principles of the amended Declaration of Helsinki and Dutch legislation. Ethical 
approval was obtained at the initiating centre Radboud University Nijmegen Medical Centre 
(RUNMC; number 2008/148; CCMO number NL23569.091.08). All study participants provided 
written informed consent. Disclosure of randomization was performed by the Department of 
Clinical Pharmacy, RUNMC, on December 10th 2012, after all tissue assessments and analyses 
were completed.
isolation of rna from biopsies and quantification of duodenal mrna levels
One biopsy of each location was weighed and taken up in 200μL TRIzol (Life Technologies, 
Pailey, UK). Tissue was homogenized by 10 strokes with a Teflon pestle and after 
homogenization another 600μL TRIzol reagent was added. Total RNA was extracted according 
to the manufacturer’s instructions (Life Technologies) with a slight modification as follows: 
prior to precipitating the RNA with iosopropyl alcohol, 7.5μg RNAse-free glycogen was added 
as a carrier to the aqueous phase. Approximately 1μg of total purified RNA was used for the 
QuantiGene 2.0 Plex assay (Affymetrix, Santa Clara, CA, USA).
RNA was incubated with Luminex beads and capture probes according to the protocol of 
the manufacturer. Target-specific probe sets for beta-2-microglobulin (β2M, NM_004048), 
glutathione S-transferase A1 (GSTA1, NM_145740), glutathione S-transferase P1 (GSTP1, 
NM_000852), KIAA1199 (NM_018689), E-cadherin type 1 (CDH1, NM_004360), peroxisome 
proliferative activated receptor delta (PPARD, NM_006238), caspase-3 (CASP3, NM_004346), 
cyclin D1 (CCND1, NM_053056), beta-catenin-1 (CTNNB1, NM_001904) and cyclooxygenase-2 
(COX-2, NM_000963) were developed by Affymetrix. Signals of cascade amplification of the 
fluorescent microspheres were detected by the Biorad Luminex100 Bio-Plex system using the 
Bio-Plex Manager 4.1 software (Bio-Rad Laboratories, Hercules, CA). The mRNA expression 
level of the housekeeping gene β2M in each sample was used for normalization. mRNA levels 
were expressed as percentage relative to the levels of β2M, which were set at 100%. The mean 
of the mRNA expression levels at the D2 and D3/D4 locations was used in the analyses.
statistical analysis
Baseline characteristics were expressed as percentage or medians with range where 
appropriate. Outcome variables were expressed as group medians with 25 and 75 percentiles. 
Differences on discrete variables were examined using Chi-square test, or Fisher’s exact test 
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when appropriate. Continuous variables were considered to be not normally distributed. 
Differences on continuous variables of baseline characteristics and outcome measurements 
between groups, including measurements in patients with FAP at baseline versus non-FAP 
patient controls, and measurements in FAP patients treated with celecoxib & UDCA versus 
patients treated with celecoxib & placebo, were tested using Mann-Whitney U test. Differences 
within study groups, comparing pre- and post-intervention measurements in patients with 
FAP, were examined using Wilcoxon Signed Rank test. For baseline characteristics, a p-value 
of <0.05 (2-sided) was considered statistically significant. Since each analysis of the outcome 
measurement comprised a set of nine mRNA expression levels, a correction for multiple 
testing was applied. In each of these analyses, a p-value of <0.01 was considered statistically 
significant. Statistical analysis was performed using SPSS statistical software version 21 (IBM 
SPSS, Chicago, IL, USA).
ReSULTS
patient characteristics
Patient characteristics of patients with FAP and non-FAP patient controls are depicted in 
Table  1. Thirty-seven patients with FAP were randomized: 19 patients received celecoxib 
& UDCA (group A) and 18 patients received celecoxib & placebo (group B). Nine patients with 
FAP (24.3%; group A, n=5; group B, n=4) discontinued intervention prior to post-intervention 
gastroduodenoscopy at 6 months. In one patient in group B, post-intervention biopsies could 
Table 1. Baseline characteristics of the study population consisting of patients with FAP and non-FAP 
patient controls.
Overall
non-FAP group
Overall
FAP group p-value
FAP group A:
Celecoxib 
& UDCA
FAP group B:
Celecoxib 
& Placebo p-value
Number of patients 16 37 19 18
Age at study entry, 
median/range (yr)
53/23-67 42/22-67 0.092(1) 42/22-67 41/27-64 0.964(1)
Sex (n, %) 0.241(2) 0.618(2)
Male 5 (31) 18 (49) 10 (53) 8 (44)
Female 11 (69) 19 (51) 9 (47) 10 (56)
Body Mass Index, median/
range (kg/m2)
26.1/
19.4-44.2
25.6/
18.8-34.5
0.779(1) 26.0/
19.2-34.5
25.6/
18.8-33.1
0.408(1)
Spigelman score at last 
surveillance before entry
0.985(2)
II 19 (51)(3) 10 (53) 9 (50)(3)
III 17 (46)(3) 9 (47) 8 (44)(3)
(1) The p-value was calculated by the Mann-Whitney U test
(2) The p-value was calculated by the Chi-square test
(3) In 1 case data on Spigelman score at last surveillance gastroduodenoscopy before study entry was missing
Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid
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not be processed and for this patient only pre-intervention measurements were included in 
the analyses.
Seventeen non-FAP patient controls underwent gastroduodenoscopy as prescribed 
by the study protocol. One patient control was excluded from analyses, due to diagnosis of 
celiac disease based on histopathological examination of the biopsies, and 16 non-FAP patient 
controls were included in the analyses. Indications for gastroduodenoscopy were dyspepsia 
(n=10), iron deficiency anemia (n=1), follow-up after previous dysplasia or metaplasia in the 
upper gastrointestinal tract (n=4), and follow-up after Helicobacter pylori eradication (n=1).
patients with fap vs. non-fap patient controls
Median mRNA levels of selected genes in endoscopically normal appearing mucosa of patients 
with FAP before clinical intervention (n=37) were compared with the levels in non-FAP patient 
controls (n=16). Results are included in Tables 2a & 2b.
mRNA levels of GSTA1 and caspase-3 were significantly lower in patients with FAP when 
compared to levels in non-FAP patient controls (GSTA1: 28.16% [25-75%: 21.62%-37.90%] vs. 
38.24% [27.25%-51.76%]; Mann-Whitney U, p=0.008); caspase-3: 3.30% [2.46%-4.68%] vs. 5.31% 
[4.14%-6.77%]; Mann-Whitney U, p=0.001). No statistically significant difference in median 
duodenal mRNA levels between patients with FAP and non-FAP patient controls were found for 
GSTP1, KIAA1199, E-cadherin-1, PPARδ, cyclin D1, β-catenin-1, and COX-2.
patients with fap pre- vs. post-intervention
Pre- and post-intervention duodenal mRNA levels of selected genes were evaluated in patients 
with FAP, either treated with celecoxib & UDCA (group A, n=14) or celecoxib & placebo (group B, 
n=13). Results are shown in Tables 2a & 2b.
Comparison of median pre-intervention mRNA levels of the selected genes indicate that 
no differences existed at baseline between patients randomly assigned to group A vs. patients 
randomly assigned to group B (Mann-Whitney U, p>0.05).
The only difference in effect when comparing both intervention groups was found for 
E-cadherin type 1 (Mann-Whitney U, p=0.006). However, when evaluating the effects within 
each treatment group, no statistically significant change in mRNA level after treatment was 
observed, given the correction for multiple testing (group A: median difference = -1.35% 
[25-75%: -5.00%-0.68%], Wilcoxon Signed Rank, p=0.048; group B: median difference = 1.76% 
[-0.61%-5.00%], Wilcoxon Signed Rank, p=0.064). For any of the other mRNA levels, the 
interventions were found to have no statistically significant effects.
DISCUSSIOn
In the present study, expression of potential risk markers for malignant transformation were 
assessed by comparing their mRNA levels in normal appearing duodenal mucosa of patients 
with FAP with levels in non-FAP patient controls. Two important differences were revealed: 
duodenal mRNA levels of GSTA1 and caspase-3 were significantly lower in patients with FAP as 
compared to non-FAP patient controls. Lower duodenal levels of the detoxification enzyme 
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Table 2a. Duodenal mRNA levels of selected genes, expressed as median percentage relative to the mRNA 
level of the housekeeping gene β2M, set at 100%. Values expressed as mean with 25 and 75 percentiles. 
(For p-values of statistical analyses comparing mRNA levels of selected genes see Table 2b.)
n
Messenger RnA Messenger RnA (continued)
KIAA1199 COX-2 CDH1 PPARD GSTA1 CASP3 CCnD1 CTnnB1 GSTP1
Patient controls 16 0.04
(0.03-0.06)
0.05
(0.04-0.07)
16.43
(11.54-22.14)
0.73
(0.52-1.12)
38.24
(27.25-51.76)
5.31
(4.14-6.77)
4.20
(2.71-5.95)
26.90
(21.88-36.03)
9.69
(6.37-15.60)
Patients with FAP Total Pre-intervention 37 0.05
(0.03-0.24)
0.04
(0.03-0.05)
13.36
(10.82-15.73) 
0.71
(0.48-0.95)
28.16
(21.62-37.90)
3.30
(2.46-4.68)
3.72
(3.03-4.69)
24.84
(19.02-28.45)
7.64
(5.70-10.71)
Group A: Celecoxib 
& UDCA
Pre-intervention 19 0.04
(0.02-0.28)
0.04
(0.03-0.06)
13.54
(10.90-18.51) 
0.74
(0.54-1.05)
30.30
(23.16-36.54)
3.30
(2.47-5.21)
3.96
(2.63-4.72)
25.89
(19.80-31.89)
7.59
(5.78-11.07)
Post-intervention 14 0.04
(0.02-0.23)
0.04
(0.03-0.05)
13.72
(10.46-15.21) 
0.63
(0.50-1.28)
27.13
(21.28-33.30)
3.20
(2.88-4.11)
3.50
(2.81-5.24)
24.05
(20.96-30.27)
7.36
(6.22-10.47)
Group B: Celecoxib 
& placebo
Pre-intervention 18 0.09
(0.03-0.22)
0.03
(0.02-0.05)
11.66
(10.28-15.42) 
0.63
(0.45-0.87)
27.96
(19.84-39.44)
3.30
(2.42-4.43)
3.63
(3.18-4.63)
21.60
(18.63-27.89)
7.73
(5.46-10.27)
Post-intervention 13 0.24
(0.05-0.84)
0.05
(0.03-0.08)
14.08
(10.79-16.87) 
0.78
(0.58-1.20)
31.74
(21.02-47.12)
2.94
(2.58-4.83)
4.56
(3.09-5.56)
25.26
(19.93-33.62)
10.82
(7.44-16.18)
Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid; β2M, beta-2-microglobulin; 
COX-2, cyclooxygenase-2; CDH1, E-cadherin type 1; PPARD, peroxisome proliferative activated receptor delta; 
GSTA1, glutathione S-transferase A1; CASP3, caspase 3; CCND1, cyclin D1; CTNNB1, beta-catenin-1; GSTP1, 
glutathione S-transferase P1.
Table 2b. P-values of statistical analyses comparing duodenal mRNA levels of selected genes. (For 
duodenal mRNA levels of selected genes see Table 2a.)
Statistical test
P-values
KIAA1199 COX-2 CDH1 PPARD GSTA1 CASP3 CCnD1 CTnnB1 GSTP1
FAP pre-intervention vs. controls Mann-Whitney U 0.253 0.021 0.060 0.438 0.008(1) 0.001(1) 0.373 0.269 0.104
FAP: pre- vs. post-intervention Group A: celecoxib & UDCA Wilcoxon Signed Rank 0.730 0.826 0.048 0.778 0.272 0.074 0.730 0.272 0.433
Group B: celecoxib & placebo Wilcoxon Signed Rank 0.046 0.345 0.064 0.279 0.173 0.600 0.075 0.101 0.013
Group A vs. B: median of differences Mann-Whitney U 0.048 0.720 0.006(1) 0.583 0.048 0.128 0.259 0.043 0.019
(1) Statistically significant with correction for multiple testing applied (p<0.01).
Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid; β2M, beta-2-microglobulin; 
COX-2, cyclooxygenase-2; CDH1, E-cadherin type 1; PPARD, peroxisome proliferative activated receptor delta; 
GSTA1, glutathione S-transferase A1; CASP3, caspase 3; CCND1, cyclin D1; CTNNB1, beta-catenin-1; GSTP1, 
glutathione S-transferase P1.
GSTA1 could point at a lower capacity to detoxify toxins and carcinogens, with subsequent 
increased susceptibility for malignant degeneration.31 Previously, we reported a significantly 
lower GST enzyme activity in colonic mucosa of patients with FAP, as compared to healthy 
controls32, but surprisingly, no differences were found in duodenal mucosa of patients with 
FAP compared to patient controls.33 However, the sample size in this study was low (n=18), 
and GSTA1 and GSTA2 were simultaneously measured at the protein level.33 In contrast, in 
the present study GSTA1 was selectively measured at mRNA level in 37 patients. GSTP1 levels 
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Table 2a. Duodenal mRNA levels of selected genes, expressed as median percentage relative to the mRNA 
level of the housekeeping gene β2M, set at 100%. Values expressed as mean with 25 and 75 percentiles. 
(For p-values of statistical analyses comparing mRNA levels of selected genes see Table 2b.)
n
Messenger RnA Messenger RnA (continued)
KIAA1199 COX-2 CDH1 PPARD GSTA1 CASP3 CCnD1 CTnnB1 GSTP1
Patient controls 16 0.04
(0.03-0.06)
0.05
(0.04-0.07)
16.43
(11.54-22.14)
0.73
(0.52-1.12)
38.24
(27.25-51.76)
5.31
(4.14-6.77)
4.20
(2.71-5.95)
26.90
(21.88-36.03)
9.69
(6.37-15.60)
Patients with FAP Total Pre-intervention 37 0.05
(0.03-0.24)
0.04
(0.03-0.05)
13.36
(10.82-15.73) 
0.71
(0.48-0.95)
28.16
(21.62-37.90)
3.30
(2.46-4.68)
3.72
(3.03-4.69)
24.84
(19.02-28.45)
7.64
(5.70-10.71)
Group A: Celecoxib 
& UDCA
Pre-intervention 19 0.04
(0.02-0.28)
0.04
(0.03-0.06)
13.54
(10.90-18.51) 
0.74
(0.54-1.05)
30.30
(23.16-36.54)
3.30
(2.47-5.21)
3.96
(2.63-4.72)
25.89
(19.80-31.89)
7.59
(5.78-11.07)
Post-intervention 14 0.04
(0.02-0.23)
0.04
(0.03-0.05)
13.72
(10.46-15.21) 
0.63
(0.50-1.28)
27.13
(21.28-33.30)
3.20
(2.88-4.11)
3.50
(2.81-5.24)
24.05
(20.96-30.27)
7.36
(6.22-10.47)
Group B: Celecoxib 
& placebo
Pre-intervention 18 0.09
(0.03-0.22)
0.03
(0.02-0.05)
11.66
(10.28-15.42) 
0.63
(0.45-0.87)
27.96
(19.84-39.44)
3.30
(2.42-4.43)
3.63
(3.18-4.63)
21.60
(18.63-27.89)
7.73
(5.46-10.27)
Post-intervention 13 0.24
(0.05-0.84)
0.05
(0.03-0.08)
14.08
(10.79-16.87) 
0.78
(0.58-1.20)
31.74
(21.02-47.12)
2.94
(2.58-4.83)
4.56
(3.09-5.56)
25.26
(19.93-33.62)
10.82
(7.44-16.18)
Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid; β2M, beta-2-microglobulin; 
COX-2, cyclooxygenase-2; CDH1, E-cadherin type 1; PPARD, peroxisome proliferative activated receptor delta; 
GSTA1, glutathione S-transferase A1; CASP3, caspase 3; CCND1, cyclin D1; CTNNB1, beta-catenin-1; GSTP1, 
glutathione S-transferase P1.
Table 2b. P-values of statistical analyses comparing duodenal mRNA levels of selected genes. (For 
duodenal mRNA levels of selected genes see Table 2a.)
Statistical test
P-values
KIAA1199 COX-2 CDH1 PPARD GSTA1 CASP3 CCnD1 CTnnB1 GSTP1
FAP pre-intervention vs. controls Mann-Whitney U 0.253 0.021 0.060 0.438 0.008(1) 0.001(1) 0.373 0.269 0.104
FAP: pre- vs. post-intervention Group A: celecoxib & UDCA Wilcoxon Signed Rank 0.730 0.826 0.048 0.778 0.272 0.074 0.730 0.272 0.433
Group B: celecoxib & placebo Wilcoxon Signed Rank 0.046 0.345 0.064 0.279 0.173 0.600 0.075 0.101 0.013
Group A vs. B: median of differences Mann-Whitney U 0.048 0.720 0.006(1) 0.583 0.048 0.128 0.259 0.043 0.019
(1) Statistically significant with correction for multiple testing applied (p<0.01).
Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid; β2M, beta-2-microglobulin; 
COX-2, cyclooxygenase-2; CDH1, E-cadherin type 1; PPARD, peroxisome proliferative activated receptor delta; 
GSTA1, glutathione S-transferase A1; CASP3, caspase 3; CCND1, cyclin D1; CTNNB1, beta-catenin-1; GSTP1, 
glutathione S-transferase P1.
were found to be similar in duodenum of patients with FAP and patient controls, which is in 
accordance with our previous data.33
The lower level of caspase-3 found in patients with FAP, can also be considered as risk 
marker, as it suggests a decrease in apoptosis, with subsequent increased survival of cells with 
damaged DNA, prone for malignant degeneration. In a recent study, we were unable to detect 
apoptotic cells by immunohistochemistry in the normal duodenum of patients with FAP (see 
Chapter 6)24, which is consistent with our current finding using mRNA analysis.
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Multiple lines of evidence, including results from in vitro studies, animal studies, as well as 
clinical studies, indicate that inhibition of COX-2 expression, at least in part, accounts for the 
anti-proliferative activity of celecoxib.34 By using immunohistochemistry, COX-2 overexpression 
was reported in oesophageal35, gastric36, colorectal37, and small intestinal cancer38, as well as in 
normal duodenal mucosa of patients with FAP.39,40 Moreover, also by immunohistochemistry, 
COX-2 levels in normal duodenal mucosa of patients with FAP were reported to be as high as 
levels in duodenal adenomas or carcinomas, and even higher than levels in normal colonic 
mucosa.40 These findings are in sharp contrast with our results from the mRNA analysis. 
Although we did find high levels of COX-2 mRNA in normal colonic mucosa (Roelofs et al., 
unpublished results), hardly any mRNA expression was detected in normal duodenal mucosa 
of either patients with FAP or non-FAP patient controls. Similar results using qPCR analysis to 
evaluate mRNA expression were previously reported for small intestinal mucosa of non-FAP 
individuals.38 These low levels of COX-2 mRNA in duodenal mucosa, in contrast to previous 
reports using immunohistochemistry, suggest that COX-2 is of minor importance in the initial 
processes of duodenal tumorigenesis in patients with FAP. Futhermore, the results cast doubt 
on the specificity of COX-2 detection by immunohistochemical staining.
Loss of functional APC in patients with FAP results in accumulation of cytosolic β-catenin 
and subsequent translocation to the nucleus11, where the β-catenin/Tcf complex activates 
cyclin D112 and PPARδ.13 Our comparison of mRNA levels of cyclin D1 and PPARδ showed 
similar values in FAP and non-FAP duodenal mucosa (p=0.37 and p=0.44, respectively). Using 
immunohistochemistry, expression levels of β-catenin and E-cadherin were found to be lower 
in normal colon mucosa of patients with FAP as compared to non-FAP controls.41 In addition, 
we previously described lower extracellular E-cadherin but higher cytoplasmic β-catenin 
expression in normal duodenal mucosa of patients with FAP, as compared to non-FAP controls.42 
In the current study, analysis of mRNA levels of β-catenin and E-cadherin markers in normal 
duodenal mucosa of patients with FAP and non-FAP patient controls could not confirm the 
previous immunohistochemical findings.
KIAA1199 was reported as a novel target of the Wnt signaling pathway and a putative marker 
for colorectal and gastic carcinogenic transformation.15,16 We assessed KIAA1199 mRNA levels to 
investigate whether this marker is also expressed in the normal duodenal mucosa of patients with 
FAP with Spigelman grade II or III adenomatosis, consequently being at substantially increased risk 
of carcinoma development. However, duodenal KIAA1199 levels in normal mucosa of patients with 
FAP as well as in non-FAP controls were low and comparison did not reveal any difference. This could 
reflect the physiologic levels of KIAA1199 present at the proliferating crypt basis in the duodenal 
epithelium, as previously detected in the colonic epithelial crypts.15 Analysis of KIAA1199 expression 
in duodenal adenomas could reveal its involvement in duodenal adenomatous transformation.
Recently, we reported that celecoxib & placebo, but not celecoxib & UDCA co-treatment, 
reduced duodenal polyp density in patients with FAP (see Chapter 6)24. In that study, cell 
proliferation, apoptosis and COX-2 expression in the normal duodenal mucosa of the patients 
with FAP were assessed immunohistochemically, but no effects of celecoxib or celecoxib & 
UDCA treatment were found. Here, we quantified mRNA levels of several potential risk markers, 
23
4
127
1
8
9
&
5
7
6
Duodenal mucosal risk markers in patients with FAP
but again, no consistent effects of either of the two interventions on levels of cell cycle related 
markers were observed. We did observe a significant difference in change in E-cadherin mRNA 
levels between both treatment groups, but pre vs. post treatment differences in E-cadherin 
mRNA levels were not significantly different within either of the two treatment groups. Group 
comparisons with larger study samples are necessary to elucidate whether actual differences in 
potential markers do exist.
The present study has several strengths. First, the study population of patients with FAP 
consists of a relatively large and unique sample from 5 out of 8 Dutch academic medical centers. 
Second, a new and relatively simple technique, which is not based on quantitative polymerase 
chain reaction (qPCR), is used to measure mRNA levels of several potential risk markers of interest 
simultaneously, in normal duodenal mucosa of patients with FAP and non-FAP patient controls. 
The following limitations are noted. First, the number of non-FAP patient controls included 
is relatively small. Consequently, group comparisons may lack sufficient statistical power to 
reveal actual differences, and comparisons in which no statistically significant difference was 
observed are therefore to be interpreted with caution. Second, mRNA level of each sample was 
determined as single measurement, however, mean mRNA levels of two different duodenal 
biopsies from the same patient taken at predefined locations of the duodenum were used in 
the analyses. Third, although of great interest, we were not able to assess mRNA expression 
levels in duodenal adenoma biopsy samples. No biopsy samples of adenomas were taken, as 
pre-intervention sampling of adenomas would have introduced bias in the primary outcome of 
the intervention study (see Chapter 6)24. 
In summary, mRNA levels of nine potential risk parameters for malignant transformation 
were assessed in normal duodenal mucosa of patients with FAP and non-FAP patient controls. 
Markers for protection against toxins and carcinogens (GSTA1) and apoptosis (caspase-3) were 
lower in patients with FAP, which could contribute to the increased susceptibility for malignant 
transformation of normal duodenal mucosa of patients with FAP. None of the nine evaluated 
potential risk markers seem to be consistently effected by either celecoxib mono-treatment 
or celecoxib & UDCA co-treatment. COX-2 levels in normal duodenal mucosa of patients with 
FAP, measured at the mRNA level, were found to be very low, contrasting previous reports of 
immunohistochemical findings.
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Familial adenomatous polyposis (FAP) is an inheritable disease that is characterized classically 
by the development of hundreds to thousands adenomatous polyps in the colorectum during 
the second and third decades of life. Virtually all patients with FAP will develop colorectal 
cancer before the age of 40 to 50 years, unless prophylactic colectomy is performed. In the 
past decades, performing colectomy as standard prophylactic measure, substantially improved 
prognosis in patients with FAP. The mortality pattern has changed and duodenal cancer now 
is one of the main cancer-related causes of death. Practically all patients with FAP develop 
premalignant duodenal adenomas, which develop to duodenal cancer in approximately 2-7% 
of patients. Duodenal cancer in patients with FAP has a poor prognosis. The clinical challenge 
is to identify patients with high-risk duodenal adenomas and intervene before progression to 
cancer occurs. Prophylactic duodenectomy may offer a prolonged disease-free interval, but 
is associated with substantial morbidity and mortality. Therefore, chemoprevention would be 
highly desirable to postpone or even avoid the necessity for radical surgery. In this respect, 
cyclooxygenase (COX) inhibiting non-steroidal anti-inflammatory drugs (NSAIDs) have been 
subject of much investigation. Although several studies showed a favorable effect of celecoxib 
on colorectal adenomas in both patients with sporadic adenomas as well as in patients with 
FAP, its value in treatment of duodenal polyposis was not well established. The finding that 
celecoxib significantly reduced duodenal adenomatosis in patients with FAP after 6 months of 
treatment with high dosage therefore seemed promising. Unfortunately, clinical trials involving 
selective COX-2 inhibitors as chemopreventive agents for colorectal cancer suggested an 
increased risk of adverse cardiovascular events. Combining low dose celecoxib with other 
substances is a suggested alternative strategy in order to minimize toxicity. Several lines of 
evidence suggest ursodeoxycholic acid (UDCA) to be a candidate for such a combination 
regimen, but other alternatives are currently explored as well, including curcumin, quercetin, 
and eicosapentaenoic acid (EPA).
The main objectives of this thesis are:
1. To evaluate the management and its outcome of sporadic duodenal adenomas and 
duodenal adenomatosis in patients with FAP, as employed in past decades, to further define 
their clinical significance and implication, and its management.
2. To explore the chemopreventive effects on duodenal adenomatosis of potentially effective 
substances in a preclinical setting, either as single treatment or in combination, for 
development of future chemopreventive strategies in patients with FAP.
3. To investigate the chemopreventive effects on duodenal adenomatosis in patients with FAP 
of treatment with celecoxib and UDCA in a multicentre randomized clinical trial.
The first section of this thesis focuses on the management of duodenal adenomas as it was 
practiced in the Netherlands in the past decades. The two studies described in this section clarify 
the clinical significance of duodenal adenomas and illustrate the challenging clinical decisions 
that patients and their physicians face in the management of duodenal adenomatosis, which is 
especially evident for patients with FAP. For the study described in Chapter 2, the database of the 
nationwide Dutch polyposis registry in Leiden was used. The centralized registration of patients 
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with FAP in the Dutch polyposis registry not only facilitates patient care by providing a system 
which supports a strict surveillance program for patients with FAP, but also provides a source 
of information for retrospective review. For scientific value, completeness of data is essential, 
and it is therefore of crucial importance that patients and their physicians remain motivated 
to keep the database complete and up to date. The value of the registered data will further 
increase by time-lapsing extension of follow-up durations and by reducing bias due to missing 
data. In Chapter 2, the surgical management of severe duodenal adenomatosis in patients with 
FAP was evaluated, with the primary focus to gain insight into the pros and cons of prophylactic 
duodenectomy. Patients who underwent (pancreatico-) duodenectomy for advanced benign 
duodenal adenomatosis, and patients who had presented with duodenal cancer, irrespective 
of whether duodenal surgery was performed, were identified and included for analyses. A total 
of 52 patients were classified according to tumor status at preoperative endoscopy, 36 patients 
with benign duodenal adenomatosis (including two cancer cases diagnosed after operation), 
and 16 patients with duodenal cancer. Results presented in Chapter 2 show, that prognosis of 
duodenal cancer in patients with FAP is poor, justifying an aggressive approach to advanced 
benign adenomatosis. Although the life time risk of duodenal cancer in Dutch patients with 
FAP seems modest, morbidity and mortality due to severe duodenal adenomatosis itself 
as well as resulting from its treatment, is considerable. Our study focused on patients with 
advanced duodenal disease. However, patients with less severe duodenal adenomatosis 
are also confronted with a constant cancer threat and periodic endoscopic surveillance, as 
recommended based on Spigelman staging (see Chapter 1, Table 1). Downgrading patient’s 
adenomatosis by radical surgical interventions does not result in exemption from this burden. 
As adenomas were found to recur in the reconstructed proximal small bowel in 50% of the 
patients, increased risk of cancer persists and continuous surveillance is warranted. Even more, 
one patient developed cancer at the hepaticojejunostomy after pancreaticoduodenectomy 
for duodenal cancer. Altogether, this urges rapid development of strategies to postpone or 
even prevent necessity of radical surgical interventions, including chemopreventive treatment 
options, which are subject of the second and third sections of this thesis.
The study described in Chapter 3 was performed to evaluate management of patients 
with sporadic duodenal adenomas and to assess the presumed association with colorectal 
neoplasms. A total of 54 patients, diagnosed with a sporadic duodenal adenoma at our institute 
between 1986 and 2008, were included in the retrospective evaluation. Although no consistent 
approach to management of sporadic duodenal adenomas was followed and overall adenoma 
recurrence after treatment was 20%, no duodenal carcinoma was diagnosed in any of the 
patients. Endoscopic removal was complete in at least 81% of cases, and no complications were 
reported. Given the registered complications in surgical intervention in this study, including 
one complication resulting in death, endoscopic intervention is preferred over surgical 
intervention, whenever possible. Of note, treatment bias greatly influenced the complication 
statistics. For patients in whom complete removal is ascertained, no regular follow-up is 
recommended, especially in elderly patients or patients with relevant co-morbidity. However, 
an optimal algorithm for treatment and follow-up for all patients with sporadic duodenal 
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adenomas could not be defined. To be able to develop a reliable evidence-based management 
protocol for patients with sporadic duodenal adenomas, international prospective multicentre 
studies are necessary, as the incidence of sporadic duodenal adenomas is low. Moreover, 
duodenal adenomas often are coincidental findings and in most cases their presence is 
found unrelated to the upper gastrointestinal complaints that were the indication to perform 
gastroduodenoscopy. Remarkably, a relatively low number of ampullary adenomas were 
diagnosed, probably due to the fact that endoscopy is generally limited to forward-viewing 
techniques. However, ampullary adenomas are more likely to undergo malignant transformation 
compared to adenomas elsewhere in the duodenum. Also given the low estimated prevalence 
of sporadic duodenal carcinomas in the general population, this implicates that a substantial 
number of adenomas are never discovered. Therefore, in contrast to duodenal adenomas in 
patients with FAP, sporadic duodenal adenomas are of less clinical importance.
However, an additional aspect in the management of patients with sporadic duodenal 
adenomas was underlined by the findings in Chapter 3. Colorectal neoplasms, including two 
cancers and fourteen adenomas, were found in 16 of 29 patients (55%) who also underwent 
colonoscopy. These findings support the previously reported association between the 
presence of sporadic duodenal adenomas and colorectal neoplasms. It was suggested that 
in some patients the association could be based on undiagnosed attenuated FAP (AFAP) or 
MYH associated polyposis (MAP). Nonetheless, a shared common pathway between sporadic 
duodenal and colorectal neoplasm seems apparent. As FAP proved to be a valuable model in 
unraveling the genetic processes in the adenoma-carcinoma sequence (see Chapter 1, Figure 2) 
in sporadic colorectal cancer, the same might be true for duodenal carcinogenesis. Based on 
the findings in Chapter 3, colonoscopy is recommended in all patients diagnosed with sporadic 
duodenal adenomas. Sigmoidoscopy seems a reasonable alternative, as the majority of the 
associated colorectal lesions were found in the left hemicolon. Future prospective evaluation 
after implementation of this recommendation in clinical practice is needed to confirm the 
benefit of colonic assessment in these patients.
In the second section of this thesis, chemopreventive effects of potentially effective 
substances were explored in human cell line models of intestinal carcinogenesis, in order to 
develop future chemopreventive treatment strategies for duodenal adenomatosis in patients 
with FAP. Curcumin, quercetin, and EPA are natural compounds which were found to reduce 
adenoma burden in patients with FAP. In Chapter 4, their effects on the phase II detoxification 
enzymes UDP-glucuronosyltransferase (UGT), glutathione S-transferase (GST), and glutathione 
(GSH) were analyzed in four tumor cell line models, in an effort to unravel their mechanism 
of action. HT-29, HuTu 80, and Caco-2 intestinal cancer cells and LT97 colon adenoma cells 
derived from a patient with FAP were treated with low-doses of curcumin, quercetin, and 
EPA. Some enhancing effects on detoxification enzymes of curcumin, quercetin, and EPA 
were found in Caco-2 and HuTu 80 cells, whereas variable effects were detected in HT-29 and 
LT97 cells. In conclusion, enhancement of the detoxification enzymes seemed only a minor 
factor in explaining the anti-carcinogenic properties of curcumin, quercetin, or EPA. However, 
detoxification enzymes could serve as target for chemopreventive interventions in patients 
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with FAP, as suggested by the results reported in Chapter 7, showing that duodenal mRNA 
levels of glutathione S-transferase A1 (GSTA1) were lower in patients with FAP, as compared to 
non-FAP patient controls.
In Chapter 5, the chemopreventive potential of low dose celecoxib, in combination with 
UDCA, for (duodenal) adenomatosis in patients with FAP was explored in vitro. The effects on 
cell proliferation, apoptosis and COX-2 expression of both substances were investigated. In this 
study, LT97 cells derived from a patient with FAP were used, together with the well-established 
HT-29 human colon adenocarcinoma cell line. Cells were exposed to low dose celecoxib or 
UDCA alone as well as in combination with taurine conjugated cholic and chenodeoxycholic 
acid, mimicking bile of patients with FAP treated with UDCA. In HT-29 cells, co-treatment 
with low dose celecoxib and UDCA resulted in a decreased cell growth (14-17%, p<0.01). A 
more pronounced decrease (23-27%, p<0.01) was observed in LT97 cells. Growth of HT-29 cells 
exposed to ‘artificial bile’ enriched with UDCA was decreased (p<0.001), either in the absence 
or presence of celecoxib. In LT97 cells incubated with ‘artificial bile’ enriched with UDCA, cell 
growth was decreased only in the presence of celecoxib (p<0.05). Results from this in vitro study 
show that co-treatment with low dose celecoxib and UDCA has growth inhibitory effects on 
colorectal adenoma cells derived from a patient with FAP. These findings suggest that celecoxib 
exerts additional beneficial growth inhibiting effects in FAP-derived adenoma cells and not in 
carcinoma cells, and further substantiates the bridge between preclinical and clinical results of 
celecoxib with UDCA as chemopreventive regimen. 
Of course, one has to realize that results in cell line models can merely serve as starting point. 
Relevant effects observed in cell line models have to be further evaluated clinically. The closer 
the model resembles the in vivo setting, the more likely it is that in vitro results are relevant in 
vivo. Most human gastrointestinal cell line models originate from colorectal neoplasms, with 
the human duodenal adenocarcinoma cell line model HuTu 80 as an exception. Unfortunately, 
our efforts to develop a cell line model derived from a duodenal adenoma of a patient with FAP 
did not succeed. Such a cell line model could boost investigations of genetic processes in FAP 
as well as the search for potential chemopreventive strategies. Efforts to establish such a cell 
line are therefore encouraged.
In the third section of this thesis, clinical chemoprevention is elaborated in two chapters. 
In Chapter 6, the results from a double-blind, randomized clinical trial performed in a 
collaboration with the Academic Medical Centres of Amsterdam, Rotterdam, Groningen, 
and Leiden, investigating the effect of celecoxib and UDCA co-treatment on duodenal 
adenomatosis in patients with FAP, are described. Nineteen patients were treated with 
celecoxib & UDCA, and eighteen patients with celecoxib & placebo for 6 months. Celecoxib in 
high doses was once more found to reduce duodenal adenomatosis in patient with FAP. Drug 
efficacy in the chemoprevention trial was evaluated by independent assessment of pre- and 
post-intervention duodenal polyp density by blinded review of endoscopic recordings by five 
gastroenterologists.
Although much effort was put in patient recruitment, even the nationwide collaboration 
proved insufficient to meet the predefined sample size requirements. In future trials on 
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potential chemopreventive agents, cross-over study designs, in which patients subsequently 
receive different treatment regimens, could help to increase statistical power without the need 
for more participants. However, besides order effects and carry-over effects inherent to these 
study types, an even greater dedication of the participating patient with FAP is required as study 
duration significantly increases with each additional condition investigated, and subsequent 
burden increases considerably. Therefore, international collaborations seem the only way to 
reach study population sizes adequate to evaluate efficacy and safety of chemopreventive 
treatment for patients with rare diseases.
The number of adverse events in patients treated with celecoxib & placebo as well as 
celecoxib & UDCA, forcing nine patients (24%) to discontinue intervention prematurely, lead to 
the conclusion that it seems unrealistic to expect that the chemopreventive regimens studied 
here will be suitable as life-time chemopreventive treatment. Moreover, in spring 2011, at 
the same time the last patient completed her intervention period in our trial, the European 
Medicines Agency (EMA) published the conclusions of their review on the authorization of 
celecoxib-containing products for use in patients with FAP. In the European Union, celecoxib 
is authorized for use in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. The 
EMA review was initiated after concerns were raised that celecoxib was used off-label after 
Pfizer voluntary withdrew marketing authorization for use in patients with FAP of its celecoxib-
containing orphan medicine Onsenal®. Pfizer decided to do so, as it was unable to provide 
confirmatory data regarding clinical benefit due to slow enrolment in a clinical trial. Based 
on available data from published and ongoing efficacy studies and post-marketing safety 
data, EMA concluded that the benefit of celecoxib in FAP patients had not been sufficiently 
demonstrated and did not outweigh the increased risk of cardiovascular and gastrointestinal 
side effects, which could result from high dose and long-term treatment. EMA stated that 
celecoxib was not to be used off-label in patient with FAP.
Notwithstanding the apparent risk of adverse events, it might still be too soon to discard 
celecoxib as potential chemopreventive agent, especially since no alternative chemopreventive 
treatment for this group of patients with increased risk of duodenal cancer is currently available. 
Celecoxib in low doses combined with other substances might prove to be efficient and safe 
as chemopreventive strategy. Results from the chemoprevention trial unexpectedly showed 
that UDCA co-treatment counteracted the favorable effect of celecoxib. Similar to celecoxib, 
UDCA was also used in high dose, and therefore benificial effects of lower doses in combination 
treatments are not to be excluded. In vitro findings from Chapter 5 support the assumption of 
efficacy of low dose UDCA in combination with celecoxib.
In Chapter 7, mRNA levels of nine potential risk markers for malignant transformation in 
duodenal mucosa of patients with FAP are investigated, being: glutathione S-transferase A1 
(GSTA1), glutathione S-transferase P1 (GSTP1), KIAA1199, E-cadherin, peroxisome proliferative 
activated receptor δ (PPARδ), caspase-3, cyclin D1, β-catenin, and COX-2. Levels in endoscopically 
normal appearing mucosa of patients with FAP were compared with levels in non-FAP patient 
controls. Levels of GSTA1 and caspase-3 were found to be significantly lower in patients with 
FAP as compared to non-FAP patient controls. These findings suggest that protection against 
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toxins and carcinogens (GSTA1) and apoptosis (caspase-3) is lower in patients with FAP, which 
could contribute to increased susceptibility for malignant transformation of duodenal mucosa 
in these patients.
None of the potential risk parameters was consistently effected by either celecoxib or 
celecoxib & UDCA co-treatment. COX-2 mRNA levels in normal duodenal mucosa of patients 
with FAP was found to be unexpectedly low, contrasting previous immunohistochemical 
reports. This discrepancy in results using different methodology needs further attention, as 
it might implicate that one or both methods are not valid and conclusions from studies using 
the invalid method are to be revised. The mechanism of action of celecoxib is complex and 
encompasses both COX-2 dependent as well as COX-2 independent pathways. In addition, 
cellular processes targeted by UDCA are also not fully elucidated. Future research is needed to 
shed more light on these processes to be able to fully understand the observed effects of the 
substances under investigation here. 
conclusions
•	 Prognosis of duodenal cancer in patients with FAP is poor, which justifies an aggressive 
approach to advanced benign adenomatosis (Chapter 2).
•	 Strict adherence to recommended endoscopic surveillance intervals in patients with FAP 
is essential for a well-timed duodenectomy to prevent development of duodenal cancer 
(Chapter 2).
•	 Given the substantial morbidity and mortality of duodenectomy, individual characteristics 
of patients with FAP are to be critically evaluated preoperatively before such radical surgical 
intervention is performed (Chapter 2).
•	 As adenomas may recur after duodenectomy, postoperative endoscopic surveillance in 
patients with FAP is mandatory (Chapter 2).
•	 Even without consistent approach to management, none of the patients diagnosed with 
sporadic duodenal adenomas developed a duodenal carcinoma during the studied period 
(Chapter 3).
•	 Whenever possible, endoscopic intervention seems preferable over surgical intervention, 
surgical interventions could be associated with more morbidity and even mortality 
(Chapter 3).
•	 Once complete removal of a sporadic duodenal adenoma is ascertained endoscopically, 
there is no strict indication for regular follow-up, especially in elderly patients or patients 
with relevant co-morbidity (Chapter 3).
•	 Colonoscopic assessment is warranted in all patients diagnosed with sporadic duodenal 
adenomas (Chapter 3).
•	 Enhancement of the phase II detoxification enzymes UDP-glucuronosyltransferase and 
glutathione S-transferase in gastrointestinal adenoma/carcinoma cells by low doses of 
curcumin, quercetin, or eicosapentaenoic acid seems only a minor factor in explaining the 
anti-carcinogenic properties of these natural compounds (Chapter 4).
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•	 Co-treatment with low dose celecoxib and ursodeoxycholic acid has in vitro growth 
inhibitory effects on colorectal adenoma cells derived from a patient with FAP (Chapter 5).
•	 Exposure of LT97 and HT-29 cells to ursodeoxycholic acid enriched ‘artificial bile’, either 
in absence or presence of celecoxib, suggests that celecoxib exerts beneficial growth 
inhibiting effects in FAP-derived adenoma cells (LT97) and not in carcinoma (HT-29) cells 
(Chapter 5).
•	 Celecoxib reduces duodenal polyp density in patients with FAP, and unexpectedly, 
ursodeoxycholic acid co-treatment counteracts this effect (Chapter 6).
•	 The adverse events that occurred during the 6 months treatment with celecoxib 
& placebo or celecoxib & ursodeoxycholic acid, require that the benefit of long term use of 
chemopreventive regimens with celecoxib for duodenal adenomatosis in patients with FAP 
is weighed against the risk of these adverse events (Chapter 6).
•	 A disturbed protection against toxins and carcinogens caused by low levels of glutathione 
S-transferase A1 and low apoptotic activity in patients with FAP as compared to non-FAP 
patient controls, could contribute to the high susceptibility for malignant transformation 
of duodenal mucosa in patient with FAP (Chapter 7).
final consideraTions and fuTure perspecTives
Since colectomy has become a standard prophylactic measure in their management, prognosis 
of patients with FAP has substantially improved. As a result, clinical relevance of duodenal 
adenomatosis has increased and is expected to further increase with the aging of the current 
cohort of patients. The clinical significance of duodenal adenomas in patients with FAP, given 
the considerable morbidity and mortality associated with severe duodenal adenomatosis 
itself as well as its treatment, require challenging decisions to be made by patients and their 
physicians. Therefore, the need for chemopreventive drug treatment becomes increasingly 
urgent. In contrast to high dose celecoxib mono-treatment which reduces the duodenal polyp 
burden, celecoxib combined with high dose UDCA has no favorable effect on duodenal polyp 
density. Unfortunately, withdrawal of authorization by the EMA of celecoxib for treatment of 
adenomatosis in patients with FAP because of the observed adverse events, might hamper 
further evaluation of the chemopreventive potential of celecoxib. Future investigations should 
continue to include low dose celecoxib and low dose UDCA, combined with other potential 
anti-carcinogenic substances, as possible chemopreventive option.
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Afkortingen: COX, cyclooxygenase; EPA, eicosapentaeenzuur; FAP, familiaire adenomateuze polyposis; 
GSH, glutathion; GST, glutathion S-transferase; GSTA1, glutathion S-transferase A1; GSTP1, glutathion 
S-transferase P1; NSAIDs, non-steroidal anti-inflammatory drugs; PPARδ, peroxisome proliferative 
activated receptor δ; qPCR, real-time quantitative polymerase chain reaction; UDCA, ursodeoxycholzuur; 
UGT, UDP-glucuronosyltransferase
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hoofdsTuk 1 (inleiding)
Familiaire adenomateuze polyposis (FAP) is een erfelijke ziekte die klassiek gekenmerkt wordt door 
de ontwikkeling van honderden tot duizenden adenomateuze poliepen in het colon en rectum 
vanaf de tweede en derde levensdecade. Tenzij profylactisch colectomie wordt uitgevoerd, 
ontwikkelen vrijwel alle patiënten met FAP vóór de leeftijd van 40 tot 50 jaar darmkanker. Sinds 
in de voorbije decennia profylactische colectomie als een standaard maatregel wordt uitgevoerd, 
is de prognose van patiënten met FAP aanzienlijk verbeterd. Naast adenomen in het colon en 
rectum, ontwikkelen vrijwel alle patiënten met FAP ook premaligne adenomen in het duodenum. 
Duodenumkanker is momenteel een van de belangrijkste kanker gerelateerde doodsoorzaken. 
Ongeveer 2-7% van de patiënten ontwikkelt duodenumkanker. De klinische uitdaging in de 
behandeling van patiënten met FAP is het tijdig identificeren van patiënten met hoog risico 
adenomen en het ingrijpen voordat progressie van deze adenomen tot kanker is opgetreden, 
aangezien duodenumkanker een zeer slechte prognose heeft. Profylactische duodenectomie kan 
een langere ziektevrije periode bieden, maar deze radicale chirurgische ingreep gaat gepaard met 
een aanzienlijke morbiditeit en mortaliteit. Om de noodzaak voor dergelijke chirurgie uit te stellen 
of zelfs te voorkomen zou chemopreventie zeer wenselijk zijn. In dit verband is veel onderzoek 
gedaan naar de effecten van cyclooxygenase (COX) remmers, de zogenaamde “non-steroidal anti-
inflammatory drugs” (NSAIDs). In verscheidene studies werden gunstige effecten van celecoxib 
(een NSAID) aangetoond op adenomen in colon en rectum, zowel in patiënten met sporadische 
adenomen, als patiënten met FAP. De waarde ervan in de behandeling van duodenale polyposis 
is echter niet uitvoerig vastgesteld. Dat 6 maanden behandeling met hoge dosis celecoxib bij 
patiënten met FAP een aanzienlijke vermindering in duodenum adenomen opleverde, leek daarom 
een veelbelovende bevinding. Helaas lijken klinische studies met selectieve COX-2-remmers als 
chemopreventie tegen colorectale kanker te wijzen op een verhoogd risico op cardiovasculaire 
ziekte. Om het risico op deze toxiciteit te minimaliseren zou het combineren van lage doseringen 
celecoxib met een ander medicament een alternatieve strategie kunnen zijn. Verschillende 
onderzoeksbevindingen suggereren dat ursodeoxycholzuur (UDCA) een  kandidaat is voor een 
dergelijke combinatiebehandeling. Ook andere alternatieven worden momenteel verkend, 
waaronder curcumine, quercetine en het omega-3 vetzuur eicosapentaeenzuur (EPA).
De belangrijkste doelstellingen van dit proefschrift zijn:
1. Het evalueren van de behandeling van duodenum adenomen en de uitkomst van 
behandeling, bij patiënten met sporadische duodenum adenomen en bij patiënten met FAP, 
zoals dit in de afgelopen decennia in Nederland plaatsvond, om zo de klinische betekenis 
van duodenale adenomatosis en de behandeling ervan verder te definiëren.
2. Het in preklinische setting verkennen van chemopreventieve effecten van potentieel 
werkzame middelen, hetzij in enkelvoudig behandeling hetzij in combinatie therapie, om zo 
toekomstige chemopreventieve behandelingsstrategieën voor duodenale adenomatosis 
in patiënten met FAP te kunnen ontwikkelen.
3. Het onderzoeken van de theoretisch veelbelovende chemopreventieve behandeling van 
duodenum adenomen bij patiënten met FAP met celecoxib en UDCA combinatietherapie, 
middels een multicentrum gerandomiseerde klinische trial.
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hoofdsTuk 2
In het in dit hoofdstuk beschreven onderzoek werd de behandeling en behandeluitkomst 
voor ernstige duodenum adenomen bij patiënten met FAP retrospectief geëvalueerd. 
Het primaire doel van de studie was het verkrijgen van inzicht in de voor- en nadelen van 
profylactische duodenectomie. Bij het nationale polyposis register in Leiden staan meer dan 
duizend patiënten met FAP geregistreerd. Wij doorzochten de databank van het register 
en includeerden de volgende patiënten voor onze analyses: (1) patiënten die een radicale 
(pancreato-) duodenectomie ondergingen in verband met vergevorderde benigne duodenale 
adenomatosis en (2 ) patiënten die zich met een duodenumcarcinoom hadden gepresenteerd, 
ongeacht of duodenale operatie was uitgevoerd. Patiënten werden geclassificeerd volgens 
tumorstatus bij preoperatieve endoscopie, als patiënten met benigne duodenale adenomatosis 
of als patiënten met duodenumkanker. Er werden 52 patiënten (25 mannen) geïdentificeerd: 
36 met benigne adenomatosis, waaronder twee patiënten die bij operatie gediagnosticeerd 
werden met kanker, en 16 met kanker. Patiënten die bij preoperatieve endoscopie duodenale 
kanker hadden, bleken in het verleden vaker gediagnosticeerd te zijn met colorectale 
kanker dan patiënten die bij preoperatieve endoscopie benigne adenomatosis hadden (44% 
versus 6%, p<0,01). In totaal ondergingen 43 patiënten duodenectomie, waarbij mortaliteit 
en morbiditeit aanzienlijk was. Bovendien ontwikkelden zich bij de helft van de patiënten 
in de gereconstrueerde proximale dunne darm opnieuw adenomen en in één patiënt zelfs 
duodenumkanker. De mediane overleving van de 18 patiënten met kanker die in het register 
werden gevonden was 11 maanden. De resultaten in dit hoofdstuk laten zien, dat de prognose 
van duodenumkanker bij patiënten met FAP slecht is, hetgeen een agressieve benadering 
van vergevorderde benigne adenomen rechtvaardigt. Strikte naleving van de aanbevolen 
intervallen voor endoscopische controle is essentieel voor een goede timing van een eventuele 
interventie. Gezien de aanzienlijke morbiditeit en mortaliteit van duodenectomie, dienen de 
individuele kenmerken van patiënten preoperatief kritisch te worden geëvalueerd. Aangezien 
zich na duodenectomie opnieuw adenomen kunnen ontwikkelen, dient endoscopische 
controle postoperatief te worden voortgezet.
hoofdsTuk 3
In dit hoofdstuk worden de resultaten beschreven van het retropectieve onderzoek naar 
de behandeling van sporadische duodenum adenomen, de uitkomst van de uitgevoerde 
behandelingen en de aanwezigheid van colorectale tumoren in deze patiënten. Hiertoe 
werden de medische dossiers van alle patiënten bij wie in ons instituut tussen 1986 en 2008 
een sporadisch duodenum adenoom werd vastgesteld retrospectief beoordeeld. Er werden 
in deze periode 54 patiënten (28 mannen) gediagnosticeerd met een sporadisch duodenum 
adenoom. Drieëndertig patiënten (61%) ondergingen een endoscopische of chirurgische 
ingreep, 5 patiënten (9%) werden alleen endoscopisch vervolgd en 16 (30%) ondergingen 
geen interventie en werden ook niet vervolgd. Volledige endoscopische resectie werd 
bereikt in 81% van de patiënten en hierbij werden geen complicaties gemeld. Chirurgische 
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interventie verliep gecompliceerd in 4 patiënten (57%), waarbij één patiënt overleed. 
In 20% van de patiënten werd een recidief adenoom vastgesteld, maar er werd geen 
carcinoom gevonden. Colorectale tumoren, waaronder 2 kankers (7%), 7 vergevorderde 
adenomen (24%) en 7 niet-vergevorderde adenomen (24%), werden gevonden in 16 van de 
29 patiënten (55%) die ook colonoscopie ondergingen. Hoewel geen consistente aanpak in 
behandeling van sporadische duodenum adenomen werd gevolgd, ontwikkelde zich tijdens 
de bestudeerde periode in geen van de patiënten een duodenum carcinoom. Endoscopische 
interventie lijkt, indien mogelijk, de voorkeur te hebben boven chirurgische interventie, 
gezien de hierbij gemelde morbiditeit en mortaliteit. Zodra bij de follow-up endoscopie 
is vastgesteld dat het adenoom volledig is verwijderd, is geen verdere controle meer te 
adviseren, vooral niet bij oudere patiënten of patiënten met relevante co-morbiditeit. Het 
is van belang een colonoscopie te verrichten bij alle patiënten die gediagnosticeerd worden 
met sporadische duodenum adenomen, aangezien duodenum adenomen en colorectale 
tumoren geassocieerd lijken voor te komen.
hoofdsTuk 4
In het hier beschreven onderzoek worden de effecten van curcumine, quercetine en 
EPA op de fase II ontgiftingsenzymen UDP-glucuronosyltransferase (UGT) en glutathion 
S-transferase (GST)/glutathion (GSH) onderzocht. Om meer inzicht te krijgen in het 
werkingsmechanisme van deze drie natuurlijke verbindingen in relatie tot hun capaciteit om 
adenomen bij patiënten met FAP terug te dringen, werden behandeleffecten geanalyseerd 
in vier cellijn modellen van intestinale kanker, namelijk de darmkankercellen HT-29, HuTu 
80 en Caco-2 en de colorectale adenoomcellen LT97, afkomstig van een patiënt met FAP. 
Een verhogend effect van curcumine en quercetine op GST en UGT expressie werd gezien 
in Caco-2, LT97 en HuTu 80 cellen. GSH was verlaagd in HT-29 cellen na behandeling met 
quercetine en EPA en verhoogd in Caco-2 cellen na behandeling met curcumine. In LT97 
cellen werd door curcumine en quercetine de GST activiteit en expressie verminderd, de 
UGT1 expressie verhoogd, terwijl onder invloed van EPA de GST en UGT expressie afnamen. 
Gezien de ambivalente effecten lijkt een inductie van de ontgiftingscapaciteit geen factor 
van betekenis om de anti-carcinogene eigenschappen van lage doseringen curcumine, 
quercetine en EPA te kunnen verklaren.
hoofdsTuk 5
In dit hoofdstuk wordt de chemopreventieve werking van lage dosis celecoxib in combinatie 
met UDCA voor (duodenale) adenomatosis bij patiënten met FAP verkend. Doel was het 
onderzoeken van in vitro effecten op de celgroei (celproliferatie en apoptose) en COX-2 
expressie van beide stoffen in enkelvoudige behandeling en in combinatie. De humane 
epitheliale cellijn LT97, verkregen uit colorectale micro-adenomen van een patiënt met FAP, 
werd als model gebruik. Ter vergelijking werd tevens gekeken in de veelgebruikte humane 
HT-29 colon adenocarcinoom cellijn. De cellen werden blootgesteld aan lage doseringen van 
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alleen celecoxib of UDCA, combinaties van celecoxib en UDCA, of combinaties van celecoxib 
en UDCA met ‘kunstmatige gal’ van patiënten met FAP, bestaande uit taurine geconjugeerd 
cholzuur en chenodeoxycholzuur. In HT-29 cellen werd een verminderde celgroei (14-17%, 
p<0,01) gezien na behandeling met lage dosis celecoxib en UDCA. Een meer uitgesproken 
vermindering (23-27%, p<0,01) werd waargenomen in LT97 cellen. De groei van HT-29 cellen 
nam af (p<0,001) als de cellen werden blootgesteld aan ‘kunstmatige gal’ verrijkt met UDCA, 
al dan niet in aanwezigheid van celecoxib. In LT97 cellen geïncubeerd met ‘kunstmatige gal’ 
verrijkt met UDCA, werd alleen een afname in celgroei gezien in aanwezigheid van celecoxib 
(p<0,05). Resultaten van deze in vitro studie tonen aan dat de combinatiebehandeling van lage 
dosis celecoxib met UDCA groei remmende effecten heeft op cellen van colorectale micro-
adenomen van een patiënt met FAP. De bevindingen suggeren bovendien dat celecoxib 
additioneel gunstige remmende effecten heeft in adenoomcellen van een patiënt met FAP en 
niet in carcinoomcellen.
hoofdsTuk 6
In dit hoofdstuk staan de resultaten beschreven van de dubbelblinde, gerandomiseerde 
klinische trial die werd uitgevoerd in een unieke samenwerking met deskundigen op het 
gebied van FAP uit de Academisch Medische Centra van Amsterdam, Rotterdam, Groningen 
en Leiden. In de trial werd de behandeling met celecoxib in combinatie met UDCA vergeleken 
met celecoxib in combinatie met een placebo, waarbij het primaire doel was om het effect 
op duodenum adenomen bij patiënten met FAP te bestuderen. Negentien patiënten werden 
behandeld met celecoxib en UDCA en 18 patiënten met celecoxib en placebo. De behandelduur 
was 6 maanden. Het effect van de behandeling op de duodenale poliepdichtheid werd 
beoordeeld door vijf maag-, darm-, leverartsen, door vergelijking van videobeelden vastgelegd 
tijdens gastroduodenoscopie vóór en ná behandeling. Als secundaire uitkomstmaten werden 
celproliferatie, apoptose en COX-2 niveaus in normaal duodenum slijmvlies geëvalueerd 
middels immuunhistochemische kleuringen en/of kwantitatieve polymerase chain reaction 
(qPCR). Bij intention-to-treat analyse werd een afgenomen poliepdichtheid waargenomen 
na celecoxib & placebo (p=0,029), terwijl een verhoogde poliepdichtheid werd gezien na 
celecoxib & UDCA behandeling (p=0,014). De verandering in duodenale poliepdichtheid 
was statistisch significant verschillend tussen beide groepen (p=0,011). Er werden geen 
veranderingen in de secundaire uitkomstmaten vastgesteld. Er werd een aanzienlijk aantal 
bijwerkingen geregistreerd. Negen patiënten (24%) stopten vanwege bijwerkingen zelfs 
voortijdig met de interventie, 5 patiënten (26%) in de groep die behandeld werd behandeld 
met celecoxib & UDCA en 4 patiënten (22%) in de groep die werd behandeld met celecoxib 
& placebo.
De resultaten van de studie tonen aan dat celecoxib de duodenale poliepdichtheid bij 
patiënten met FAP verminderd, maar dat toevoeging van UDCA aan de behandeling met 
celecoxib dit effect teniet doet. Bij langdurig gebruik van celecoxib in chemopreventieve 
behandelschema’s voor duodenale adenomatosis bij patienten met FAP dienen de gunstige 
effecten te worden afgewogen tegen de (risico’s op) bijwerkingen.
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hoofdsTuk 7
In de laatste studie in dit proefschrift worden de messenger RNA (mRNA) niveaus van negen 
potentiële risico markers voor maligne transformatie in duodenum slijmvlies van patiënten 
met FAP onderzocht. De mRNA-niveaus van glutathion S-transferase A1 (GSTA1), glutathion 
S-transferase P1 (GSTP1), KIAA1199, E-cadherine, peroxisome proliferative activated receptor δ 
(PPARδ), caspase-3, cycline D1, β-catenine, en cyclooxygenase-2 (COX-2) werden gemeten met 
de QuantiGene 2.0 Plex assay, een nieuwe en relatief eenvoudige techniek die niet gebaseerd 
is op qPCR. Niveaus in endoscopisch normaal-ogend slijmvlies van 37 patiënten met FAP 
werden vergeleken met de niveaus in 16 niet-FAP controle patiënten. Daarnaast werden de 
niveaus beoordeeld bij de patiënten met FAP die deelnamen aan de gerandomiseerde studie 
beschreven in Hoofdstuk 6, vóór en ná behandeling met celecoxib & UDCA (n=14) of celecoxib 
& placebo (n=13). De mRNA niveaus van GSTA1 en caspase-3 bleken significant lager in patiënten 
met FAP in vergelijking met niet-FAP controle patiënten. Dit suggereert dat de bescherming 
tegen giftige en kankerverwekkende stoffen (GSTA1) en het beschermingsmechanisme van 
geprogrammeerde celdood oftewel apoptose (caspase-3) lager is bij patiënten met FAP. Dit 
zou kunnen bijdragen aan een verhoogde gevoeligheid voor maligne transformatie van het 
duodenum slijmvlies bij deze patiënten. De behandeling met celecoxib of celecoxib & UDCA 
leek geen effect te hebben op de onderzochte potentiële risico markers. De COX-2 mRNA-
niveaus in normaal-ogend duodenum slijmvlies van patiënten met FAP was opvallend laag, 
hetgeen in tegenspraak is met resultaten van eerder onderzoek waarin COX-2-niveaus met 
immuunhistochemische methoden werden geëvalueerd.
conclusies
•	 De prognose van duodenumkanker in patiënten met FAP is slecht, hetgeen een agressieve 
benadering in de behandeling van vergevorderde benigne duodenum adenomen 
rechtvaardigt (Hoofdstuk 2).
•	 Strikte naleving van de aanbevolen intervallen voor endoscopische controle in patiënten 
met FAP is essentieel voor een goede timing van een duodenectomie ter voorkoming van 
de ontwikkeling van duodenumkanker (Hoofdstuk 2).
•	 Gezien de aanzienlijke morbiditeit en mortaliteit van duodenectomieën in patiënten met 
FAP, dienen individuele patiëntenkenmerken preoperatief kritisch te worden geëvalueerd 
voordat een dergelijke ingrijpende chirurgische ingreep wordt uitgevoerd (Hoofdstuk 2).
•	 Aangezien na duodenectomie recidief adenomen in patiënten met FAP frequent voorkomen, 
dienen ook postoperatief de endoscopische controles te worden voortgezet (Hoofdstuk 2).
•	 Ondanks het feit dat er geen consistente aanpak in de behandeling van sporadische 
duodenum adenomen is, ontwikkelde geen van deze patiënten tijdens de bestudeerde 
periode een carcinoom (Hoofdstuk 3).
•	 Waar mogelijk lijkt endoscopische interventie de voorkeur te hebben boven chirurgische 
interventie, aangezien chirurgische ingrepen worden geassocieerd met meer morbiditeit 
en zelfs mortaliteit (Hoofdstuk 3).
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•	 Zodra volledige resectie van een sporadisch duodenum adenoom endoscopisch is 
vastgesteld, bestaat er geen strikte indicatie meer voor controle, vooral niet bij oudere 
patiënten of patiënten met relevante co-morbiditeit (Hoofdstuk 3).
•	 Alle patiënten met een sporadisch duodenum adenoom dienen ook een colonoscopie te 
ondergaan, gezien de associatie met colorectale neoplasieën (Hoofdstuk 3).
•	 Verhoging van de spiegels van fase II ontgiftingsenzymen UDP-glucuronosyltransferase 
en glutathion S-transferase in gastrointestinale epitheelcellen door lage doses curcumine, 
quercetine en eicosapentaeenzuur lijkt geen factor van betekenis in de verklaring van de 
anti-carcinogene eigenschappen van deze natuurlijke verbindingen (Hoofdstuk 4).
•	 Behandeling met de combinatie van lage dosis celecoxib en ursodeoxycholzuur heeft groei 
remmende effecten op LT97 colorectale adenoomcellen afkomstig van een patiënt met FAP 
(Hoofdstuk 5).
•	 Resultaten van blootstelling van colorectale adenoomcellen LT97 en adenocarcinoomcellen 
HT-29 aan met ursodeoxycholzuur verrijkt ‘kunstmatige gal’, al dan niet in aanwezigheid 
van celecoxib, laten zien dat celecoxib additionele groeiremmende effecten heeft in de 
LT97 adenoomcellen en niet in de HT-29 carcinoomcellen (Hoofdstuk 5).
•	 Celecoxib vermindert de duodenale poliepdichtheid bij patiënten met FAP. Behandeling 
met celecoxib in combinatie met UDCA doet dit effect echter teniet (Hoofdstuk 6).
•	 Gezien het aanzienlijk aantal bijwerkingen tijdens de 6 maanden behandeling met 
celecoxib & placebo of celecoxib & ursodeoxycholzuur, is bij een langdurige behandeling 
met celecoxib voor duodenale adenomatosis bij patiënten met FAP een afweging van de 
voordelen tegen de risico’s op bijwerkingen noodzakelijk (Hoofdstuk 6).
•	 Verminderde bescherming tegen toxische en carcinogene stoffen (lagere niveaus van 
glutathion S-transferase A1) en verminderde geprogrammeerde celdood (lagere niveaus 
van caspase-3), zouden kunnen bijdragen aan een verhoogde gevoeligheid voor maligne 
transformatie van het duodenum slijmvlies in patiënten met FAP (Hoofdstuk 7).
afsluiTende overWegingen en ToekomsTperspecTieven
Sinds colectomie een standaard profylactische maatregel in de behandeling is geworden, 
is de prognose van patiënten met FAP aanzienlijk verbeterd. Het gevolg is dat de klinische 
relevantie van duodenale adenomatosis is toegenomen en de verwachting is dat deze met 
de veroudering van het huidige cohort van patiënten met FAP in de toekomst verder zal 
toenemen. Dit betekent dat de uitdagende beslissingen waarmee patiënten en hun artsen in 
de behandeling worden geconfronteerd, door de aanzienlijke morbiditeit en mortaliteit van 
zowel de ernstige duodenale adenomatosis zelf als de behandeling ervan, alleen maar zullen 
toenemen. Al met al wordt de behoefte aan medicamenteuze behandeling steeds urgenter. 
Hoewel de behandeling van celecoxib gecombineerd met ursodeoxycholzuur, beide in 
hoge doseringen, geen gunstig effect op duodenale poliepdichtheid bleek te hebben, werd 
het gunstige effect van hoge dosis celecoxib mono-therapie opnieuw vastgesteld. Helaas 
werd naar aanleiding van de waargenomen bijwerkingen de indicatiestelling van celecoxib 
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voor adenomatosis bij patiënten met FAP ingetrokken. Dit zou een verdere evaluatie van de 
chemopreventieve potentie van celecoxib kunnen belemmeren. Toekomstige studies dienen 
lage doseringen celecoxib en UDCA, in combinatie met andere potentiële anti-carcinogene 
middelen, als mogelijke chemopreventieve opties te blijven evalueren.
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BJORN VAN HEUMEN werd geboren op 4 november 1976 te Nijmegen. Hij volgde het 
Voorbereidend Wetenschappelijk Onderwijs (VWO) aan het Kandinsky College te Nijmegen. 
Na 3 jaar opleiding geneeskunde aan de Katholieke Universiteit Leuven (België) gevolgd 
door 2 jaar opleiding psychologie aan de Katholieke Universiteit Nijmegen, werd hij in 2000 
toegelaten tot de opleiding geneeskunde aan de Katholieke Universiteit Nijmegen (thans: 
Radboud Universiteit). Tijdens zijn opleiding geneeskunde kwam hij via het keuzeblok Erfelijke 
darmkanker in contact met Dr. Nagengast. Onder diens begeleiding maakte hij tijdens 
zijn wetenschappelijk onderzoeksstage verder kennis met het vakgebied Maag-, Darm- en 
Leverziekten. Na een afsluitend co-assistentschap in Techiman (Ghana) behaalde hij in 2007 
zijn artsexamen. Na zijn afstuderen ging hij aan de slag als arts-assistent-niet-in-opleiding 
op de afdeling Interne geneeskunde in het Slingeland Ziekenhuis te Doetinchem, waar hij 
behalve binnen de Interne geneeskunde ervaring opdeed in de Cardiologie, Longziekten 
en Neurologie. In oktober 2008 maakte hij de overstap naar het Radboud Universiteit 
Nijmegen Medisch Centrum, in de functie van coördinerend arts-onderzoeker van het KWF-
gesubsidieerde onderzoeksproject naar preventie van progressie van duodenale adenomatosis 
in patiënten met familiaire adenomateuze polyposis (FAP) onder leiding van Dr. Nagengast en 
Dr. Peters. Op 1 juli 2011 is hij gestart met zijn opleiding tot maag-darm-leverarts (opleider: 
Prof. Dr. Drenth). In dit kader is hij begonnen met de vooropleiding Interne geneeskunde in 
het Canisius Wilhelmina Ziekenhuis Nijmegen (opleider: Dr. Dofferhoff). Tijdens deze eerste 
periode van zijn specialistenopleiding heeft hij zijn promotieonderzoek afgerond, hetgeen 
heeft geresulteerd in dit proefschrift. Inmiddels heeft hij zijn opleiding voortgezet in het 
Rijnstate ziekenhuis te Arnhem (opleider: Dr. Wahab). Bjorn woont in Nijmegen samen met 
Judith van Vliet, neuroloog in opleiding. Zij zijn de ouders van dochter Mirre. In november dit 
jaar verwachten zij hun tweede kind.
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De afronding van mijn promotietraject was nooit gelukt zonder de hulp van de volgende 
mensen.
Dr. Nagengast, beste Fokko. Ik ben je ontzettend dankbaar dat jij mij enthousiast hebt 
gemaakt voor het vakgebied van de Maag-, darm-, leverziekten en mij de uitvoering van het 
KWF project hebt toevertrouwd. Regelmatig kwam ik bij je binnen lopen voor overleg. Steevast 
was je reactie dat je daar nu echt even geen tijd voor had, door drukte rondom patiëntenzorg 
of onderwijstaken. Maar nadat je mij deelgenoot had gemaakt van je meest recente frustratie, 
spraken we dan toch altijd even de liggende zaken door. Vervolgens leek je alle werkdruk 
vergeten en stond je uitgebreid stil bij je ervaringen tijdens een internationaal congres, de 
laatste aflevering van BBC’s Masterchef, of de onovertroffen rijeigenschappen van je nieuwe 
BMW (‘bovendien geweldig dat er ook een studie naar het automerk is vernoemd’ [Biomedische 
Wetenschappen]). Fantastisch. Ontzettend bedankt voor je enthousiasme.
Dr. Peters, beste Wilbert. Ik heb grote bewondering voor je relativeringsvermogen. Wij hebben 
enorm geworsteld met diverse laboratoriumtechnische problemen. Op alles wat met COX-2 te 
maken had leek een vloek te rusten. Maar tegenslag dwingt tot heroverwegen en het zoeken naar 
alternatieve methoden. Hierdoor kan ik mij nu gelukkig prijzen met een laboratoriumervaring 
die zeker niet voor alle artsen is weggelegd. Als mij de moed zelfs al uit mijn schoenen begon 
weg te lekken, wist je mij toch te motiveren door te zetten. Immers, elke onderzoeksuitkomst 
is een rapporteerbaar resultaat. Bedankt voor al je ondersteuning, inclusief tuinonderhoud voor 
dummy’s. En natuurlijk voor jouw (soms onbegrijpelijke) lessen in de wetenschap van het rikken.
Prof. Dr. Drenth, beste Joost. Aangezien mijn promotieonderzoek werd gesuperviseerd 
door twee zeer ervaren seniorwetenschappers, was jouw rol als promotor inhoudelijk beperkt. 
Desondanks toonde je veel interesse in de voortgang van mijn onderzoek en gaf je bruikbare 
adviezen. Veel dank daarvoor. Ik zie uit naar de komende jaren waarin jouw rol als opleider in 
mijn verdere ontwikkeling tot MDL-arts juist groot gaat zijn. Uiteraard kan ik het niet laten een 
opmerking te maken over jouw clubvoorkeur. Vooral de clubkleuren stemmen mij uiteraard tot 
groot ongenoegen. Hoe geweldig is het daarom dat jij, zoals je al lang geleden hebt beloofd, 
op de dag van mijn promotie gehuld gaat in de kleuren van mijn clubvoorkeur. Ik zou haast 
zeggen dat ik het daarvoor allemaal heb gedaan!
Prof. Dr. Kampman, beste Ellen. Je was betrokken bij de subsidieaanvraag bij het KWF en 
later bij de opstartfase van mijn onderzoeksperiode en de trial. Je hebt geholpen de zaken op 
de rails te zetten. Bedankt daarvoor.
Hartelijk dank aan alle patiënten die bereid waren om deel te nemen aan mijn onderzoeken, 
want zonder deelnemers geen klinische studies en dus geen wetenschappelijke vooruitgang!
De leden van de manuscriptcommissie en overige leden van de corona bedank ik voor hun 
bereidwilligheid om zitting te nemen in de commissie en zich in mijn werk te verdiepen.
Moeders van mijn promotie. Hennie, ik wens je een verdere carrière zonder COX-2-
bepalingen toe! Veel dank voor je oneindige inzet en doorzettingsvermogen. Daar heb ik zeer 
veel respect voor.  Maria, door jouw inspanningen voor de patiëntenzorg van o.a. patiënten 
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met FAP is wetenschappelijk onderzoek met patiënten met FAP in het UMC St. Radboud haast 
eenvoudig geworden. Dames, bedankt voor al jullie ondersteuning, en gezelligheid natuurlijk.
Onmisbaar voor het slagen van mijn onderzoeken en het schrijven van de artikelen 
waren de bijdragen van mijn coauteurs. Vooral de coauteurs van de chemopreventie-trial en 
hun lokale trialcoördinatoren Christine en Karin (AMC) en Lida, Babs en Maartje (LUMC) zijn 
er niet makkelijk vanaf gekomen. Zonder jullie tijd en energie waren wij niet tot dit resultaat 
gekomen. Speciale dank gaat uit naar Iris Nagtegaal, soms een soort derde copromotor, en 
Elisa, afdeling Pathologie.
Nou ben ik van tijd tot tijd een enorme mopperaar, het is niet anders. Daarom mijn oprechte 
excuses aan de mensen die mij tijdens mijn fulltime onderzoeksperiode hebben moeten dulden 
als kamergenoot en mijn al maar intensiverende tirades over eender welke frustratie hebben 
moeten aanhoren. Eén kamergenoot heeft zelfs overplaatsing aangevraagd... Bedankt Loes, 
Michelle, Melissa, Ria, Karin en Merel, voor het delen van voorspoed en tegenslag, ik vond het 
in ieder geval erg geslaagd! Dan wel niet bij mij op de kamer gezeten, maar toch ook altijd in de 
buurt voor een praatje, een bakkie pleur of een potje rikken, collega’s op of rond het lab MDL: 
René, Jody, Manoe, Evelyn, Wybrich, Wim, en in barrak ‘De Buitenhoek’: Jannes, Geert, Polat, 
Mieke, Serena, Martijn, Tom, Robin, Mark, Sanne, dank jullie wel.
Tijdens mijn onderzoek heb ik met studenten geneeskunde en biomedische wetenschappen 
mogen samenwerken: Marieke, Erik, Maartje, Karlien, Harm, Sanne en Julia. Ik hoop dat het 
voor jullie net zo leerzaam is geweest als het voor mij was om jullie te begeleiden.
Dames van het secretariaat MDL, dank voor de behulpzaamheid. Hetzelfde geldt voor alle 
mensen op de endoscopieafdeling (administratief, verpleegkundigen, artsen): er was altijd alle 
medewerking als ik weer eens aankwam met mijn paparassen, formalinepotjes en container 
met vloeibare stikstof. Super.
Voor al mijn vrienden (‘Leuven’, ‘Gang 6’, ‘Geneeskunde Nijmegen’, anders): bedankt 
voor alle gezamenlijke ervaringen en herinneringen, en natuurlijk het ophalen ervan, wat een 
verrijking! Ik zal er nooit genoeg van krijgen.
Lieve (schoon-)familie, bedankt voor jullie onvoorwaardelijke steun tijdens mijn lange 
studiecarrière met hindernissen en het begrip dat mijn opleidingssituatie en later werksituatie 
in combinatie met promotieonderzoek (te) weinig tijd laat voor onze sociale aangelegenheden.
Lieve Judith, hoe kan ik je in een paar regels bedanken voor alle ruimte die je me hebt 
gegeven naast mijn opleiding mijn promotie tot een einde te brengen. Niet. Ik ben oneindig 
gelukkig met jou en onze Mirre.
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